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Abstract 
 
Chronic obstructive pulmonary disease (COPD) is an inflammatory condition of the 
lung  caused  by  an  abnormal  response  to  particles  and  noxious  gases,  primarily 
cigarette smoke. Patients suffer daily symptoms and can have episodes of worsening 
symptoms termed acute exacerbations. Exacerbations are associated with impaired 
quality  of  life,  faster  lung  function  decline,  higher  mortality  and  increased  risk  of 
hospitalisation.  The  aetiology  of  COPD  exacerbations  is  controversial;  however 
respiratory viral and bacterial infections are an important feature of exacerbations.  
 
This study utilised real-time qPCR to measure prevalence and load of human rhinovirus 
(HRV) in stable COPD and during the time-course of naturally occurring exacerbations 
and their recovery. HRV was assessed in association with upper respiratory tract (URT) 
symptoms  namely  cold  symptoms  and  sore  throats,  secondary  bacterial  infection, 
patient  reported  outcomes  and  exacerbation  frequency.  Additionally,  respiratory 
syncytial  virus  (RSV)  was  semi-quantitatively  examined  in  stable  COPD  and  at 
exacerbation.  
 
The original contribution of this work to the field is that HRV prevalence and load are 
highest at exacerbation presentation and decrease during recovery. HRV load is higher 
in the presence of URT symptoms compared to the load without, and the load remains 
higher for longer with both symptoms compared to  only one. This study described 
novel  evidence  for  the  development  of  secondary  bacterial  infection  after  HRV 
infection in natural exacerbations, and demonstrated that HRV infection is associated 
with  patient  reported  outcomes.  Patients  with  HRV  had  higher  exacerbation 
frequencies  compared  to  those  without  HRV.  RSV  prevalence  did  not  change 
significantly between stable COPD and exacerbation.   
 
The findings from this thesis have important implications in terms of exacerbation 
therapy.  The  evidence  provided  may  allow  appropriate  targeting  of  therapeutic 
interventions therefore reducing exacerbation severity and frequency.  These findings 
emphasise  the  importance  of  rapid  development  of  therapeutic  targets  for  the 
prevention and treatment of HRV infection in COPD patients.   
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1.1  Chronic obstructive pulmonary disease 
Chronic  obstructive  pulmonary  disease  (COPD)  is  a  preventable  and  treatable  but 
progressive  airway  disease  which  encompasses  several  heterogeneous  phenotypes 
predominantly bronchitic and emphysematous. The chronic bronchitic component of 
COPD was first described in 1814 by British physician Charles Badham as a disabling 
disorder,  using  the  word  “catarrh”  when  referring  to  chronic  cough  and  mucus 
secretions  (Badham,  1814).  Chronic  bronchitis  is  defined  clinically  based  on  the 
presence of cough and sputum production for three months per year for two or more 
consecutive years (GOLD Report 2014; Scadding, 1959). The emphysematous aspect of 
COPD is characterised radiologically by the pathological appearance of large airspaces 
where there has been airway damage and destruction of alveolar walls (Horowitz et 
al., 2009). In 1829, French physician René Laennec discovered that certain patients 
with  obstructed  airways  disease  had  hyper  inflated  lungs  which  did  not  empty 
efficiently (Laennec, 1829). This led the way to the development of the spirometer by 
John Hutchinson in 1846. In 1947, the spirometer was adapted to record values of 
forced vital capacity (FVC) which is the amount of air that can be forcibly exhaled from 
the lungs after taking the deepest breath possible (Yernault, 1997). It also records 
values for forced expiratory volume in one second (FEV1) which is the volume of air 
exhaled during the first second of a forced expiratory manoeuvre. Both of these are 
now important measurements in COPD (Yernault, 1997).  
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The most widely accepted definition of COPD as described by the Global Initiative for 
COPD  (GOLD)  is  “a  preventable  and  treatable  disease  with  some  significant 
extrapulmonary effects that may contribute to the severity in individual patients. Its 
pulmonary component is characterised by airflow limitation that is not fully reversible. 
The  airflow  limitation  is  usually  progressive  and  associated  with  an  abnormal 
inflammatory response of the lung to noxious particles or gases” (GOLD Report 2014). 
The  heterogeneous  nature  of  COPD  has  led  to  the  concept  of  multiple  underlying 
phenotypes within COPD. By studying these phenotypes individually we can better our 
understanding and therefore treatment of this disease.  
1.1.1  History and aetiology 
COPD has been described in a number of different terms throughout the past. Several 
decades ago, a debate rose regarding the definition of this heterogeneous disease. In 
the 1950s and 1960s, two rival hypotheses emerged: the Dutch hypothesis and the 
British hypothesis. At the first Bronchitis symposium in the Netherlands in 1961, Orie 
put forward the hypothesis that various forms of airway obstruction such as asthma, 
chronic bronchitis and emphysema, should not be considered as separate diseases but 
different  expressions  of  one  disease  entity  (Orie,  1961)  with  both  host  and 
environmental factors playing a role in pathogenesis. This theory was later termed the 
“Dutch hypothesis” by Fletcher in 1969. In contrast, an alternative hypothesis termed 
the “British hypothesis” (Fletcher, 1976) suggested that a hereditary predisposition Chapter 1 – Introduction 
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towards  developing  allergy  and  bronchial  hyperreactivity  were  considered  to  be 
important denominators of disease susceptibility.  
 
The  British  hypothesis  originated  from  the  clinical  observations  that  infectious 
exacerbations of COPD led to a continuing decline in lung function, were a risk factor 
for permanent decline in FEV1 (Tager and Speizer, 1975) and that chronic bronchitis 
predisposed the lungs to subsequent infection resulting in airway damage leading to 
further progressive airflow limitation (Stuart-Harris et al., 1953). The proteinase (also 
referred  to  as  protease)-antiproteinase  theory  is  a  combination  of  the  Dutch  and 
British hypotheses as broadly speaking the Dutch hypothesis is a genetic hypothesis 
and the British, an environmental one. The proteinase-antiproteinase hypothesis arises 
from the genetic defect in the levels of α1-anti-trypsin (AAT) in emphysema and also 
the observation that smoking increases the number of elastase-containing neutrophils. 
The British hypothesis was contested when Fletcher (Fletcher, 1976) and colleagues 
(Johnston et al., 1976) found no relationship between bronchial infections and FEV1 
decline and therefore the concept of two diseases, chronic bronchitis and emphysema, 
emerged.  
1.1.2  Pathogenesis and Inflammation 
In  the  healthy  lung,  the  airways  are  defended  by  mechanisms  such  as  mucociliary 
clearance, epithelial barriers and the recruitment of immune and inflammatory cells 
(Mizgerd, 2012). As inhalation is the most common route of entry to the lungs, they Chapter 1 – Introduction 
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are well adapted to eliminate foreign agents which may cause infection or irritation 
within  the  airways.  Alveolar  macrophages  ensure  pathogens  do  not  persist  in  the 
airways  and  cause  harm;  they  are  supported by  other  immune  cells of  the  innate 
immune system such as neutrophils (Barnes, 2008). The innate defence in the airways 
is  designed  to  remove  foreign  and  potentially  harmful  particles  and  resolve 
inflammation, both of which are beneficial responses in the case of healthy individuals. 
In patients with COPD however, the actions of the immune system can result in an 
abnormal  and  exaggerated  inflammatory  response  that  can  progress  to  pathology 
within the lung (Baines et al., 2011).   
 
Cigarette smoke is likely to account for approximately 80-90% of COPD cases in the 
developed  world  (Sethi  and  Rochester,  2000).  In  COPD  patients,  cigarette  smoke 
interferes  with  the  innate  defences  by  increasing  mucus  production,  reducing 
mucociliary  clearance,  disrupting  the  epithelial  cell  barrier  and  stimulating  the 
migration of immune cells such as neutrophils, macrophages and monocytes, natural 
killer (NK) cells, dendritic cells, CD4
+, CD8
+ and B-cell lymphocytes to the area of tissue 
damage  (Hogg  et  al.,  2004).  The  production  of  these  cells  in  turn  leads  to  an 
abundance  of  pro-inflammatory  cytokines  and  chemokines  such  as  IL-6,  IL-8, 
neutrophil  elastase,  myeloperoxidase  and  matrix  metalloproteinases  (MMPs) 
(Yamamoto et al., 1997) within the airway. It is the abnormal inflammatory response 
to the inhalation of noxious particles found in COPD patients that leads directly, and 
indirectly, to airway and parenchymal lung damage (Hogg et al., 2004).  
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Cigarette  smoking  leads  to  airway  inflammation  in  all  those  that  smoke,  with  or 
without  COPD  (Yanbaeva  et  al.,  2007).  However  in  patients  with  COPD,  the 
pathological abnormalities persist even after the removal of the noxious stimuli, for 
example following smoking cessation, and from this it has been suggested that certain 
individuals are more susceptible to the development of COPD (Cosio et al., 2009). The 
characteristic irreversible airflow limitation of COPD is caused by a thickening of the 
airway wall due to fibrosis and inflammation, and also hypersecretion of mucus in the 
lumen of the airway (Figure 1.1). 
 
 
Figure 1.1: In the specimen of the small airways (membranous bronchioles) from the healthy 
lung of a non-smoker (Panel A), the airway walls are thin, and intact alveoli are attached 
along its circumference. In a comparable specimen from the lung of a smoker with COPD 
(Panel B), the diameter of the airway is narrowed, the airway wall is thickened, and many of 
the alveolar attachments are broken. CD8+ T lymphocytes (in red) infiltrate the airway wall 
in the specimen from the smoker with COPD (Panel B) but not in the specimen from the non-
smoker (Panel A) (immunostaining with antihuman CD8; counterstained with haematoxylin) 
(Cosio et al., 2009). Chapter 1 – Introduction 
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Airway epithelial cells and macrophages activate transcription factors such as nuclear 
factor-κβ (NF-κβ) which is present in the cytosol in an inactive form. NF-κβ regulates 
the synthesis of many of the cytokines and chemokines that are secreted in COPD such 
as IL-8, TNF-α and nitric oxide (NO) which play a role in the amplification of airway 
inflammation  (Caramori  et  al.,  2003).  Bronchial  airway  biopsies  have  shown  an 
increase in the number of neutrophils in the airway lumen of COPD patients but there 
is  no  evidence  for  the  activation  of  mast  cells  (Hogg,  2004).  The  combination  of 
epithelial-cell growth factors and inhaled cigarette smoke can cause chronic irritation 
within  the  airways  which  can  lead  to  epithelial  cells  showing  pseudostratification 
(there  appears  to  be  more  than one  layer  of  cells  when  in  fact there  is  just  one) 
(Barnes, 2008). Mucus hyperplasia and increased mucin expression have been found in 
COPD  patient biopsies  (Caramori  et  al.,  2004). COPD  patient  lungs have  also  been 
shown to have a higher production of elastolytic enzymes such as neutrophil elastase 
and several MMPs. Furthermore a reduction in the levels of antiproteinases such as 
AAT (section 1.1.4.1) has been shown in rare cases of emphysema caused by a genetic 
deficiency (Tuder et al., 2006). Macrophages are derived from circulating monocytes 
which respond to chemoattractants and migrate to the lungs. Macrophages are found 
in high numbers in the lungs of COPD patients and it is believed that they may co-
ordinate  the  inflammation  of  COPD  by  the  release  of  chemokines  that  attract 
monocytes, T cells, proteinases and neutrophils (Figure 1.2). Neutrophils are found in 
increasing numbers in the sputum of COPD patients compared to healthy smokers and 
non-smokers, which has been shown to correlate with disease severity (Keatings et al., 
1996). This neutrophilia is linked to an increase in the production of chemokines such Chapter 1 – Introduction 
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as CXCL1/GROα and IL-8. T helper 1 (Th1) CD4+ T cells are attracted to the lungs by 
CXCR3 ligands such as CXCL0, CXCL10 (also known as IP-10) and CXCL12 (Costa et al., 
2008; Saetta et al., 2002) that are released from interferon-γ (IFN-γ). T helper 2 (Th2) 
cells have also been shown to be significantly higher in the bronchoalveolar lavage 
fluid  of  patients  with  COPD  compared  to  healthy  controls;  p=0.01  (Barczyk  et  al., 
2006). The immunological responses in COPD patients are still not fully understood but 
it has been proposed that immunoglobulins secreted by T cells, and their regulation, 
may  be  activated  by  either  bacterial  or  viral  antigens  from  chronic  bacterial 
colonisation  or  latent  viral  infection  in  the  patient’s  airways.  Further  hypotheses 
suggest that there may be an autoimmune component in COPD in which new antigenic 
epitopes are developed as a result of the tissue damage caused by cigarette smoking, 
oxidative stress or chronic bacterial infection (Agustí et al., 2003).  Chapter 1 – Introduction 
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Figure 1.2: Summary of the inflammatory and immune cells involved in COPD (Barnes, 2008).  Chapter 1 – Introduction 
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Until  recently  the  focus  of  inflammation  and  inflammatory  changes  with  regard  to 
COPD has been in the airways (Sinden and Stockley, 2010). However it is becoming 
more  apparent  that  systemic  inflammation  plays  a  role in the  disease  itself  and  in 
relation to secondary inflammation. 
1.1.2.1  Systemic Inflammation 
The inflammatory response observed in the lungs of COPD patients shows evidence of 
innate  and  acquired  immune  activation  (Cosio  et  al.,  2009).  The  accumulation  of 
inflammatory components in these patients contributes not only to lung damage and 
injury but to further immune activation. Systemic inflammation has been reported in 
patients with COPD, especially those with increasing severity in the stable state and has 
been measured by examining changes in circulating cytokines such as IL-6 and TNF-α 
(Yanbaeva et al., 2007), chemokines including IL-8 and leptin (Takabatake et al., 1999), 
and  other  proteins  such  as  C-reactive  protein (CRP)  (Broekhuizen  et  al.,  2006)  and 
fibrinogen  (Donaldson  et  al.,  2005).  Systemic  inflammation  been  shown  to  be 
associated  with  an  accelerated  decline  in  lung  function  and  is  higher  during  COPD 
exacerbations  (Donaldson  et  al.,  2005).  Smoking  may  be  a  contributor  to  systemic 
inflammation (Fröhlich et al., 2003) and it has been shown that COPD patients have 
greater levels of systemic inflammation compared to healthy controls (Schols et al., 
1996). It is unclear whether the systemic inflammation seen during COPD is due to 
systemic  marker  over-spill  from  the  lungs  or  whether  systemic  inflammation  just Chapter 1 – Introduction 
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reflects  the  generalised  proinflammatory  state  (Barnes  and  Celli,  2009;  Sinden  and 
Stockley, 2010). Furthermore, it has been suggested that systemic inflammation could 
be a result of a comorbid disease which in turn affects the lungs (Sinden and Stockley, 
2010).  
1.1.3  Oxidant/antioxidant imbalance 
Cigarette  smoke  contains  an  estimated  4700  different  chemical  compounds  and 
approximately 10
15-10
17 oxidants such as free radicals, nitric oxide and nitrogen dioxide 
per puff (Church and Pryor, 1985). As well as this, cigarette smoke stimulates tissues in 
the lungs to produce oxidants (Barreiro et al., 2010) and both of these factors lead to 
high levels of oxidants being present resulting in uncontrolled tissue destruction. In the 
body  of  healthy  individuals,  oxidants  that  are  produced  are  counteracted  by 
antioxidants such as glutathione and vitamin C. Antioxidants work as reducing agents 
by reducing the oxidants and therefore removing oxidative stress (MacNee, 2000). It is 
believed  that  an  imbalance  between  oxidants  and  antioxidants  plays  a  role  in  the 
pathogenesis of COPD and that COPD patients have an increased oxidative burden. This 
can lead to many of the pathogenic processes that are associated with COPD including 
increased  inflammation  and  direct  injury  to  the  lung  (MacNee,  2005).  It  has  been 
shown that oxidative stress is higher in the lungs of patients with COPD compared to 
healthy  smoking  subjects  (MacNee, 2000);  this is  not  surprising  as  cigarette  smoke Chapter 1 – Introduction 
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introduces so many oxidants. However, oxidative stress was also found to be higher in 
COPD patients compared to smokers without COPD (MacNee, 2000) suggesting that 
there  are  other  mechanisms  contributing  to  oxidative  stress  in  COPD  patients,  in 
addition to smoke. Chronic airway inflammation is a major secretor of reactive oxygen 
species  (ROS)  as  both  neutrophils  and  macrophages,  which  migrate  in  increased 
numbers into the lungs of COPD patients (Barnes, 2004), can generate ROS via the 
NADPH  oxidase  system  (Rahman  and  MacNee,  1996).  ROS  are  chemically  reactive 
molecules containing oxygen and are a natural by-product of the normal metabolism of 
oxygen (Bayr, 2005). When ROS levels increase dramatically, damage to cell structures 
(oxidative  stress)  can  occur  (MacNee,  2001).  As  the  iron  content  the  alveolar 
macrophages of smokers is higher than in non-smokers (MacNee, 2001) the resultant 
increased free iron in the airspaces of smokers can simulate the stimulation of ROS 
(Thompson  et  al.,  1991).  Oxidants  present  in  cigarette  smoke  can  also  stimulate 
alveolar macrophages to produce ROS and to release mediators that attract immune 
cells such as neutrophils which in turn drive further increases production of ROS. 
1.1.4  Causation  
The predominant aetiological agent of COPD is cigarette smoking with approximately 
one  in  five  smokers  developing  COPD.  However,  exposure  to  other  environmental 
factors  such  as  air  pollutants,  noxious  particles  or  gases,  biomass  fuels,  poverty, Chapter 1 – Introduction 
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nutritional factors and infection have also been found to lead to the development of 
COPD (Anthonisen et al., 2005). Similarly, the use of or exposure to biomass fuels has 
been linked to COPD development particularly in females, occurring more commonly in 
developing  countries  where  this  type of fuel  is  more  readily  used  in the  home for 
cooking and heating where ventilation is often very poor or absent (Liu et al., 2007).  
1.1.4.1 Genetics 
Although  at  least  85%  of  COPD  patients  develop  COPD  from  tobacco  smoking,  a 
significant  minority  of  cases  are  thought  to  be  due  to  other  aetiological  factors 
(Babusyte et al., 2007). More recently, increasing attention has been given to the role 
of genetics in pre-disposing certain individuals to COPD. For example AAT deficiency is 
a well-established, but rare, genetic cause of COPD development with approximately 1-
2% of COPD patients having AAT as the principle factor (DeMeo and Silverman, 2004). 
AAT is a proteinase inhibitor that is coded for by the SERPINA1 gene (Brantly et al., 
1988) found on the proteinase inhibitor locus. It is synthesised by hepatocytes in the 
liver and functions as a serine proteinase inhibitor or serpin that provides essential 
protection  to  the  lung  tissue  against  action  from  proteolytic  enzymes  such  as 
neutrophil elastase, which breaks down elastin in the lungs, and proteinase 3 (PR3) 
(Sinden and Stockley, 2013). The active site of AAT binds to elastase which results in its 
permanent inactivation (DeMeo and Silverman, 2004). Four main AAT phenotypes exist 
in the general population, identified by the differences in speed of the proteins on gel Chapter 1 – Introduction 
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electrophoresis.  These  are  normal  alleles,  deficiency  alleles,  null  alleles  and 
dysfunctional alleles. Those that inherit null alleles have AAT protein levels that are not 
detectable  in  the  serum  which  means  they  are  particularly  at  risk  of  acquiring 
emphysema (Luisetti and Seersholm, 2004). Normal alleles are the most prominent 
phenotype and are found in approximately 95% of the Caucasian population (DeMeo 
and  Silverman,  2004).  Neutrophilia,  frequently  seen  in  the  lungs  of  COPD  patients 
secrete neutrophil elastase resulting in the loss of alveolar structure (Mordwinkin and 
Louie,  2007).  In  healthy  individuals,  AAT  would  bind  to  the  neutrophil  elastase, 
inhibiting  it,  and  therefore  preventing  alveolar  damage  and  degradation.  In  AAT 
deficient subjects, elastase cannot be countered efficiently resulting in the damage of 
lung tissue and the development of emphysema (Abboud et al., 2005). Although the 
role of neutrophil elastase in the pathogenesis of emphysema in AAT subjects is well 
investigated, there may be other proteinases such as PR3 that are also relevant. PR3 is 
found  in  the  azurophil  granules  of  neutrophils  and  has  also  been  shown  to  cause 
emphysema in animal models (Kao et al., 1988). A study by Sinden and Stockley in 2013 
looking at stable COPD patients with either AAT deficiency or with “usual” COPD with 
chronic bronchitis showed that PR3 was detected in most sputum samples and was 
higher than the neutrophil elastase activity in both groups (Sinden and Stockley, 2013). 
It was also found that PR3 levels were significantly higher at exacerbation compared to 
the stable state (p=0.037) suggesting that PR3 may have a role in the pathophysiology 
of COPD in these groups (Sinden and Stockley, 2013).  Chapter 1 – Introduction 
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Genetic susceptibility studies have demonstrated that TNF-α and interleukin-13 (IL-13) 
promoter polymorphisms are significantly associated with the  presence of smoking-
related  COPD.  A  study  involving  non-COPD  long-term  smokers  as  controls 
(FEV1/FVC≥70%) and long-term smokers with COPD (FEV1/FVC<70%) showed that single 
nucleotide polymorphisms encoded by the ADAM33 gene are associated with COPD in 
long-term  smokers  (Sadeghnejad  et  al.,  2009)  suggesting  there  may  be  a  genetic 
mechanism that leads to some long-term smokers developing COPD whereas others do 
not.   
1.1.5  Diagnosis 
The diagnosis of COPD is confirmed clinically based on three factors. Firstly, patients 
must have a history of chronic lower respiratory tract symptoms such as dyspnoea, 
wheeze, cough and sputum production which begin or worsen in middle to later life 
and continue to do so. Secondly there should be a history of sufficient exposure to 
noxious  particles  or  gases.  If  there  is  not,  there  should  be  evidence  of  increased 
susceptibility such as strong family history of COPD or AAT (Patel and Hurst, 2011). 
Thirdly, confirmatory post-bronchodilator spirometry testing is required following a set 
of recommendations defined by GOLD (GOLD Report 2014) (Table 1.1 below). The test 
requires the patient to take a large breath and then breathe out as hard and fast as 
they can into the spirometer. The amount of air the patient exhales in the first second Chapter 1 – Introduction 
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of the breath is called the forced expired volume in one second (FEV1). The forced vital 
capacity  (FVC),  which  quantifies  the  volume  of  expired  air  from  the  lungs,  is  also 
measured. COPD is diagnosed if the FEV1: FVC ratio is <0.7. The joint guidelines set by 
the European Respiratory Society (ERS) and American Thoracic society (ATS) state that 
COPD diagnosis is confirmed if the ratio of FEV1: SVC (slow vital capacity) is within the 
lower limit of detection of the normal distribution, rather than at a fixed value of 0.7 
(Shirtcliffe et al., 2007). In the London COPD cohort, the fixed ratio of 0.7 rather than 
the lower limit of normal is used.  
Table  1.1:  Spirometric  classification  of  COPD  severity  based  on  the  FEV1  from  the  GOLD 
guidelines (GOLD Report 2014). 
Grade/Severity of COPD  Spirometric cut off 
I  Mild  FEV1/FVC < 0.70 
      FEV1 ≥ 80% predicted 
II  Moderate  FEV1/FVC < 0.70 
      50% ≤ FEV1 < 80% predicted 
III  Severe  FEV1/FVC < 0.70 
      30% ≤ FEV1 < 50% predicted 
IV  Very Severe  FEV1/FVC < 0.70 
     
FEV1  <  30%  predicted  or  FEV1  <  50%  predicted  plus 
chronic respiratory failure Chapter 1 – Introduction 
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1.1.6  Epidemiology and Impact 
Currently, COPD is the third most common cause of mortality (Lozano et al., 2012) and 
has a significant impact in terms of both morbidity and mortality. Between 1980 and 
2000, recorded deaths due to COPD rose 14% in men and 185% in women (Pauwels et 
al.,  2001).  Biological  differences  between  men  and  woman  may  account  for  the 
difference in this percentage increase. Women have smaller lungs and larger airways 
than men of comparable size (Mead, 1980). Lung size may be related to decline in lung 
function  and  airway  size  may  influence  smoke  distribution  which  could  mean  a 
mechanical factor is responsible for an increased sensitivity of females to cigarette 
smoke. Alternatively hormonal factors have been suggested to play a role; studies using 
animal models have shown that female rats have a greater increase in both the number 
and size of goblet cells on exposure to cigarette smoke compared to male rats (Hayashi 
et al., 1978). Other factors such as differences in the inflammatory response and airway 
responsiveness have also been suggested as well as the likelihood of women being 
more regularly exposed to biomass fuel in developing countries compared to men (Liu 
et al., 2007). Furthermore, this difference could partly be attributed to the changes in 
the numbers of young women smoking in modern times.  
 
COPD has become a major global health burden resulting in 30, 000 deaths annually in 
the UK alone (Wildman et al., 2007). As the predominant risk factor associated with the Chapter 1 – Introduction 
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development of COPD is  tobacco smoking, it is considerably more cost-effective to 
educate and encourage people to stop smoking, prior to the development of COPD 
rather  than  to  treat  them  clinically  after  COPD  has  been  diagnosed.  However  in 
patients who have stopped smoking therapy is often required to ease symptoms.  
1.1.7  Therapy in stable COPD 
Although  there  is  no  cure  for  COPD,  there  are  a  number  of  therapies  available  to 
alleviate  symptoms  and  improve  disease  indices  including  lung  function  and 
exacerbation  frequency.  The  most  effective  and  successful  treatment  for  COPD  is 
smoking  cessation;  an  aggressive  smoking  intervention  programme  showed  a 
significant reduction in the age-related decline in FEV1 in middle-aged smokers with 
mild airway obstruction (Anthonisen et al., 2002). In 1977 Fletcher and Peto reported 
that smoking cessation in a healthy smoker will make little difference to their FEV1 if 
their lungs are not being dramatically affected by the smoke (Figure 1.3). However in 
patients with airway obstruction, smoking cessation may dramatically reduce the rate 
of FEV1 decline such that the subsequent loss of lung function will slow to the normal 
rate  (Fletcher and Peto, 1977). However whether or not patients continue to smoke, 
some degree of pharmacotherapy is usually required once established COPD is present.  
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Figure 1.3: Risks for various men if they smoke: differences between these lines illustrate the 
effects that smoking, and stopping smoking, can have on FEV1 of men who are liable to 
develop  COPD  if  smoking.  Death,  the  underlying  cause  of  which  is  irreversible  chronic 
obstructive  lung  disease,  whether  the  immediate  cause  of  death  is  respiratory  failure, 
pneumonia,  cor  pulmonate,  or  aggravation  of  other  heart  disease  by  respiratory 
insufficiency. Although this shows rate of loss of FEV1 for one particular susceptible smoker, 
other  susceptible  smokers  will  have  different  rates  of  loss,  thus  reaching  “disability”  at 
different ages (Fletcher and Peto, 1977).   
 
1.1.7.1 Bronchodilators  
Bronchodilators are a common treatment in stable COPD for the relief of symptoms, 
mainly dyspnoea  (Cazzola and Matera, 2014). They are delivered by inhalation and Chapter 1 – Introduction 
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work  by  altering  airway  smooth  muscle  tone.  Widening  of  the  airways  results  in 
improved  expiratory  flow  and  lung  emptying,  reduced  hyperinflation  and  improved 
exercise  performance.  Bronchodilators  are  used  either  as  needed  when  symptoms 
arise (as a ‘reliever’) or regularly to prevent symptoms (as a ‘preventer’). There are two 
main  types  of  bronchodilator,  beta2-agonists  and  anticholinergics  and  their  main 
function is to reduce symptoms and increase exercise tolerance. 
 
a.  Beta2-agonists 
Beta2-agonists  are  the  most  common  class  of  bronchodilator.  Their  main  mode  of 
action is to stimulate airway beta2-adrenergic receptors and increase levels of cyclic 
AMP. This reduces functional antagonism to bronchoconstriction and results in smooth 
muscle relaxation and airway dilation (GOLD Report 2014). Short-acting beta2-agonists 
(SABAs) such as salbutamol and terbutaline have a rapid onset but short duration of 
action  (4-6  hours)  (van  Schayck  et  al.,  1991)  and  are  therefore  usually  taken  as 
relievers.  Long-acting  beta2-agonists  (LABAs)  such  as  salmeterol,  formoterol  and 
indacaterol produce effects after approximately 20 minutes but last for 12-24 hours 
(Decramer  et  al.,  2013),  and  are  therefore  usually  taken  regularly  as  preventers. 
Regular use has been shown to improve FEV1 and symptoms (Skillrud et al., 1986); in 
particular, both formoterol and salmeterol significantly improve FEV1 (Boyd et al., 1997; 
Cazzola et al., 1995), dyspnoea (Ulrik, 1995), quality of life  (Rossi et al., 2002) and 
exacerbation frequency (Rossi et al., 2002). Indacaterol lasts for 24 hours with a larger Chapter 1 – Introduction 
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bronchodilator effect that has been shown to be significantly greater that formoterol or 
salmeterol in terms of health status, exacerbation rate and symptomatic improvements 
(Rossi  and  Polese,  2013).  Side  effects  of  beta2-agonists  include  sinus  tachycardia, 
tremor, hypocalcaemia and rarely tachyphylaxis and occasional hypoxia (Khoukaz and 
Gross, 1999; Polverino et al., 2007; Uren et al., 1993).  
 
b.  Anticholinergics 
Anticholinergics  are  muscarinic  antagonists,  another  type  of  bronchodilator,  which 
work by blocking the effect of acetylcholine on muscarinic receptors and therefore 
preventing bronchial  constriction  (Cazzola  et  al.,  2013).  The  short-acting  muscarinic 
antagonist  (SAMA)  ipratropium,  targets  M2  and  M3  receptors  and  modifies  signal 
transmission at the pre-ganglionic junction. Like SABAs, it can be inhaled or nebulised 
and has a rapid onset of action (15 minutes) suitable for use as reliever therapy, lasting 
up to 6 hours. Long-acting muscarinic antagonists (LAMA) such as tiotropium block M1 
and M3 receptors (Disse et al., 1999) and the long duration of action over 24 hours 
allows use as a once-daily preventer (van Noord et al., 2000). New long-acting LAMAs 
are mainly M3 receptor blockers with less M1 and minimal M2 activity. Tiotropium has 
been shown to reduce exacerbations and related hospitalisations (Tashkin et al., 2008), 
improve symptoms (Vincken et al., 2002), health status (Casaburi et al., 2002) and the 
effectiveness  of  pulmonary  rehabilitation  (Tashkin  et  al.,  2008).  Side  effects  of 
anticholinergics include dryness of the mouth and glaucoma. A 2010 meta-analysis of Chapter 1 – Introduction 
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safety data from large published trials (Llor et al., 2012) raised concerns regarding an 
excess of cardiovascular mortality using the Respimat, a soft-mist tiotropium delivery 
device, in patients with a history of arrhythmia. However, a large and well-conducted 
trial,  involving  17,135  patients  and  adequately  powered  to  detect  differences  in 
mortality between tiotropium dose and delivery methods, has recently found this not 
to be the case (Wise et al., 2013).  
1.1.7.2  Inhaled corticosteroids (ICS) 
ICS are the most effective anti-inflammatory therapy for many chronic inflammatory 
diseases  such  as  asthma;  however  the  long-term  effect  of  ICS  in  COPD  is  limited 
(Barnes,  2006).  Regular  treatment  has  been  shown  to  improve  symptoms,  lung 
function, quality of life and reduce exacerbation frequency (Spencer et al., 2004) in 
patients with an FEV1 <60% predicted. In asthma the efficacy and side effects of the 
drugs are dependent on the dose but this is not necessarily the case for COPD patients 
(Bateman  et  al., 2008).  Side effects of  ICS  are  mainly  local  and  include  oral  fungal 
infections.  The TORCH trial first highlighted an increased rate of pneumonia in COPD 
patients  taking  ICS  compared  to  those  on  alternative  treatments  (Calverley  et  al., 
2011). This finding has been subsequently confirmed in the inspire study (Wedzicha et 
al.,  2008),  and  appears  to  be  dose-dependent  (Suissa  et  al.,  2013).  Garcha  and 
colleagues showed that higher ICS dose was significantly correlated to higher airway 
bacterial load in the stable state (Garcha et al., 2012). The risk-benefit ratio of ICS in Chapter 1 – Introduction 
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COPD  is  therefore  not  as  clear-cut  as  previously  thought,  although  they  remain 
important treatments in COPD.   
1.1.7.3  Combination therapy 
The combination of ICS and long-acting bronchodilator therapy (beta2-agonist), usually 
in  a  single  inhaler  (e.g.  fluticasone  &  salmeterol,  budesonide  &  formoterol, 
beclomethasone & formoterol) has been shown to be more effective in improving lung 
function and health status than either treatment given individually (Wedzicha et al., 
2013). Combination therapy is also associated with reducing exacerbations in moderate 
and severe COPD patients (Wedzicha et al., 2013); however, as stated previously, there 
is  an  increase  in  pneumonia  (Crim  et  al.,  2009).  The  addition  of  tiotropium to  the 
combination  therapy  improves  quality  of  life,  lung  function  and  may  reduce 
exacerbations  however  more  studies  into  triple  therapy  are  required  (Perng  et  al., 
2006).  
1.1.7.4 Vaccinations 
Vaccines that contain killed or live inactive  pathogens are most effective in elderly 
COPD patients. Influenza vaccinations can reduce lower respiratory tract  infections, 
hospitalisation and death (Nichol et al., 1994; Wongsurakiat et al., 2003). The vaccine is 
adjusted yearly to ensure appropriate protection against the most prevalent influenza Chapter 1 – Introduction 
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strains at that time, and the vaccine should be given yearly (Woodhead et al., 2005). 
Influenza vaccination has been shown to reduce the incidence of community acquired 
pneumonia in elderly patients with severe COPD (Alfageme et al., 2006). The incidence 
of  pneumococcal  infections  is  highest  at  the  extremes  of  age,  and  therefore 
pneumococcal polysaccharide vaccine is separately recommended for all COPD patients 
over 65 years of age and other patients with co-morbidities such as cardiac disease 
(Jackson et al., 2003).  
1.1.8  Comorbidities 
COPD  has  many  comorbidities  associated  with  it  which  can  lead  to  exacerbations, 
hospital  admissions,  more  intense  symptoms  and  even  mortality  (Patel  and  Hurst, 
2011).  The  most  common  comorbidities  include  psychological  conditions, 
musculoskeletal and cardiovascular problems and COPD patients are more likely to die 
from a comorbid disease than from COPD itself (Patel and Hurst, 2011). In a large, 
randomised control trial of inhaled combined fluticasone/salmeterol in 2007, causes of 
death were recorded. All 6184 patients had an FEV1 of <60% and well characterised 
COPD. Of the 911 deaths, only 40% were definitely or probably related to COPD with 
50% unrelated to COPD and 9% unknown (McGarvey et al., 2007). This illustrates the 
importance of comorbidities in COPD and that the appropriate management of them 
may have large mortality benefits. Some comorbidities occur coincidentally due to their Chapter 1 – Introduction 
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occurrence  in  later  life  such  as  osteoporosis  and  Alzheimer’s  disease.  Others  have 
shared risk factors such as smoking but have not been shown to be any more common 
in patients with COPD such as oral and laryngeal cancers and smoking-related bladder 
cancer. However there are many-comorbidities that have increased incidence when 
shared risk factors are accounted for. These include cardiovascular disease such as 
congestive  heart  failure,  myocardial  infarction,  stroke  (Donaldson  et  al.,  2010)  and 
ischemic heart disease (Patel et al., 2012). Similarly, gastro-oesophageal reflux disease 
(García Rodríguez et al., 2008), depression and anxiety (Quint et al., 2008), skeletal 
muscle dysfunction (Swallow et al., 2007) and diabetes (Areias et al., 2014) have all 
been shown to be related to COPD. Table 1.2 below shows the prevalence of individual 
comorbidities. 
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Comorbidity   Prevalence in COPD (%) 
Osteoporosis/osteopenia  50-70 
Hypertension  40-60 
Gastro-oesophageal reflux disease  30-60 
Skeletal muscle dysfunction  32 
Depression  25 
Ischemic heart disease  10-23 
Previous myocardial infarction  4-32 
Anaemia  17 
Diabetes  12-13 
Previous stroke  10-14 
Arrhythmia  6-14 
Chronic renal failure  6-11 
Congestive heart failure  5-7 
Obstructive sleep apnoea  1-4 
Table 1.2: The prevalence of comorbidities in COPD (Patel and Hurst, 2011).  
 
The  majority  of  COPD patients  have  at  least one  important  comorbidity  and these 
extra-pulmonary comorbidities, which often have pathophysiological links, can have a Chapter 1 – Introduction 
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large impact on morbidity and mortality, increased risk of hospitalisation and greater 
healthcare costs (Patel and Hurst, 2011).  
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1.2  Acute Exacerbation of COPD 
1.2.1  Exacerbations 
COPD  patients  can  suffer  episodes  of  acute  worsening  of  respiratory  symptoms 
associated  with  variable  degrees  of  physiological  deterioration  known  as  acute 
exacerbations of COPD (AE-COPD). An exacerbation is defined in the GOLD guidelines 
as “an event in the natural course of the disease characterised by a change in the 
patient’s baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day 
variations, is acute in onset, and may warrant a change in regular medication  in a 
patient  with  underlying  COPD”  (GOLD  Report 2014).  In  practice  and in  the  London 
COPD cohort, an exacerbation is defined as a worsening of two or more symptoms for 
two or more consecutive days with at least one symptom being a major symptom. 
Major symptoms  are dyspnoea, increased sputum purulence and increased sputum 
volume and the minor symptoms are cough, wheeze, sore throat and cold symptoms. 
The impact of an exacerbation may take a patient several weeks to return to the stable 
state  and  can  lead  to  irreversible  deterioration  of  lung  function  (Seemungal  et  al., 
2000).  Chapter 1 – Introduction 
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1.2.2  Frequent and non-frequent exacerbators 
The impact of COPD varies from patient to patient including how frequently a patient 
suffers from an exacerbation. If a patient in the London COPD cohort has less than two 
exacerbations  per  year,  they  are  defined  as  an  infrequent  exacerbator  using  the 
London COPD cohort definition. If, however, they suffer two or more exacerbations per 
year, they are considered a frequent exacerbator. Frequent exacerbators experience a 
poorer quality of life (Seemungal et al., 1998), greater airway inflammation (Bhowmik 
et al., 2000) and faster lung decline (Donaldson et al., 2002) compared to infrequent 
exacerbators. A study by Hurst and colleagues from the ECLIPSE observational study in 
2010 tested the hypothesis that there is a frequent exacerbator phenotype of COPD in 
2138  patients  with  COPD.  The  study  reported  that  exacerbations  become  more 
frequent and more severe as the severity of COPD increases; exacerbation rates for 
patients  with  moderate  disease  (GOLD  stage  2)  were  0.85  per  person  per  year 
compared to 1.34 in those with severe disease (GOLD stage 3) and 2.00 with very 
severe disease (GOLD stage 4) (Hurst et al., 2010). They also reported that the major 
determinant  of  frequent  exacerbations  in  all  GOLD  stages  of  COPD  severity  was  a 
history of exacerbations and that the frequent exacerbator phenotype can be identified 
on  the  basis  of  a  history  of  exacerbations.  Among  patients  who  had  frequent 
exacerbations in year 1 and 2, 71% went on to have frequent exacerbations in year 3 Chapter 1 – Introduction 
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whereas  74%  of  patients  who  had  no  exacerbations  in  year  1  and  2  also  had  no 
exacerbations in year 3 (Hurst et al., 2010).  
1.2.3  Treatment for exacerbations  
The three classes of medication most commonly used for acute exacerbations of COPD 
are  antibiotics,  oral  steroids  and  bronchodilators,  singly  or  in  combination.  Viral 
infection is often indicated by the presence of cold symptoms whereas increases in 
sputum volume or purulence suggest bacterial overgrowth and a possible benefit from 
antibiotic therapy (Anthonisen et al., 1987).  
1.2.3.1  Antibiotics  
Although the infectious agents involved in COPD exacerbations can be viral or bacterial, 
evidence underlying the use of antibiotics for exacerbations in incomplete. There is 
strong  evidence  supporting  the  use  of  antibiotics  in  severe  exacerbations  requiring 
hospitalisation  (Vollenweider et  al.,  2012)  or  when  patients  have  clinical  signs  of a 
bacterial  infection  such  as  increase  in  sputum  purulence  (Stockley  et  al.,  2000).  In 
addition, antibiotics have been shown to reduce the risk of short-term mortality in 
moderate or severe COPD patients with  typical exacerbation symptoms (Llor et al., 
2012). A typical treatment course of antibiotics for COPD exacerbations is 7-10 days 
with a second course given if symptoms do not improve (GOLD Report 2014). Antibiotic Chapter 1 – Introduction 
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selection should be tailored according to patient tolerance and the airway pathogens 
that  are  likely  to  be  prevalent.  Antibiotic  classes  have  good  activity  against  the 
spectrum of bacteria usually found in the airway include β-lactams, fluroquinolones, 
macrolides and tetracyclines. The most commonly prescribed antibiotics in the London 
COPD  cohort  are  amoxicillin  and  co-amoxiclav  (combination  of  amoxicillin  and 
clavulanic  acid)  which  inhibit  synthesis  of  the  peptidoglycan  cell  wall  in  replicating 
bacteria  (Tomasz,  1979).  Macrolide  antibiotics  such  as  erythromycin,  clarithromycin 
and  azithromycin  are  important  as  they  have  also  been  shown  to  have  anti-
inflammatory properties in addition to their anti-bacterial properties, such as reducing 
IL-8 production and neutrophil migration and/or function (Cameron et al., 2012). This 
has  led  to  a  renewed  interest  in  using  macrolides  prophylactically  to  reduce 
exacerbation frequency, and there is a growing body of evidence for this (Albert et al., 
2011;  Seemungal  et  al.,  2008).  There  are  concerns,  however,  regarding  a  possible 
increase in cardiovascular events (Ray et al., 2012), hearing loss (Albert et al., 2011) and 
the  induction  of  bacterial  resistance  (Serisier,  2013).  At  present  therefore,  routine 
usage of prophylactic antibiotics is not recommended.  
1.2.3.2 Oral corticosteroids 
Oral corticosteroids in COPD exacerbations have been shown to shorten recovery time, 
improve lung function, reduce the risk of recurrent exacerbation and reduce the length 
of hospital stay (Davies et al., 1999; Maltais et al., 2002). There is insufficient data to Chapter 1 – Introduction 
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confirm the optimal duration of oral corticosteroid treatment at COPD exacerbation 
but 7-10 days is usual in clinical practice (Walters et al., 2005). Short-term side effects 
of oral corticosteroids include mood changes, increased appetite and impaired diabetic 
control. Longer-term side effects, which usually only occur if the duration of therapy 
extents into months or patients are prescribed repeated short courses, include adrenal 
insufficiency,  peripheral  muscle  weakness,  glucose  intolerance,  osteoporosis,  easy 
bruising and weight gain.  
 
In  a  study  comparing  groups  of  patients  given  either  budesonide,  prednisolone  or 
placebo  to  treat  acute  exacerbations  of  COPD,  it  was  found  that  budesonide  and 
prednisolone significantly improved FEV1 compared to the placebo group but there was 
no difference between the two treatment groups (Maltais et al., 2002). However a 
significant number of subjects given prednisolone became hyperglycaemic (Maltais et 
al., 2002). Short courses of oral steroids are generally well tolerated however, and 
remain one of the mainstays of  treatment for COPD exacerbation. A study in 2013 
showed how short courses of oral steroids for example 5 days, can be as efficient as 
longer courses for most COPD exacerbations (Sin and Park, 2013). 
1.2.3.3 Bronchodilators  
Patients may increase their bronchodilator therapy (also known as reliever medication) 
during  COPD  exacerbation,  and  higher doses may  be  administered  by  nebulisation. Chapter 1 – Introduction 
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SABAs with or without SAMAs are usually the preferred bronchodilators for treatment 
of  symptoms  of  exacerbations  (GOLD  Report  2014)  in  the  form  of  salbutamol  in 
response  to  increased  symptoms  such  as  breathlessness,  cough,  wheeze,  chest 
tightness.  
1.2.4  Micro-organisms and COPD exacerbations  
Respiratory  illnesses  can  develop  in  the  upper  and  lower  respiratory  tract  and  are 
predominantly due to infection by bacteria, viruses or fungi. In healthy individuals, 
these infections are naturally resolved by the immune system leading to a controlled 
inflammatory  response.  In  COPD  patients  however,  infections  can  result  in  an 
exaggerated increase in inflammation on an already inflamed COPD airway, causing 
greater inflammation which may lead to an exacerbation (Wedzicha and Seemungal, 
2007)  (Figure  1.4).  Evidence  suggests  that  50-70%  of  COPD  exacerbations  have  an 
infectious aetiology (Sapey and Stockley, 2006) with viruses being a key trigger. A study 
by Papi and colleagues found that 78% of patients with severe exacerbations requiring 
hospitalisation were positive for a viral and/or a bacterial infection; 48.4% positive for a 
virus and 54.7% for bacteria compared to those in the stable state where only 6.2% 
were positive for a virus and 37.5% for bacteria (Papi et al., 2006).  
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Figure 1.4: Triggers of COPD exacerbations and the vicious circle hypothesis in COPD adapted 
from Sethi and Murphy, 2001; Wedzicha and Seemungal, 2007. Chapter 1 – Introduction 
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1.2.4.1 Viruses at COPD exacerbation 
As  previously  discussed,  exacerbations  of  COPD  are  associated  with  airway  and 
systemic inflammation that can be triggered by aetiological factors such as bacterial or 
viral infection. Bacterial infections are considered to be a significant cause of COPD 
exacerbations  (Garcha  et  al.,  2012)  which  is  highlighted  by  the  large  scale  use  of 
antibiotics given at exacerbation. Their exact role remains contentious as bacteria are 
only found in approximately half of exacerbations but are also found in patients who 
are  stable  (Mallia  and  Johnston,  2006).  There  has  been  increasing  evidence  that 
respiratory  viruses  cause  COPD  exacerbations;  the  prevalence  of  viruses  has  been 
shown to be higher at exacerbation compared to in the stable state with a respiratory 
virus being detected in 48% of exacerbations (Papi et al., 2006).  
 
An  association  between  the  presence  of  respiratory  viruses  and  greater  airway 
inflammation has been reported (Wilkinson et al., 2006), and epidemiological data has 
shown that many patients report cold symptoms during their exacerbations (Hurst et 
al., 2005; Jenkins et al., 2012). Viral infections are associated with increased severity 
and  frequency  of  COPD  exacerbations  (Seemungal  et  al.,  2000)  and  virus-induced 
exacerbations  appear  to  peak  during  the  winter  months.  This  coincides  with  the 
increased  prevalence  of  respiratory  viral  infection  in  the  community  and  is  also 
reflected  in  the  increased  utilisation  of  hospitals  during  winter  (Donaldson  and 
Wedzicha,  2006).  In  2003  two  studies  reported  a  higher  prevalence  of  respiratory Chapter 1 – Introduction 
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viruses in sputum and nasal lavage of COPD patients at exacerbation compared to in 
the stable state; 56% vs. 19%, p<0.01 (Rohde et al., 2003) and 64% vs. 7% (Tan et al., 
2003). This evidence together suggests that respiratory viral infection may be as, if not 
more, important than bacterial infection in triggering COPD exacerbations (Seemungal 
et al., 2001).   
 
Earlier studies carried out in the 1970s and 1980s investigating the role of viruses in 
COPD exacerbations detected viruses in only 10% to 20% of exacerbations (Smith et al., 
1980). The diagnostic tools used in these studies were less advanced than that of today 
and  had  low  sensitivity,  especially  in  the  case  of  human  rhinovirus  (HRV).  The 
development of modern molecular tests such as polymerase chain reaction (PCR) in 
1983, has allowed further detection of viruses at more sensitive levels, allowing their 
association with COPD exacerbations to be more accurately defined (McManus et al., 
2008).  A  study  by  Perotin  and  colleagues  detected  viruses  in  44%  of  exacerbation 
samples using PCR techniques but in only 7% when using classical viral culture assays 
(Perotin et al., 2013). Viral infections are associated with more severe exacerbations in 
terms  of  a  greater  burden of  symptoms  which  result  in  longer recovery  times  and 
greater likelihood of hospitalisation (Seemungal et al., 2000).  
 
Although viruses have been detected in >50% of exacerbations, this number depends 
greatly on the technique used for detection. A study by Seemungal and colleagues in Chapter 1 – Introduction 
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2001 using nasal samples and quantitative PCR (qPCR) showed that 39% of all reported 
exacerbations were associated with viruses. Of these 66 detected viral exacerbations, 
39 (59.0%) were associated with HRV, 17 (25.8%) with respiratory syncytial virus (RSV),  
7 (4.2%) with coronavirus and 26 (3.0%) with influenza B (Seemungal et al., 2001). Of 
the 83 patients, 53 (64%) had at least one respiratory virus detected at exacerbation 
and these patients overall had higher exacerbation frequencies. Viral exacerbations 
were associated with increased dyspnoea and colds along with a median symptom 
recovery time of 13 days, longer than the typical 6 day recovery time seen in non-viral 
associated  exacerbations  (GOLD  Report  2014).  A  separate  study  by  Greenberg  and 
colleagues, using serological and viral culture, showed that 23% of hospitalised COPD 
patients were infected with a virus and that the mean time to return to symptomatic 
baseline was 2 weeks (Greenberg et al., 2000). This result, which detects viral infection 
at a lower prevalence compared to other studies, strengthens the idea that viral culture 
does not detect the prevalence of viruses as efficiently or accurately as qPCR. It may 
suggest that the viral load in samples taken from exacerbating patients after admission 
to hospital may have decreased considerably by the time the sample is taken. Patients 
who are hospitalised will have often developed the viral infection a number of days 
before they are admitted to hospital so taking an “exacerbation presentation” sample 
after admission, may be an unfair representation of peak viral load as this may have 
occurred a number of days before the infection began.  Chapter 1 – Introduction 
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1.2.4.2 Mechanism of viral infection in COPD 
As  mentioned  previously  (section  1.1.2),  COPD  is  associated  with  proinflammatory 
cytokines and neutrophil chemokines such as TNF-α, IL-8, GRO-α and leukotriene B4 
(LTB4). At exacerbation, inflammatory mediators are increased leading to exaggerated 
airway inflammation compared to patients in the stable state (Mallia and Johnston, 
2006). Exacerbations are associated with the activation of NF-κβ in macrophages in 
sputum samples (Caramori et al., 2003) and it has been demonstrated, in vitro, that 
HRV  infection  can  cause  NF-κβ  activation  (Papi  and  Johnston,  1999).  This  is  one 
potential  mechanism  in  which  respiratory  viruses  can  up-regulate  proinflammatory 
mediators in the airways leading to heightened inflammation. These mediators which 
have a chemotactic effect on neutrophils (IL-8, ENA-78 and LTB4), lymphocytes and 
monocytes (RANTES), and the up-regulation of adhesion molecules (TNF-α) may be key 
elements in the increased inflammation that occurs during a COPD exacerbation (Figure 
1.5).  
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Figure 1.5: Mechanisms  of virus-induced COPD exacerbations.  Viral infection of epithelial 
cells leads to the release of proinflammatory cytokines and chemokines. Chemokines attract 
inflammatory cells that release toxic products, stimulating mucus production and leading to 
tissue  damage  with  possible  long-term  loss  of  lung  function.  Some  mediators  such  as 
endothelin-1  have  a  direct  effect  in  causing  bronchoconstriction  and  vasoconstriction, 
resulting in airflow obstruction and impaired gas exchange (Mallia and Johnston, 2006). 
 
After an initial viral infection, cytokines are released by airway epithelial cells leading to 
an influx of inflammatory cells (Mallia and Johnston, 2006). The inflammatory cells 
release products such as neutrophil elastase and reactive oxygen species (as described 
in section 1.1.3). This in turn leads to tissue damage, increased mucus production and 
further cytokine release (Mallia and Johnston, 2006). Interestingly, some studies have 
reported increases in inflammatory cell counts at  exacerbation compared to in the Chapter 1 – Introduction 
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stable state (Hurst et al., 2006; Mercer et al., 2005) where-as others have reported no 
differences (Bhowmik et al., 2000). A study by Hurst and colleagues in 2006 found a 
significant  increase  in  total  leukocyte  sputum  count  at  exacerbation  (6.47  log10 
cells/ml) compared to the stable state (5.86 log10 cells/ml) (p<0.001) and also in nasal 
wash samples (p=0.043) (Hurst et al., 2006). Other studies have reported increased 
neutrophil, eosinophils and lymphocyte counts from the stable state to exacerbation 
(all p<0.05) (Mercer et al., 2005). One study by Papi and colleagues reported that levels 
of  sputum  neutrophils  were  increased  during exacerbation  compared  to  the  stable 
state,  regardless  of  aetiology,  however  the  eosinophil  count  was  only  increased  in 
patients  found  to  have  a  viral  infection  (Papi  et  al.,  2006).  The  variability  and 
differences in the results found between these studies indicates the need for further 
study in carefully selected populations to determine exacerbation aetiology.  
1.2.4.3 Human rhinovirus infection 
There  are  a  number  of  viruses  that  have  been  detected  at  exacerbation  including 
coronavirus, RSV, influenza, parainfluenza and adenovirus, however, it has been shown 
that the most commonly detected virus is HRV (Seemungal et al., 2001a). HRV has been 
identified in up to 60% of virus-associated exacerbations (“GOLD Report 2014,” n.d.). 
Figure 1.6 adapted from work by Seemungal and colleagues illustrates HRV as the most 
prevalent virus at exacerbation highlighting the importance of it as an exacerbation 
trigger.  Chapter 1 – Introduction 
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Figure  1.6:  A  breakdown  of  the  respiratory  viruses  detected  at  COPD  exacerbation 
(Seemungal et al., 2001) 
 
HRV  is  one  of  the  major  groups  of  viruses  that  cause  the  common  cold  in  the 
population worldwide. It belongs to the Picornaviridae family of which there are >100 
serotypes (Flint et al., 2000). It is a small, non-enveloped icosahedral particle of 24-30 
nm in size (Greenberg, 2003). The HRV virion contains a viral capsid which originates 
from  a  single  polyprotein  which  is  translated  from  the  viral  RNA  genome  and  is 
proteolytically cleaved in the host cells. The capsid forms four virus-encoded proteins; 
VP1, VP2, VP3 and VP4. VP1 – 3 are found on the surface of the capsid whereas VP4 is 
found internally within the virus and is responsible for anchoring the viral RNA to the Chapter 1 – Introduction 
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centre of the capsid. Immunity to HRV is serotype-specific due to the variations in the 
VP1 – 3 surface proteins which leads to antigenic diversity and therefore limits the 
production  of  an  effective  vaccine  (Flint  et  al.,  2000).  The  capsid  contains  a  single 
strand  of  positive  sense  RNA  of  approximately  7  kilobases  in  length  which  wraps 
around the viral genome. It is built from 60 subunits arranged as 12 pentamers. Each 
subunit contains the four capsid proteins in an identical arrangement. The capsids of 
HRV have deep canyons surrounding the 12 fivefold axes of symmetry in the pentamers 
and these canyons are the site of interaction with the cell surface receptor, ICAM-1 
(Figure  1.7).  The  binding  site  on  the  capsid  for  the  low-density  lipoprotein  (LDL) 
receptor is located on the star-shaped plateau at the fivefold axis of symmetry (Flint, 
2004). The HRV virion attaches to the nasal or bronchial epithelium by one of these two 
epithelial receptors depending on whether the HRV serotype is part of the major or 
minor  group.  Over  90%  of  HRV  serotypes  belong  to  the  major  group  and  these 
serotypes bind with ICAM-1 on the epithelial cell surface whereas the minor group HRV 
serotypes bind with LDL receptors (Flint et al., 2000; Flint, 2004). Infection occurs when 
HRV successfully binds to the cell membrane via one of these two receptors. It then 
uncoats itself allowing the viral RNA to enter into the cell cytoplasm which is where the 
synthesis of virions occurs (Flint, 2004). Once in the cell, the viral RNA attaches to the 
host cell machinery and uses it to translate and synthesise the viral polyprotein and to 
replicate  the  viral  RNA (Flint,  2004).  Replication  occurs using two,  partially  double-
stranded RNAs called the replicative intermediates (RIs). Both the sense RNA strand Chapter 1 – Introduction 
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and  antisense  RNA  strand  are  used  as  a  templates  while  the  viral  polyprotein  is 
translated from the viral genome and undergoes multiple proteolytic cleavage to form 
both structural (VP1- VP4) and non-structural proteins. The four capsid proteins are 
then packaged with viral RNA to form the mature virion which is released out of the cell 
by cell lysis (Flint, 2004). The synthesis of RNA can be detected within 6-8 hours after 
the  initial  infection  and  within  48-72  hours,  the  production  of  viral  RNA  and  viral 
particles, peaks (Flint, 2004).  
 
 
Figure 1.7: Transverse section through the centre of a pentamer depicting entry of its cellular 
receptor, ICAM-1 (Friedlander and Busse, 2005).  
 
HRV is spread via direct contact and by aerosols (Monto, 2002) and can occur in all 
human populations, however it appears to cause more significant morbidity in those Chapter 1 – Introduction 
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who are immunocompromised, elderly or very young (Hicks et al., 2006; Monto et al., 
1987). In the majority of the healthy population, HRV infection leads to a self-limiting 
illness that usually resolves by itself without any form of medical attention (Monto, 
2002).  Both  upper  and  lower  respiratory  symptoms  can  be  experienced  with  HRV 
infection including rhinitis, rhinorrhoea, sore throat, cough, sputum production and 
wheeze. Headaches, tiredness and fever are often present also (Monto et al., 2001). A 
number  of  studies  have  shown  that  HRV  infection  plays  an  important  role  in  the 
respiratory tract of the elderly and contributes significantly to morbidity and mortality 
in this population (Hicks et al., 2006; Louie et al., 2005). 
 
The respiratory conducting airways are divided into upper and lower airways at the 
levels of the larynx. Most HRV serotypes have an optimal growth temperature of 33°C 
which is the temperature of the nasal epithelium (Papadopoulos et al., 2000). A key 
issue regarding the role of viruses in the onset of exacerbations was whether upper 
respiratory viruses such as HRV could infect the lower airway as well as the upper. For 
many years it was thought that they could not due to the evidence suggesting the 
optimal temperature for HRV replication or growth was 33°C (Papadopoulos et al., 
1999). However Papadopoulous and colleges showed that HRV can replicate in the 
lower airway by using in situ hybridisation to exclude any sample contamination from 
the  upper  airway.  They  concluded  that  although  most  HRV  serotypes  replicate 
optimally at 33°C, the higher temperature of the lower airways is not a preventative Chapter 1 – Introduction 
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factor for their replication, and some strains may even prefer it (Papadopoulos et al., 
1999).  Other  studies  have  shown  positive  detection  of  HRV  using  sputum  samples 
suggesting  that  HRV  can  infect  the  lower  airway  as  well  as  the  upper.  A  study  by 
Seemungal and colleagues in 2000 showed the prevalence of HRV to be 40% higher in 
induced sputum samples than in nasopharyngeal samples by PCR (Seemungal et al., 
2000). Similarly, a study by Gern and colleagues in which subjects were experimentally 
infected with HRV found that before inoculation, none of the 23 lower airway samples 
were found to be positive for HRV, however after inoculation 80% of samples were 
positive (Gern et al., 1997). This evidence suggests lower airway infection by HRV is 
likely and therefore may contribute to virus-induced exacerbations of COPD.  
 
Further data in support of HRV causing COPD exacerbations comes from a study by 
Mallia  and  colleagues  in  2011  in  which  mild  COPD  patients  were  experimentally 
infected  with  HRV  (Mallia  et  al.,  2011).  The  study  investigated  the  time-course  of 
experimental HRV infection as a model of COPD exacerbations using 13 mild COPD 
subjects and 13 control subjects in which low-dose HRV was diluted and inoculated into 
both nostrils. The study measured changes in upper and lower respiratory symptoms, 
lung  function,  inflammatory  markers  in  the  blood  and  sputum,  BAL  and  blood  cell 
counts and HRV load in sputum and nasal lavage. It was found that upper respiratory 
tract symptom scores were significantly higher than baseline in both groups and that 
on  days  13-16  post-inoculation  scores  were  significantly  higher  in  COPD  patients Chapter 1 – Introduction 
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compared  to  controls.  Between  days  11  and  35  post-inoculation,  lower  respiratory 
tract symptoms were significantly greater in the COPD group compared with control 
subjects. IL-6 levels in BAL significantly increased from baseline in COPD subjects but 
not in controls and there was a significant increase in BAL lymphocyte percentage from 
baseline  in  COPD  subjects  but  not  controls.  Sputum  neutrophil  levels  increased 
significantly from baseline in COPD subjects but not controls and were found to be 
significantly  higher  in  COPD  patients  compared  to  controls.  IL-8  levels  increased 
significantly  from  baseline  in  COPD  subjects  but  no  significant  change  was  seen  in 
control subjects.  
 
HRV load was determined by qPCR techniques in induced sputum samples and in nasal 
lavage. HRV load in nasal lavage samples increased rapidly 48 hours after inoculation in 
both COPD and control subjects. However between Days 3-15, nasal lavage HRV load 
was higher in COPD subjects than controls and this was significant on Day 6. Sputum 
HRV load was higher in COPD patients compared to controls on Days 5 and 9 with the 
load peaking on Day 5. The HRV load remained significantly higher in the COPD subjects 
compared to controls, up until Day 15 (Figure 1.8).  
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Figure 1.8: The time-course of experimental HRV load measured by  qPCR at inoculation, 
exacerbation and during recovery in patients with COPD vs control subjects (Mallia et al., 
2011).  
 
This study shows that experimentally infecting COPD patients with HRV induces upper 
and lower respiratory tract symptoms, airflow obstruction, neutrophilic inflammation 
and an increase in inflammatory markers. This experimental work supports previous 
evidence for the role of HRV in triggering exacerbations (Mallia et al., 2011) however 
was limited to using mild COPD patients, infected with a low dose of virus.   
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Measuring the changes of HRV prevalence and load during the time-course of natural 
exacerbation and recovery has not yet been investigated, but is an important area to 
study to allow our knowledge of HRV infection in COPD to expand.  
1.2.4.4 Respiratory Syncytial Virus  
The work by Seemungal and colleagues in 2001 (Figure 1.6) showed HRV to be the most 
commonly detected virus at COPD exacerbation, however RSV was the second most 
commonly detected virus at exacerbation with 25.8% of viruses being RSV (Seemungal 
et al., 2001a). RSV contains a negative-sense, single-stranded RNA, and is an enveloped 
virus  of  the  Paramyxoviridae  family  which  has  previously  been  recognised  as  a 
paediatric  pathogen  (Henderson,  1987).  More  recently  however,  RSV  has  become 
recognised as an important adult pathogen (Dowell et al., 1996) especially in older 
patients  (Griffin  et  al.,  2002),  those  who  are  immunocompromised  (Englund  et  al., 
1988) and in COPD patients (Falsey, 2005). In certain high-risk populations, RSV has 
been found to have a similar health burden as influenza and in the United States, 
around 10,000 deaths in over 65s are attributed to RSV infection each year (Thompson 
et al., 2003). As discussed in reference to HRV, the development of PCR techniques has 
allowed re-evaluation of the contribution of viruses such as RSV in diseases such as 
COPD. Previous methods of RSV detection using culture techniques were particularly 
difficult with RSV due to its thermolability (Falsey, 2007). ELISA techniques were found 
to be faster than culture however the low sensitivity and specificity of these methods Chapter 1 – Introduction 
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led to inaccurate results especially in subjects with low RSV loads (Falsey et al., 1996). 
Techniques  such  as  PCR  are  only  useful  if  they  follow  sound  methods  of  sample 
collection; for RSV infection it seems that sputum is more sensitive than using nasal 
samples (Falsey, 2005).  
 
Epithelial cells lining the airway are often the first cells to be targeted for viral infection 
and replication  (Becker et al., 1992). Following an RSV infection via the respiratory 
epithelium,  these  cells  produce  increased  levels  of  inflammatory  and 
immunomodulatory  molecules  such  as  IFN-β  and  IL-1α  (Garofalo  et  al.,  1996),  IL-8 
(Noah  and  Becker,  1993),  IL-11  (Elias  et  al.,  1994),  IL-6  and  TNF-α  (Garofalo  and 
Haeberle, 2000), and ICAM-1 (Stark et al., 1996) which are important in pulmonary 
defence. The production of these inflammatory and modulatory molecules is one in 
which  epithelial  cells  contribute  to  cytokine  generation,  induction  of  the  host  cell 
antiviral  state  and  leukocyte  recruitment  and  activation.  It  may  be  due  to  the 
production of these molecules that RSV has been shown to be implicated as a cause of 
acute exacerbations of COPD (Ramaswamy et al., 2009). Figure 1.9 illustrates potential 
differences  in  the  pulmonary  defence  against  RSV  in  COPD  patients  compared  to 
normal controls (Ramaswamy et al., 2009). 
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Figure 1.9: Potential differences in pulmonary defence against RSV in COPD patients. Factors 
that include age, environmental exposures, genetics, COPD itself (e.g. bacterial colonisation, 
chronic inflammation), or a combination of these may alter the host response to RSV thereby 
increasing  susceptibility  to  or  severity  of  infection.  Altered  defence  responses  include 
antiviral innate and adaptive, as well as inflammation that may lead to COPD exacerbation 
(Ramaswamy et al., 2009).  
 
Like other enveloped viruses, RSV infection occurs by fusing its membrane directly with 
the endosomal or plasma membrane via cell surface receptors. This integration of cell 
surface receptors leads to activation of fusion at a neutral pH. In RSV, receptor binding 
and fusion are due to two major viral surface glycoproteins; G and F. The G protein is a 
highly glycosylated protein that is responsible for the binding of the virion to cells, 
whereas F, the fusion protein, includes membrane merging  and the release of the viral 
capsid into the cytoplasm of the targeted cell through the fusion pore (Razinkov et al., Chapter 1 – Introduction 
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2002). Once the viral nucleocapsid is released into the cell cytoplasm, RNA synthesis 
begins (Flint 2004).  
 
Another mechanism that RSV can use to evade the host’s immune system is to use the 
non-structural proteins (NS1 and NS2) to antagonise IFN-α, IFN-β and IFN-λ responses 
which  results  in  impaired  antiviral  immunity  and  possible  persistence  of  the  virus 
(Spann et al., 2004). It also has the ability to escape an established immune response 
(Guerrero-Plata et al., 2006) as well as avoiding early abortion of infection via inhibition 
of apoptosis in the host cells (Krilov et al., 2000). These immune evasion and escape 
mechanisms  could  also  help  to  explain  persistence  and  subsequence  lung  damage 
contributing to COPD pathogenesis.  
 
There are two distinct antigenic groups of RSV (RSV-A and RSV-B) however it is not 
clear whether infection by different strains affects COPD differently (Mufson et al., 
1985). To date there is sparse data comparing the effects of RSV-A to RSV-B infection. 
However a study in which mice were infected with two different strains of RSV-A (Line 
A2 and Line 19) at similar viral titres, strain-specific variations in cytokine expression, 
goblet  cell  by  hyperplasia  MUC5AC  expression  and  airway  hyper-reactivity  were 
reported to be higher in the Line-19 strain compared to the A2. (Lukacs et al., 2006). In 
contrast, studies involving humans reported no differences in viral effects of infection 
with different RSV strains. In a study of elderly patients, RSV-A was responsible for 45% Chapter 1 – Introduction 
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of infection and RSV-B, 55% (Falsey, 2005). The main structural difference between the 
groups is in the G glycoprotein which is the protein that is proposed to be the most 
important in the induction of persistence (Tripp et al., 2001).     
1.2.4.5 Viruses in stable COPD  
Historically, the role of viruses in stable COPD has not been well studied. More recent 
studies however have reported that there is evidence for viral involvement in stable 
COPD as well as at exacerbation. RSV has been shown to be in approximately 23-28% of 
stable COPD subjects (Borg et al., 2003; Seemungal et al., 2001). One study reported 
that RSV viral RNA was persistent in 32.8% of 241 sputum samples from 74 subjects 
with moderate to severe stable COPD (Wilkinson et al., 2006). Studies comparing viral 
presence at COPD exacerbation and in the stable state have predominantly found that 
the prevalence is higher at exacerbation compared to in the stable state.  However 
there have been studies that have shown a higher prevalence of RSV in the stable state 
(23.5%) compared to exacerbation (14.2%) (Seemungal et al., 2001). Persistent RSV in 
COPD is associated with higher levels of IL-6, IL-8, MPO and also faster lung function 
decline (Wilkinson et al., 2006). In contrast, other studies have not reported higher RSV 
prevalence in the stable state compared to exacerbation (Papi et al., 2006) and did not 
find RSV persistence in COPD (Falsey et al., 2006). This disparity could be due to a 
combination of factors including PCR technique, different PCR sensitivity cut off levels, Chapter 1 – Introduction 
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differences in the severity of COPD patients included in the study, and differences in 
the populations studied (Sikkel et al., 2008).  
 
Adenovirus has also been reported to have a similar rate of detection in stable COPD 
and at exacerbation (McManus et al., 2007). Although it has been suggested in some 
studies that it is uncommon for adenovirus to cause latent or acute infection in COPD 
subjects (McManus et al., 2007), other studies have hypothesised that adenovirus may 
lay  dormant  in  cells  and  may  be  involved  in  the  pathogenesis  of  COPD.  A  study 
evaluating lung tissue from COPD patients found levels of adenovirus DNA to be higher 
than  in  matched  healthy  smokers  (Matsuse  et  al.,  1992).  This  latent  adenovirus 
infection has been shown to increase the lung volume and airspace volume in a guinea 
pig model and decrease the surface to volume ratio when in combination with cigarette 
smoke compared to cigarette smoke exposure alone (Meshi et al., 2002). It has also 
been  hypothesised  that  latent  adenoviral  infection  could  induce  persistent 
inflammation in the lungs which results in emphysema. It has been shown that the 
adenovirus E1A gene is more highly expressed in both the alveolar and bronchiolar 
epithelial cells of COPD patients compared to controls (Hayashi, 2002). The presence of 
adenovirus and RSV in stable COPD may contribute to the pathogenesis of COPD as 
there are some common pathological features such as the large presence of CD8+ T 
lymphocytes that appear in respiratory viral infection as well as in COPD; however this 
hypothesis has not been proven to date. Studies of airway inflammation in stable COPD Chapter 1 – Introduction 
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patients have shown that the disease is characterised by infiltration of macrophages, 
neutrophils  and  CD8+  T  lymphocytes  and  increased  expression  of  cytokines, 
chemokines and adhesion molecules (Mallia and Johnston, 2006).  
1.2.4.6 Bacteria  
Historically, healthy lungs were thought to be a sterile environment and not associated 
with any form of microflora. The theory was that any inhaled bacteria were rapidly 
removed  via  phagocytosis  by  alveolar  macrophages  (Erb-Downward  et  al.,  2011). 
However more recently it has been shown that the ‘sterility’ of the respiratory tract is 
not maintained in COPD patients. A study by Monso and colleagues reported that 25% 
of COPD patients in the stable state were colonised by bacteria, with this study using 
the protected specimen brush for microbiology sampling (Monsó et al., 1995). Further 
studies looking at sputum, brushings and bronchial lavage reported similar findings. 
Sethi and colleagues found that 34.6% of COPD patients had bacteria detected in BAL 
fluid (Sethi et al., 2006) and Banerjee and colleagues reported 40% of COPD subjects 
had bacteria in their sputum (Banerjee et al., 2004). The prevalence of bacteria has 
been  shown  to  be  significantly higher  in  stable  patients  with  severe  COPD  (53.8%) 
compared to those with moderate (27.8%) or mild (11.55); p=0.004 (Zalacain et al., 
1999).  Bacterial  species  such  as  Haemophilus  influenzae  (H  influenzae),  Moraxella 
catarrhalis (M catarrhalis) and Streptococcus pneumoniae (S pneumoniae) (Lode et al., 
2007)  have  been  shown  to  be  commonly  associated  with  COPD  particularly  at Chapter 1 – Introduction 
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exacerbation,  although  they  are  able  to  be  cultured  in  approximately  one-third  of 
stable COPD patients (Rosell et al., 2005). These three airway bacteria are referred to 
as “typical airway bacteria” as they are commonly associated with infection in COPD 
patients. The bacteria colonisation in the stable state of COPD is associated with the 
same organisms that are found at exacerbation. Bacteria have been found in clinically 
significant concentrations in the airways of 4% of healthy adults, 29% of patients with 
stable COPD, and 54% of patients at exacerbation (Rosell et al., 2005). The prevalence 
of typical bacteria has been reported to be significantly higher at exacerbation (56.5%) 
compared to in the stable state (44.2%); p=0.024 as has typical bacterial load, 10
8.3 
colony  forming  units/ml  (cfu/ml)  vs  10
7.3  cfu/ml,  p<0.001  (Figure  1.10)  with  H 
influenzae being the most prevalent species in both disease states (Garcha et al., 2012). 
This study also confirms that qPCR is significantly more discriminatory than culture at 
detecting these three main airway bacteria with 59.3% of samples being positive for 
bacteria using qPCR compared to 24.3% using culture; p<0.001 (Garcha et al., 2012).   
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Figure 1.10: Quantitative PCR comparison of load of typical airway bacteria in stable COPD 
(n=242) and at exacerbation (n=131) in unpaired samples. Species: SP = S pneumoniae, MC = 
M Catarrhalis, HI = H influenzae (Garcha et al., 2012).  
 
Although it is widely accepted that typical airway bacteria can trigger the onset of an 
exacerbation,  the  mechanism  behind  this  is  not  so  clearly  defined.  It  has  been 
hypothesised that it is the airway bacterial load that is the driver of exacerbations as it 
is strongly associated with inflammatory markers (Hill et al., 2000). Whether it is an 
increase in the load of already colonising bacteria that leads to an exacerbation or a 
new bacterial infection altogether is not clear. An alternative hypothesis suggests that 
intra-species switching of bacterial strains may be the cause of exacerbation onset; 
using molecular typing, isolation of a new strain of  H influenzae, M catarrhalis or S Chapter 1 – Introduction 
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pneumoniae was shown to be significantly increased with a risk of an exacerbation 
(p<0.001) (Sethi et al., 2002).  
 
Bacteria have been shown to be associated with increases in inflammatory markers 
such  as  IL-6,  IL-8,  TNF-α  and  neutrophil  elastase.  The  degree  of  inflammation  was 
reported to be bacterial species-specific, with higher bacterial loads being associated 
with higher levels of lower airway inflammation (Hill et al., 2000). Bacteria themselves 
are able to produce products and proteolytic enzymes that cause local cellular necrosis 
and apoptosis which can lead to tissue damage (Abusriwil and Stockley, 2007) but are 
also  able  to  activate  different  cell  types  in  the  lungs,  triggering  the  release  of 
chemokines and cytokines via various proinflammatory signalling pathways and the 
interferon pathway. Various cells including neutrophils, macrophages and lymphocytes 
are then recruited into the affected area which in turn can release neutrophil elastase 
and cathepsins (Abusriwil and Stockley, 2007). Some bacteria such as Pseudomonas 
and Streptococcus spp. are able to cause direct cellular effects with the induction of 
epithelial cell apoptosis and neutrophil necrosis  which can cause further release of 
proteinases and proinflammatory mediators. This can lead to further impairment of 
host  defences  such  an  increases  in  mucus  secretion  and  impaired  ciliary  function 
(Abusriwil and Stockley, 2007). A vicious cycle of infection and inflammation can be set 
up in which bacterial infection or colonisation leads to inflammation which results in 
further destruction of already impaired immune defences. This  in turn leads to re-Chapter 1 – Introduction 
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infection  or  colonisation  of  the  airway  with  bacteria  (Sethi  et  al.,  2009)  meaning 
bacteria themselves can be a contributory factor in the persistence of inflammation in 
COPD (Abusriwil and Stockley, 2007).  
 
Other  bacteria,  termed  as  atypical  bacteria,  such  as  Chlamydophila  pneumoniae, 
Legionella  pneumophila  and  Mycoplasma  pneumoniae  are  infrequently  identified  in 
COPD patients using conventional culture techniques. A study using qPCR techniques to 
investigate the presence of atypical bacteria in stable and exacerbating COPD patients 
reported that out of 176 sputum samples (97 in the stable state, 79 at exacerbation) 
from 80 COPD patients, only 6 samples were positive (5 for L pneumophilia and 1 for M 
pneumoniae) (Garcha et al., 2012). Similarly another study that used qPCR analysis to 
detect atypical bacteria colonisation in 248 sputum samples from COPD patients found 
just 1 sample (0.4%) to be positive for atypical bacteria (L pneumophila) (Diederen et 
al., 2007). This low level of detection suggests that the role of atypical pathogens in 
COPD is minor at both exacerbation and in the stable state and so do not require 
specific therapy.   
1.2.5  Co-infection of virus and bacteria  
Recently,  the  subject  of  viral  and  bacterial  interactions  at  COPD  exacerbation  has 
become of considerable interest. Although COPD exacerbations are associated with Chapter 1 – Introduction 
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viral and bacterial infections, it is not known whether bacterial infection occur de novo 
or whether they are precipitated by viral infections. Few studies have reported on co-
infection between bacteria and viruses at COPD exacerbation however all these studies 
support the hypothesis that one infection may follow the other (Cameron et al., 2006; 
Hutchinson et al., 2007; Kherad et al., 2010; Papi et al., 2006).  
 
A  study  in  2006  performed  by  Papi  and  colleagues,  showed  viral  and  bacterial  co-
infection  in  25% of  samples  (Papi et al.,  2006)  whereas  Hutchinson and  colleagues 
reported that 36% of exacerbations in which a virus was detected at onset, developed a 
secondary  bacterial  infection  over  the  following  7  days,  and  overall,  78%  of 
exacerbations in which H influenzae was isolated in the first 5 days after onset were 
preceded by viral symptoms (Hutchinson et al., 2007).  
 
Patients  hospitalised  due  to  exacerbations  have  more  marked  lung  function 
impairment  and  increased  length  of  stay  in  the  context  of  viral  and  bacterial  co-
infection than those with non-infectious exacerbations (Papi et al., 2006). Secondary 
bacterial infection may also play a part in exacerbation recurrence (Hurst et al., 2009) 
and further studies are required to assess the longer term effects of these key findings.  
 
 In 2006, Wilkinson and colleagues demonstrated that typical airway bacterial load was 
higher in the presence of HRV; exacerbations that were positive for both H influenzae Chapter 1 – Introduction 
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and HRV had increased bacterial loads (10
8.56(0.31) cfu/ml) than exacerbations without 
both pathogens (10
8.05(0.77) cfu/ml); p=0.018 (Wilkinson et al., 2006b). This may indicate 
that viral infections impact on the severity of exacerbations indirectly as they increase 
the bacterial load causing an extended or recurrent exacerbation in addition to the 
direct effects caused by the viral infection itself (Wilkinson et al., 2006).  
 
A more recent experimental study exploring co-infection by Mallia and colleagues in 
2012 examined whether HRV infection can precipitate secondary bacterial infection in 
vivo,  and  examined  temporal  relationships  between  the  two  using  an  HRV 
experimental  model  (Mallia  et  al.,  2012).  Moderate  COPD  patients  and  controls 
(healthy smokers and non-smokers) were experimentally infected with a low-dose of 
HRV. It was found that 60% of subjects with COPD developed a secondary bacterial 
infection, measured using culture techniques, after an initial HRV infection, measured 
using qPCR, which was significantly more frequently than in the controls. Sputum HRV 
load peaked on Days 5-9 post inoculation whereas bacterial load peaked on Day 15 
(Figure  1.11).  No  patients  were  found  to  be  positive  for  bacteria  before  the  HRV 
infection which suggests that the bacterial infections were either due to bacteria that 
were present at levels below the sensitivity of culture in the stable state and that 
immune suppression due to the viral infection resulted in increased growth of these 
organisms to a detectable level, or that the bacterial infections were de novo infections 
due  to  acquisition  of  new  organisms.  Further  studies  need  to  be  performed  to Chapter 1 – Introduction 
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investigate the predominant mechanism behind the development of this secondary 
bacterial infection, including using alternative detection methods such as qPCR and 
sequencing for bacterial detection rather than culture, and including COPD subjects 
that have bacterial colonisation before an HRV infection.   
 
 
Figure  1.11:  The  time-course  of  sputum  HRV  load  and  bacterial  load  in  COPD  patients 
experimentally infected with HRV (Mallia et al., 2012).  
 
The concept of viral and bacterial co-infection has also been explored when studying 
RSV infections. In 2006 Avadhanula and colleagues found that RSV (along with human 
parainfluenza  virus  and  influenza)  enhanced  the  adhesion  of  H  influenzae  and  S 
pneumoniae  to  primary  and  immortalised  cells  lines.  RSV  infection  increased  the 
expression of several known receptors for pathogenic bacteria which in turn increased Chapter 1 – Introduction 
88 
 
the adherence of both these bacteria to airway epithelial cells under in vitro conditions 
(Avadhanula et al., 2006). It has also been shown that the G protein of RSV may work as 
a  cell  surface  receptor  for  both  H  influenzae  and  S  pneumoniae  which  therefore 
facilitates increased bacterial binding to virus-infected cells (Avadhanula et al., 2007). 
Together, this body of evidence suggests that HRV and to some extent, RSV, are able to 
interact  with  bacteria  in  ways  that  enhance  severity  during  COPD  exacerbation 
(Ramaswamy et al., 2009).  
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1.3  Aims and objectives 
The hypothesis of this study is that HRV prevalence and load increase significantly from 
the stable state to COPD exacerbation. The overall aim of this thesis is to investigate 
the  role  of  respiratory viral  infection,  in particular  HRV,  at  COPD  exacerbation  and 
during recovery. This will be assessed by a number of different methods:  
 
  Changes in the prevalence and load of HRV between the stable state and COPD 
exacerbation will be measured using a sensitive quantitative PCR (Chapter 3). 
 
  The time-course of HRV prevalence and load during naturally-occurring COPD 
exacerbations and recovery will be explored (Chapter 4). 
 
  The relationship between HRV load and upper respiratory tract symptoms in the 
stable state, at exacerbation and during recovery will be examined (Chapter 5). 
 
  Investigation  of  the  co-infection  of  HRV  and  typical  airway  bacteria  during 
naturally-occurring COPD exacerbations and recovery (Chapter 6). 
 
  Determine any associations between HRV infection and COPD patient reported 
outcomes such as EXACT and CAT scores (Chapter 7). 
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  Examine whether the presence of HRV during COPD exacerbation is related to 
exacerbation frequency (Chapter 7). 
 
  Explore the changes in prevalence and load in semi-quantitative analysis of RSV 
in the stable state and at exacerbation (Chapter 8). 
  
This will be the first study to investigate the role of HRV infection using viral load 
measurements  during  the  complete  time-course  of  naturally-occurring  COPD 
exacerbations. By addressing these points I aim to provide significant contributions to 
our  understanding  of  the  role  of  HRV  infection  in  naturally  occurring  COPD 
exacerbations. Chapter 2 – Methods 
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2.1  London COPD cohort  
The London COPD cohort is a long-standing, rolling cohort of approximately 200 patients 
enrolled at any one time. The COPD patients are part of a long-term study in the Centre 
for  Respiratory  Medicine,  Division  of  Medicine,  at  the  Royal  Free  Hospital,  University 
College London. The London COPD cohort is funded by the Medical Research Council, 
United Kingdom (Ref. G0800570). 
2.1.1  Ethics and consent 
Ethical  approval  for  the  London  COPD  cohort  was  granted  by  the  Royal  Free  London 
National Health Service Foundation trust (Ref. 09/H0720/8), and patients gave informed 
written  consent  allowing  sputum  and  blood  samples  to  be  collected,  and  spirometry 
readings to be taken. Approval was also given to allow daily diary card data to be obtained 
from patients. Chapter 2 – Methods 
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2.2  Patient subjects  
2.2.1  Recruitment  
All 146 patients studied were recruited to the London COPD cohort, by cohort clinicians or 
by  Beverly  Kowlessar,  the  research  nurse,  if  they  had  COPD  defined  by  a  number  of 
criteria;  all  patients  were  either  current  or  past  smokers  and  were  not  recruited  if 
suffering from other respiratory diseases. When seen by a London COPD cohort clinician, 
patients were informed about the cohort study and given the option to opt out and be 
removed from the study. They were also informed they were able to leave the study at 
any  point.  Upon  recruitment,  patients  were  given  a  unique  study  number  to  ensure 
confidential  identification.  Spirometry  measurements  were  obtained  using  volumetric 
storage spirometer (Vitalograph 2160; Maids Moreton) to ensure they had COPD; a forced 
expiratory volume in one second (FEV1) of ≤ 80% of a normal value predicted from age, 
height and sex, and an FEV1: forced vital capacity (FVC) ratio of ≤70% (Seemungal et al., 
1998). On recruitment, the attending cohort clinician took a smoking history such as pack-
year history and current smoking status along with a history of chronic symptoms such as 
dyspnoea,  wheeze,  cough  and  sputum  production.  Age,  gender,  height,  weight, 
maintenance therapy details, daily respiratory symptoms, social history, number of times 
outside the house during a week, contact with children and the number of visitors the 
patient receives in their home were also recorded at recruitment. Occupational history Chapter 2 – Methods 
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was recorded along with family history relating to COPD. Blood, urine and sputum samples 
were also collected from the patient. Patients were excluded if they were housebound 
and therefore unable to attend clinic appointments, or if they were unable to fill in daily 
diary cards. Patients with a history of any other significant respiratory diseases were also 
excluded. Patients had no treatment (either antibiotics or oral steroids) for the six weeks 
prior to recruitment.  
2.2.2  Daily diary cards 
At recruitment, patients were instructed on how to use daily diary cards provided by the 
clinic,  to  record  a  number  of  parameters,  in  order  to  monitor  their  condition.  Each 
morning patients recorded their respiratory daily peak flow using a volumetric storage 
spirometer (Vitalograph 2160, Maids. Moreton, Buckingham, UK) which measures their 
maximal expiratory flow. The values recorded were compared to the reading taken whilst 
the patient was in the stable state, allowing any changes to be noted by the clinician at 
the next visit. In the evening, patients recorded how many hours they had spent outdoors 
each day, along with the number of footsteps they had taken using a pedometer (Yamax 
Digi-Walker SW-200). Any changes in symptoms experienced by the patient that day were 
recorded on the diary card as well as any changes in medication taken. An example of a 
daily diary card is shown in the appendix.   Chapter 2 – Methods 
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2.2.3  Clinic visits 
Patients in the London COPD cohort were routinely seen in the research clinic every three 
months and their completed daily diary cards collected. These routine visits were defined 
as stable state visits providing there had been no exacerbation onset in the four weeks 
before, or during the two week interval after the visit. Once a year, patients underwent a 
comprehensive  review  when  FEV1  and  FVC  were  measured  with  by  spirometry  and  a 
history of smoking habits was taken.  
 
Where possible, patients provided spontaneous sputum samples at each clinic visit during 
the stable state (3-month intervals), exacerbation presentation and recovery (3 days, 7 
days, 14 days, 35 days and 56 days post-exacerbation). Figure 2.1 illustrates which patient 
samples were included in each analysis. Patients were given 24-hour phone access to a 
respiratory  clinician  and  were  taught  to  report  any  changes  in  symptoms  as  early  as 
possible to ensure optimum conditions for sputum sample collection.  
 
 
   Chapter 2 – Methods 
96 
 
 
Figure 2.1: COPD patient groups analysed showing maximum number of samples available for each analysis. Patient samples may have been 
included in more than one sub-analysis Chapter 2 – Methods 
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2.3  Definition of an exacerbation  
Patients recorded increases in major or minor symptoms on their daily diary cards. 
Major symptoms included dyspnoea, increased sputum volume and increased sputum 
purulence and minor symptoms included wheezing, cold symptoms, cough and sore 
throat. This daily recording of symptoms was used to precisely determine the onset and 
recovery of exacerbations. Exacerbation onset was defined as the first of two or more 
days in which patients recorded a worsening of two or more symptoms with at least 
one being a major symptom. Symptoms were disregarded in identifying exacerbation 
onset if recorded continuously in the five day period preceding suspected exacerbation 
onset. Some exacerbations were identified in the absence of any diary card data; if the 
patient was admitted to hospital, had been treated by their GP or another physician 
outside of the study, or had used their rescue pack. A rescue pack is medication that is 
held  by  the  patient  at  home  which  consists  of  oral  antibiotics  and  systemic 
corticosteroids,  usually  for  a  week,  to  be  started  in  case  of  the  onset  of  an 
exacerbation. If an exacerbation was treated by any of these means, no sputum sample 
was taken from the patient. 
 
Patients were strongly encouraged to contact the study team via the dedicated phone 
line should they experience any increase in their daily respiratory symptoms. They were 
attended to within 48 hours by a physician from the study team, their symptoms were Chapter 2 – Methods 
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reviewed and the exacerbation was confirmed according to the symptomatic definition 
stated above. Expectorated sputum was collected in a sterile container from the COPD 
patients. The  median time  between  the onset of the  exacerbation  and  the  sample 
being collected was 2 days. After the exacerbation sputum samples were taken from 
the patients, they were treated according to the prevailing guidelines (“GOLD Report 
2014,” n.d.) and clinical judgment with increased inhaled therapy, antibiotics and/or 
oral steroids.  
2.3.1  Exacerbation frequency 
An annual exacerbation rate was calculated for each patient by dividing the number of 
exacerbations a patient experienced, by the number of years of diary card data in 2012 
and 2013. This time period was chosen as it was contemporaneous with 90% of the 
samples. Patients with less than one year of diary card data were given an exacerbation 
rate equal to the number of events recalled in the previous year. Previous work has 
shown a good correlation between the number of exacerbations recorded on diary 
cards and the number of exacerbations recalled by the patient over the same 1 year 
period  (Quint  et  al.,  2010)  and  it  has  been  shown  that  exacerbation  frequency 
represents a relatively stable patient phenotype (Hurst et al., 2009). Chapter 2 – Methods 
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2.4  Sputum  
2.4.1  Collection 
Patients  expectorated  sputum  into  a  sterile  pot  after  rinsing  their  oral  cavity  with 
water. If patients were unable to produce sputum spontaneously, they were induced 
by a cohort clinician or respiratory nurse. Before induction, oxygen saturations and pre-
bronchodilator  FEV1  were  measured  and  200  mg  Salbutamol  was  subsequently 
administered using a multidose inhaler (Ventolin, GSK). After 10 minutes, the post-
bronchodilator FEV1 was measured and patients were instructed to blow their nose and 
rinse  their  mouth  out  with  water.  In  total,  three  sets  of  five  minutes  nebulisation 
(DeVilbiss UltraNeb2000 ultrasonic nebuliser) were performed with 3% saline (Pin et 
al., 1992). The aerosol output was approximately 2 mL/min with a mean particle size of 
0.5-5 µm in diameter. After the initial five minutes of nebulisation, FEV1 and oxygen 
saturation measurement was repeated for a further five minutes unless the FEV1 had 
fallen  by  more  than  20%  compared  with  the  post-bronchodilator  value.  After  the 
second  round  of  nebulisation  if  the  FEV1  had  not  fallen  by  more  than  20%,  the 
procedure was repeated for a third and final time. If at any point the fall in FEV1 was 
greater  than  20%,  nebulisation  was  stopped  immediately.  Patients  were  able  to 
expectorate sputum at any time during the induction process. The inducted sputum Chapter 2 – Methods 
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was collected in sterile sputum pots and processed in the same way as spontaneously 
expectorated sputum (Bhowmik et al., 1998).  
2.4.2  Processing 
The  sputum  samples  produced  were  processed  in  the  lab  on  the  day  they  were 
obtained by either a cohort clinician or the laboratory manager (Raymond Sapsford). 
The sample was separated from contaminating saliva using disposable forceps and the 
weight of the sputum was recorded. The sputum was diluted eight-fold in phosphate 
buffer solution (PBS) (Sigma, P-4417). Approximately 15-20, 3 mm glass beads (33212 
4G;  VWR  International  Ltd,  Poole  UK)  were  added  to  the  sputum-PBS  before  the 
mixture  was  homogenised  by  vortexting  (Whirlimixer,  Fisons,  Ipswich,  UK)  for  15 
seconds. The beads allow the cells within the sputum to be lysed so any intracellular 
viruses could be released and later detected. The homogenised sample was agitated on 
an IKA VIBRAX tube shaker (IKA Werke GmbH % Co. KG, Germany) for 15 minutes at 
room temperature (RTP) and then vortexed for another 15 seconds. The homogenised 
sputum was then aliquoted into 500 µl microcentrifuge tubes and stored at -80°C for 
subsequent analysis.  Chapter 2 – Methods 
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2.5  Real-time quantitative polymerase chain reaction  
2.5.1  RNA extraction using TRI Reagent LS 
RNA extraction involves the purification of RNA from biological samples, in this case 
sputum. The technique used in this study was the single-step total RNA isolation TRI 
Reagent LS (Sigma, T3809-LS) method (Chomczynski and Sacchi, 1987). It is a mixture of 
guanidine thiocyanate and phenol, and works alongside chloroform to homogenise or 
lyse biological samples separating them into 3 phases; an aqueous phase containing 
RNA, an interphase containing DNA and an organic phase containing proteins. Each 
component can then be isolated further. This is a very effective method of isolating 
intact RNA with little or no DNA or protein contamination. As the purification of RNA 
can be complicated due to the presence of ribonuclease enzymes that rapidly degrade 
the RNA in cells and tissues, all tubes and pipette tips used in the RNA extraction 
process and PCR set up were RNase/DNase free and were also placed under UV light 
for 30-40 minutes before use. All surfaces were cleaned with “RNaseZap” (Invitrogen, 
AM9782).   
 
When required, samples were removed from the -80°C freezer and thawed at room 
temperature for 15-20 minutes. Once thawed, 750 µl of TRI reagent was added to the 
500 µl of processed sputum. The samples were vortexed for 4 minutes and after 5 Chapter 2 – Methods 
102 
 
minutes incubation at RTP, 200 µl of chloroform (Sigma, C2432) was added and the 
samples vortexed for a further 4 minutes. The samples were incubated on ice for 10 
minutes before being spun in a microfuge  (Eppendorf, 5415C) at 12,000 x g for 15 
minutes. The top aqueous layer containing the RNA was removed and transferred to a 
UV-sterilised  1.5  mL  microcentrifuge  tube  and 500  µl  of  isopropanol  (Sigma  I9516) 
added. The samples were left on ice for 15 minutes before being centrifuged at 12,000 
x g for 20 minutes. The supernatant was removed and 200 µl of 80% ethanol (Sigma 
E7023) added to the RNA pellet. After being spun in the microfuge for a further 5 
minutes at 12,000 x g, the pellets were allowed to air dry for 30 minutes before being 
resuspended in 30 µl of RNase free water. Both positive (virus spiked sputum sample) 
and negative (water) controls were included in the RNA extraction.  
2.5.2  Reverse Transcription 
The extracted RNA was immediately reverse transcribed to generate complementary 
DNA  (cDNA)  using  the  High-Capcaity  cDNA  Reverse  Transcription  Kit  (Applied 
Biosystems  4368814,  Carlsbad,  California).  Prior  to  plate  set  up,  the  2x  reverse 
transcription (RT) master mix was prepared on ice. Loaded into each well of the 96-well 
PCR plate was 10 µl of RNA sample along with 10 µl of the 2x RT mastermix giving 20 µl 
reaction  volumes  (see  table  2.1  for  reagents  included).  All  samples  were  run  in 
duplicate along with controls: a negative water control, a positive control of highly Chapter 2 – Methods 
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concentrated HRV1B and template control of the 2x RT mastermix with no RNA sample 
to ensure no contamination. The plate was sealed and loaded into the PCR machine 
(Techne TC-412 Thermal Cycler, Kieson). The RT programme was set up as follows; 10 
minutes  at  25°C,  2  hours  at  37°C  and  5  minutes  at  85°C.  Plates  containing  the 
converted  cDNA  were  stored  at  4°C  until  required  for  qPCR  (maximum  of  5  days 
storage).  
 
Reagent  Volume (µl) 
10x RT Buffer  2 
25x dNTP mix (100 mM)  0.8 
Multiscribe
TM Reverse Transcriptase  1 
10 x RT Primers   2 
PCR Grade Water   4.2 
RNA Sample  10 
Table 2.1: Reagents used to make up 2x RT mastermix for reverse transcription. Chapter 2 – Methods 
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2.5.3  Plaque assay – quantification of plaque forming units 
As part of the current study, it was required that the HRV load present in a sample be 
recorded in plaque forming units per mL (pfu/mL) to more appropriately and easily 
relate it to previous literature and to ensure consistency of viral qPCR results within the 
department. In order to achieve absolute quantification of HRV load using qPCR, the 
generation of a standard curve was required. The standard curve was prepared using a 
plaque  assay  from  tissue  culture  grown  HRV1B  (American  Type  Culture  Collection, 
ATCC) using a HeLa Ohio cell line. At 75-80% confluency, the HeLa Ohio cells were 
passaged. The growth medium (GM) (Sigma, DMEM) was removed from the flask that 
contained the cells, and 20 mL of PBS added to the flask to “wash” the cells. Trypsin 
EDTA  -  1%  (Invitrogen)  was  then  added  to  the  flask  in  order  to  detach  the  cells 
enzymatically. After incubation for 3-4 minutes with 3 mL of trypsin, the cells detached 
from the flask surface. The trypsinisation was halted by the addition of 10 mL of GM 
before the cells were transferred from the flask to a 50 mL falcon tube and centrifuged 
at 250 x g for 7 minutes. The cells were then resuspended in GM and subcultured into 
more flasks at a dilution of 1:10 in order to continue their growth. For the plaque assay, 
the  cells  were  seeded  in  6-well  plates  (Sarstedt,  Nümbrecht,  Germany)  at  a 
concentration of 8 x 10
5 in 3 mL of maintenance media (MM) in preparation for the 
viral  titration.  The  cell  concentration  was  determined  by  adding  10  µl  of  growth 
medium (GM) containing cells to 90 µl of trypan blue (Sigma, T8154) which stains cells Chapter 2 – Methods 
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blue allowing them to be counted using a haemocytometer (depth 0.1mm). Using x400 
magnification, the cells were counted and the value multiplied by 10
5 to determine the 
number of cells/mL.  
 
The cell concentration was determined using the following formulae: 
 
8 x 10
5 x number of wells needed  =       volume of cells required 
number of cells/mL 
 
Total volume required   –   volume of cells required  =     volume of MM to be added. 
 
The  cells  were  incubated  at  37°C  and  5%  CO2  for  24  hours  or  until  they  reached 
confluency.  
 
Serial dilutions of human rhinovirus (HRV) stock were prepared by dilution with PCR-
grade H20 in the range of 10
-4 to 10
-8 as shown in figure 2.2 below:  Chapter 2 – Methods 
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Figure 2.2. Serial dilutions of virus stock were made before adding to the cell monolayer in 
the 6-well plates. Taken from www.virology.ws. 
The MM was aspirated from the wells without disturbing the cell layer and 200 µl of 
the corresponding HRV dilution was added to each well. Each dilution was done in 
duplicate. A control (cc) was included where only media (without HRV) was added to 
the cells. The titration plate set up (Figure 2.3) is demonstrated below:  
 
 
Figure 2.3: Titration plate set up to calculate HRV titre using the plaque assay method. Chapter 2 – Methods 
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The plates were incubated for 2 hours at 33°C on a rocker allowing the HRV to infect 
the cells evenly. The HRV was aspirated from the cells and 3 mL of overlay medium 
(containing 800 µl of 1M MgCl2) was added. The warm overlay medium containing 3% 
agar (Sigma, A5306) was allowed to cool and set. After 5 days of incubation at 33°C and 
5% CO2, 3 mL of 10% formalin was added to the cells and incubated at RTP for 1 hour. 
The agar plugs were removed without damaging the cell layer at the bottom. The cell 
layer was stained with 1 mL of 3,7-bis(Dimethylamino)phenazathionium chloride, Basic 
Blue 9, Tetramethylthionine chloride (methylene blue, M9140 Sigma) and incubated for 
15 minutes at RTP. The stain was removed by aspiration and the plates inverted to 
allow  the  plaques  to  clear.  The  plaques  appear  as  clear  circles  against  a  blue 
background as demonstrated in Figure 2.4. 
 
Figure 2.4: Example of a titration plate showing clear plaque in the cell monolayer. Taken 
from www.fr.wikipedia.org 
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The  viral  titre  is  a  quantitative  measurement  of  the  biological  activity  of  the 
recombinant  virus  and  is  expressed  as  pfu per  mL.  To  calculate  the  viral  titre, the 
number of plaques formed was counted at x200 magnification under the microscope.  
 
 
The following formula was used to determine the titre (pfu/mL) of the viral stock: 
 
Number of plaques formed  =       pfu/mL 
d x V 
 
NB: d =dilution factor, V = volume of diluted virus added to the well 
2.5.4  Standard curve preparation for HRV qPCR 
As  described  above,  the  generation  of  a  standard  curve  was  required  to  achieve 
absolute  quantification  of  the  HRV  load  and  was  generated  using  HRV  stock  at  a 
concentration of 1.35x10
7 pfu/ mL (calculated by plaque assay, section 2.5.3). The HRV 
stock underwent serial dilutions from 10
7 to 10
-2 and each dilution was assessed by 
qPCR in triplicate. The cycle threshold (Ct) value (the number of PCR cycles required to 
reach a threshold fluorescence) of each sample was plotted against the concentration 
of each sample generating a standard curve (Figure 2.5).  
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Figure  2.5:  Standard  curve  generation  for  absolute  quantification  of  HRV  load.  (A)  Serial 
dilutions of known quantities of cDNA ran on PCR. The concentration ranged from 7.62 log 
pfu/mL, down to 1.01 log pfu/mL (B) Standard curve generated, relating cDNA concentration 
to Ct value. The equation for the linear regression line (shown on the graph) allows the 
quantity of an unknown sample to be determined.  Chapter 2 – Methods 
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2.5.5  Quantitative HRV PCR  
Real-time  qPCR  assays  were  developed  and  optimised  to  allow  rapid  and  sensitive 
detection  of  viral  genetic  material  in  clinical  samples.  Thermocycling  and  real-time 
detection of qPCR products were performed using the ABI Prism 7500 real-time qPCR 
System (Applied Biosystems). An internal amplification control (IAC) was incorporated 
in the qPCR to detect any PCR inhibition. The IAC selected here targeted the phyB gene 
from the potato species Solanum tuberosum (known as SPUD) (Nolan et al., 2006). It 
was incorporated in the PCR mastermix in order to detect any inhibition occurring in 
individual samples. This gene was previously validated as an IAC (Nolan et al., 2006). 
Details of SPUD primers and probe can be found in Table 2.6. The mastermix illustrated 
in Table 2.5 formed the basis of each PCR reaction. Into each well of the 96-well PCR 
plate,  22.5  µl  of  mastermix  was  added  to  2.5  µl  of  cDNA  sample  creating  a  total 
reaction volume of 25 µl. A standard curve was previously created as described in 
section 2.5.4. Each PCR run included two standards as a positive control ensuring each 
PCR plate was run successfully. The standards also allowed the absolute quantification 
of the HRV load in any positive samples. The controls also included a negative control 
(no cDNA sample) and a control containing no QuantiTect Probe PCR Master Mix. All 
HRV samples were run in duplicate and the lower limit of detection for the HRV qPCR 
was 10.23 pfu/ mL (1.01 log10 pfu/ mL). This was achieved by examining the standard 
curve and identifying the lowest concentration at which the cycle threshold is crossed.  Chapter 2 – Methods 
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The qPCR conditions for HRV were set up as follows; heating to 95°C for 15 minutes 
activating the Taq polymerase, 45 cycles of denaturation at 95°C for 15 seconds and 
annealing/extension for 80 seconds at 58°C Table 2.2). The primers and probes for HRV 
RT-PCR were based on protocols developed previously in the department and bind 
within  the  untranslated  region  of  the  genome  sequence.  The  primers  used  were 
generic  primers  that  were  designed  to  detect  as  many  HRV  serotypes  as  possible 
including both major and minor types  (Jacobs et al., 2013). The primers and probe 
sequences are shown in Table 2.6. Standard curves were developed by running PCRs 
with serial dilutions of known concentrations of virus (section 2.5.4).  
 
Temperature (°C)  Time 
95 
 
95 
 
58 
15 minutes 
 
15 seconds  
 
80 seconds 
Table 2.2: The qPCR conditions for HRV primers and probe.  
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2.5.6  Semi-quantification of RSV  
As the RSV qPCR was required to be semi-quantitative, there was no need to generate 
a  standard  curve.  Relative  quantification  was  used  for  RSV  rather  than  absolute 
quantification as was used for HRV, where Ct values were compared to determine 
relative viral loads between samples. The upper and lower limits of RSV detection by 
qPCR needed to be measured. For the RSV-A, serial dilutions of neat RSV A2 stock 
(1x10
7 pfu/ mL) donated from Dr Maximillian Habibi at Imperial College London were 
set up from 10
7 to 10
2 (Figure 2.6A). For the RSV-B, serial dilutions of neat RSV-B stock, 
obtained from ATCC, were set up from 10
7 to 10
2 (Figure 2.6B). These dilutions were 
used to spike sputum samples which underwent RNA extraction, reverse transcription 
and qPCR to determine the upper and lower limits of RSV-A and -B detection.  
 
The  qPCR  conditions  for  the  semi-quantification  of  RSV-A  were  set  up  as  follows; 
heating  to  95°C  for  15  minutes  activating  the  Taq  polymerase,  40  cycles  of 
denaturation at 95°C for 15 seconds and annealing/extension for 60 seconds at 57°C 
(Table  2.3).  For  RSV-B  the  set  up  was  as  follows;  heating  to  95°C  for  15  minutes 
activating the Taq polymerase, 40 cycles of denaturation at 95°C for 15 seconds and 
annealing/extension for 60 seconds at 60°C (Table 2.4). The primers and probes for RSV 
RT-PCR  were  developed  by  Bill  Carmen’s  lab  in  West  of  Scotland  virology  service 
(Perkins et al., 2005) and are shown in Table 2.6. The RSV genome (ID: U39661) was Chapter 2 – Methods 
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used as a source for primer3 software (www.primer3.ut.ee) to locate where the RSV 
primers bind to. The forward and reverse primers for RSV bind within the pneumovirus 
nucleocapsid protein gene (ID: AAC57032).  Chapter 2 – Methods 
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 Figure 2.6. Dilution curve generation for semi-quantification of (A) RSV A and (B) RSV B. 
Serial dilutions of cDNA were run on PCR. Chapter 2 – Methods 
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Temperature (°C)  Time 
95 
 
95 
 
57 
15 minutes 
 
15 seconds  
 
60 seconds 
Table 2.3: The qPCR conditions for RSV-A primers and probe.  
 
Temperature (°C)  Time 
95 
 
95 
 
60 
15 minutes 
 
15 seconds  
 
60 seconds 
Table 2.4: The qPCR conditions for RSV-B primers and probe.  
   
x40 cycles 
x40 cycles Chapter 2 – Methods 
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Reagent  Volume (µl) 
QuantiTect Probe PCR Master Mix  12.5 
HRV/RSV Forward Primer (20 µl)  1 
HRV/RSV Reverse Primer (20 µl)  1 
HRV/RSV Probe (20 µl)  0.35 
PCR Grade Water   6.35 
cDNA Template   2.5 
IAC   1 
IAC Forward Primer (50 µl)  0.125 
IAC Reverse Primer (50 µl)  0.075 
IAC Probe (50 µl)  0.1 
Table 2.5: Reagents used to make up the mastermix for qPCR. IAC = internal amplification 
control. 
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Oligo Name  Sequence (written 5' - 3') 
Primers 
HRV – Forward  TGADTCCTCCGGCCCCT 
HRV – Reverse   AAAGTAGTYGGTCCCRTCC 
RSVA – Forward 
RSVA – Reverse  
RSVB – Forward  
AGATCAACTTCTGTCATCCAGCAA 
TTCTGCACATCATAATTAGGAGTATCAATT 
AAGATGCAAATCATAAATTCACAGGA 
RSVB – Reverse   TGATATCCAGCATCTTTAAGTATCTTTATAGTG 
   
IAC – Forward   AACTTGGCTTTAATGGACCTCCA 
IAC – Reverse   ACATTCATCCTTACATGGCACCA 
Probes 
HRV – Probe  6-FAM – AATGYGGCTAACCT – MGB  
 
RSVA – Probe   FAM – CACCATCCAACGGAGCACAGGAGAT – BHQ-1 
RSVB – Probe 
 
SPUD – Probe   
FAM – TTCCCTTCCTAACCTGGACATAGCATATAACATACCT – BHQ-1 
 
Cy5 – TGCACAAGCTATGGAACACCACGT – BBQ  
Table 2.6: Primer and probe sequences for quantitative HRV and RSV RT-PCR (purchased 
from Applied Biosystems UK), including IAC primers and probe sequences (purchased from 
TIB MOLBIOL). 
Bacterial qPCR methods were carried out by Dr Davinder Garcha (Garcha et al., 2012).  Chapter 2 – Methods 
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2.5.7  HRV qPCR optimisation  
To  ensure  consistency  between  results,  primers  and  probe  that  had  already  been 
developed and used within the department were to be used for HRV detection in this 
study. The protocol was optimised by performing RNA extraction, reverse transcription 
and qPCR on sputum samples spiked with pure HRV16 at different concentrations, on 
water samples spiked with HRV16 at different concentrations and on water samples 
without any virus. This did not seem to yield positive results on the PCR which could 
have been due to a number of factors; 1) primer/probe set had been degraded, 2) viral 
stock  used  for  spiking  was  no  longer  viable  or  3)  RNA  contamination/degradation. 
These factors were resolved on a step-by-step basis. Dr Nathan Bartlett from Imperial 
College provided some cDNA to allow the already obtained primers and probe, to be 
tested. As this produced successful results, it was clear the problems lay within the RNA 
extraction or reverse transcription steps. The water sample that wasn’t spiked with 
virus was showing positive results on the PCR suggesting contamination during one or 
more parts of the protocol. The aim was to go through each reagent used until the 
source of the contamination was eliminated. The first reagent used during the RNA 
extraction is TRI regent and it was soon realised that it was the TRI reagent that had 
become contaminated with HRV and was therefore contaminating all the samples, and 
making them show up as false-positive for HRV on the PCR. However the PCR showed 
similar results in terms of HRV load for samples spiked with neat HRV and those spiked Chapter 2 – Methods 
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with lower concentrations. This suggested that the HRV being detected was from the 
contamination from the TRI reagent as opposed to from the HRV16 spike. Dr Nathan 
Bartlett of Imperial College London kindly donated some HRV1B which was used to 
spike sputum and water samples. The protocol was run again and this time the PCR 
showed differences in the HRV load in samples spiked with different amount of virus 
suggesting the HRV16 was non-viable. Fresh HRV stocks were ordered from ATCC which 
were used in setting up the standards for the qPCR. 
 
To illustrate the repeatability of the qPCR, the Ct values from the two duplicate PCR 
runs (run 1 and run 2) for 30 HRV-positive samples were plotted against each other 
(Figure 2.7).  
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Figure 2.7: Repeatability curve showing Ct values for 30 HRV-positive. Each sample was run in 
duplicate to obtain a Ct value “run 1” and “run 2”.  
 
2.6  EXACT Questionnaire 
Permission to use the EXACT questionnaire to score symptom intensity was obtained 
from  United  BioSource  Company  (UBC,  Bethesda,  MD,  USA).  For  use  in  this  study, 
patients completed a paper version of the EXACT  questionnaire  at each clinic visit, 
based on the symptoms they experienced on the day of completion. An example of the 
EXACT questionnaire is shown in the appendix.   Chapter 2 – Methods 
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2.7  CAT Questionnaire 
Patients completed a paper version of the CAT questionnaire at each clinic visit, based 
on the symptoms they experienced on the day of completion. An example of the CAT 
questionnaire is shown in the appendix.   
2.8  Aushon Multiplex Immunoassay  
Levels of biomarkers in sputum samples were measured using the Aushon multiplex 
immunoassay platform (Aushon BioSystems, Billerica, MA).  Samples were incubated 
for one hour on the array plates that were pre-spotted with capture antibodies specific 
for  each  protein  biomarker.  Plates  were  decanted  and  washed  four  times  before 
adding a cocktail of biotinylated detection antibodies to each well.  After incubating 
with detection antibodies for 30 minutes, plates were washed four times and incubated 
for  30  minutes  with  streptavidin-horseradish  peroxidase  conjugate.  All  incubations 
were done at room temperature with shaking at 200 RPM. Plates were again washed 
before  adding  a  chemiluminescent  substrate.  The  plates  were  immediately  imaged 
using the Aushon Cirascan CCD Imaging System, and data was analysed using Aushon 
Cirasoft Software in collaboration with Novartis.  Chapter 2 – Methods 
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2.9  Statistical analysis 
Data were analysed using PASW Statistics V.21 SPSS (IBM Corporation, New York, USA). 
The Kolmogorov-Smirnov test for normality was applied; a non-parametric test that 
assesses  the  equality  of  continuous,  one-dimensional  probability  distributions.  HRV 
loads were reported as median and interquartile range (IQR). For graphical illustrations, 
log10  transformed  data  were  presented  as  mean  (±95%  CI)  or  median  (IQR).  Non-
parametric data were analysed using non-parametric statistical tests such as Mann-
Whitney  U  tests  and  Wilcoxon  tests  for  unpaired  and  paired  data,  respectively. 
Parametric  data  were  compared  used  t-tests.  Correlations  between  continuous 
variables were analysed using Spearman’s Rank or Pearson’s correlation in a univariate 
analysis. A probability value of p<0.05 was considered to be statistically significant. Chapter 3 – HRV in stable COPD and at exacerbation 
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CHAPTER 3. HRV prevalence and load in stable 
COPD and at exacerbation  
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3.1  Introduction 
This  study  aimed  to  assess  changes  in  HRV  prevalence  and  load  from  patients  in the 
London COPD cohort, in the stable state and at COPD exacerbation, using real-time qPCR 
in naturally occurring exacerbations.  
 
Patients in the London COPD cohort are seen in clinic every 3-6 months whilst in the stable 
state. Some patients in the COPD population are unable to spontaneously expectorate 
sputum in the stable state whereas others are able to produce it spontaneously. It is often 
the patients that suffer from chronic bronchitis which are able to produce sputum, as 
chronic bronchitis is associated with chronic spontaneous sputum production for at least 3 
months of the year, for 2 consecutive years (GOLD Report 2014). However, patients that 
have  a  more  emphysematous  phenotype  are  often  unable  to  spontaneously  produce 
sputum. At exacerbation however, approximately 50% of patients in the London COPD 
cohort are able to spontaneously expectorate sputum (Patel et al., 2012). As discussed 
previously,  the  major  symptoms  defining  the  onset  of  an  exacerbation  are  increased 
sputum volume, increased sputum purulence and increased dyspnoea.  
 
Compared to the number of studies reporting viral infection at COPD exacerbation, there 
are fewer studies that focus on the presence of viruses in stable COPD, however viruses 
have been shown to be detected in the stable state. Seemungal and colleagues reported Chapter 3 – HRV in stable COPD and at exacerbation 
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that 16.2% of stable COPD samples had a respiratory virus present using quantitative PCR 
methods,  and  that  in  45%  of  the  virus-positive  samples,  human  rhinovirus  (HRV)  was 
detected.  Furthermore,  it  was  shown  that  patients  in  which  a  respiratory  virus  was 
detected in the stable state, had a significantly higher exacerbation frequency than those 
without virus detected (p=0.043) (Seemungal et al., 2001).  
 
More commonly, viral infection, in particular HRV, has been shown to be associated with 
exacerbations in both asthma (Friedlander and Busse, 2005) and COPD  (Mallia et al., 
2011;  Quint  et  al.,  2010;  Seemungal  et  al.,  2001;  Stock,  2014;  Wu  et  al.,  2014).  Viral 
detection in sputum samples, has been shown to increase at exacerbation compared to 
the stable state, 56% vs 19% (p<0.01) (Rohde et al., 2003). Liao and colleagues also found 
an increase in HRV prevalence from the stable state to exacerbation in sputum samples 
(5.3% vs 21.9%) but found a lower prevalence in both disease states when using nasal 
samples (3.5% vs 13.2%) (Liao et al., 2014). Furthermore, in a study by Tan and colleagues, 
viral detection in nasal lavage samples using PCR, was shown to increase from 7% in the 
stable state to 64% at COPD exacerbation (Tan et al., 2003). 
 
In a study using culture techniques as opposed to PCR for virus detection, only 10% to 20% 
of exacerbations were found to be positive for the presence of a virus (Smith et al., 1980). 
Additionally, Beckham and colleagues showed that 57% of 88 respiratory viral infections 
were identified using culture or serological techniques with RT-PCR techniques identifying Chapter 3 – HRV in stable COPD and at exacerbation 
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a  further  38  infections  (Beckham  et  al.,  2005).  Although  these  differences  in  viral 
prevalence could be due to factors such as differences in sampling times where HRV has 
been  shown  to  be  more  prevalent  in  the  winter  months  compared  to  the  summer 
(Wedzicha  and  Seemungal,  2007),  or  that  samples  taken  from  different  geographic 
populations may have different HRV detection rates, the differences in viral detection 
rates between these studies suggest that culture techniques are less sensitive at detecting 
viral presence compared to PCR and that PCR is a more accurate method of determining 
the presence of viruses. Consequently, in the current study, the prevalence and load of 
HRV in both the stable state and at exacerbation were measured using qPCR techniques. A 
further potential limitation of previous studies include the method of data analysis with 
some  studies  using  only  unpaired  analysis  between  stable  and  exacerbation  states 
resulting in a potential population bias (Monsó et al., 1995; Rosell et al., 2005). In this 
study, the data were analysed using unpaired analysis in the overall population as well as 
paired  analysis  in  a  smaller  subset  of  patients  that  were  able  to  produce  sputum 
spontaneously in both disease states. 
 
In order to further the current knowledge of HRV infection in COPD and potentially reduce 
the frequency of exacerbations, this study aimed to assess changes in the prevalence and 
load of HRV in patients from the London COPD cohort using paired and unpaired analysis, 
in the stable state and at natural COPD exacerbation using real-time qPCR.  Chapter 3 – HRV in stable COPD and at exacerbation 
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3.2  Characteristics of patients in unpaired analysis 
A total of 58 stable state samples and 279 exacerbation samples from 146 COPD patients 
were analysed between January 2008 and March 2014 as part of the sample collection 
performed in the London COPD cohort. The baseline clinical  characteristics of the 146 
patients included are shown in Table 3.1 below.   
 
 
 
 
 
 
 
Table  3.1:  Baseline clinical  characteristics  of  146  patients  in  the  London  COPD  Cohort, who 
participated in study of HRV presence at COPD exacerbation and in the stable state in unpaired 
samples. Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.18 (±0.5) 
FVC, litres  2.56 (±0.9) 
FEV1/FVC, %  46.1 (±14.8) 
Predicted FEV1, %  47.0 (±21.7) 
Current Smoker, %  33 
Age, years  69.8 (±8.5)  
Male gender, %  59 Chapter 3 – HRV in stable COPD and at exacerbation 
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3.3  Results – unpaired analysis 
3.3.1  HRV prevalence in unpaired analysis 
From  a  total  of  58  stable  state  samples,  10  (17.2%)  had  HRV  detected.  Of  279 
exacerbation samples, 117 (41.9%) were positive for HRV which was significantly higher 
than in the stable state (p=0.001) (Figure 3.1).  
 
 
Figure  3.1:  Comparison  of  HRV  prevalence  in  the  stable  state  (n=58)  and  at  COPD 
exacerbation (n=279) in unpaired samples; *p=0.001.  Chapter 3 – HRV in stable COPD and at exacerbation 
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3.3.2  HRV load in unpaired analysis  
Specifically examining unpaired samples that were positive for HRV (n=10 in the stable 
state  and  n=117  at  exacerbation),  it  was  identified  that  the  mean  (±SEM)  HRV  load 
increased significantly at exacerbation (3.76 (±0.18) log10 pfu/ml) compared to the stable 
state (2.11 (±0.29) log10 pfu/ml); p=0.008 (Figure 3.2).  
 
Figure 3.2: Comparison of mean HRV load in the stable state (n=10) and at COPD exacerbation 
(n=117) in unpaired samples; *p=0.008. Data shown as mean (±95% CI).  Chapter 3 – HRV in stable COPD and at exacerbation 
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In absolute terms, there was also a significant increase in the mean HRV load from the 
stable state to exacerbation (926.25 pfu/ml vs 4.11E+06 pfu/ml; p=0.042) (Figure 3.3).  
 
Figure 3.3: Comparison of mean HRV load in HRV-positive samples in the stable state (n=10) and 
at COPD exacerbation (n=117) in unpaired samples in absolute terms; *p=0.042. Data shown as 
mean (±95% CI). 
 Chapter 3 – HRV in stable COPD and at exacerbation 
131 
 
3.4  Characteristics of patients in paired analysis 
A sub-analysis of 50 COPD patients who had paired stable and exacerbation state sputum 
samples was performed to reduce any bias that may occur when different patients are 
used to reflect changes in HRV prevalence and load at different COPD states. Pairs  of 
sputum samples, one taken in the stable state and one at exacerbation were analysed. A 
total of 54 stable state samples and 54 exacerbation samples from the 50 patients were 
analysed between January 2008 and December 2012. This sub-analysis involved stable 
state samples being obtained less than 365 days prior to an exacerbation. The baseline 
clinical characteristics of these 50 patients included are shown in Table 3.2 below.   
 
 
 
 
 
 
 
Table  3.2:  Baseline  clinical  characteristics  of  50  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV presence at COPD exacerbation and in the stable state in paired 
samples. Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.17 (±0.5) 
FVC, litres  2.53 (±0.9) 
FEV1/FVC, %  46.1 (±14.9) 
Predicted FEV1, %  46.7 (±20.7) 
Current Smoker, %  35 
Age, years  69.4 (±8.5)  
Male gender, %  60 Chapter 3 – HRV in stable COPD and at exacerbation 
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3.5  Results – paired analysis 
3.5.1  HRV prevalence in paired analysis  
From a total of 54 stable state sputum samples, it was found that 9 (16.7%) were positive 
for HRV. Of 54 exacerbation samples, 37 (68.5%) showed such presence demonstrating a 
significantly higher prevalence of HRV at exacerbation compared to the stable state in 
paired analysis (p<0.001) (Figure 3.4).  
 
Figure 3.4: Comparison of HRV prevalence in the stable state (n=54) and at COPD exacerbation 
(n=54) in paired samples; *p<0.001.  Chapter 3 – HRV in stable COPD and at exacerbation 
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Of the 54 pairs of stable state and exacerbation samples, 5 (9.3%) pairs had HRV present 
at both time points, 32 (59.3%) were positive for HRV at exacerbation only, 4 (7.4%) were 
positive for HRV in the stable state only and 13 (24.1%) were not positive for HRV at either 
time point (Figure 3.5). The percentage of pairs with HRV present at only exacerbation 
was significantly higher than those who had HRV detected in the stable state only, at both 
disease states and at neither time point (all p<0.001). There was a significantly higher 
percentage of pairs who did not have HRV detected at either time point compared to the 
percentage of those who had HRV in the stable state only (p=0.017) or at both disease 
states (p=0.039).  
   Chapter 3 – HRV in stable COPD and at exacerbation 
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Figure  3.5:  Comparison  of  the  percentage  of  sample  pairs  (n=54)  positive  for  HRV  at 
exacerbation only, in the stable state only, in the stable state and at exacerbation (both states), 
and in neither the stable state or at exacerbation (neither state); *p<0.001.   
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3.5.2  HRV load in paired analysis  
The HRV load in HRV-positive samples from patients in whom there was paired stable 
state and exacerbation samples available, was then compared. The 9/54 samples that 
were found to be positive for HRV in the stable state had a mean HRV load of 1.96 (±0.27) 
log10 pfu/ml. The 37/54 samples that had HRV detected at exacerbation had a mean load 
of  3.76  (±0.33)  log10  pfu/ml  which  was  significantly  higher  than  in  the  stable  state 
(p=0.011) (Figure 3.6).  
 
Figure 3.6: Comparison of mean HRV load in HRV-positive samples in the stable state (n=9) and 
at COPD exacerbation (n=37) in paired samples; *p=0.011. Data shown as mean (±95% CI).  Chapter 3 – HRV in stable COPD and at exacerbation 
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Additionally, it was established that 37 of the 54 pairs (68.5%) had a higher HRV load at 
exacerbation compared to the stable state, 13 showed no signs of HRV presence at either 
stable or exacerbation states, and four showed a fall in HRV load from the stable state to 
exacerbation (Figure 3.7). 
 
Figure 3.7: Changes in HRV load in 50 patients with paired stable state (n=54) and exacerbation 
state (n=54) data.  
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Five of the 54 pairs were HRV-positive at both the stable state and at exacerbation. The 
HRV load was significantly higher in the exacerbation state (4.01 (±0.68) log10 pfu/ml) 
compared to in the stable state (1.88 (±0.48) log10 pfu/ml); p=0.034 (Figure 3.8).  
 
 
Figure 3.8: Comparison of mean HRV load in the stable state (n=5) and at COPD exacerbation 
(n=5) in paired samples positive for HRV at both disease states; *p=0.034. Data shown as mean 
(±95% CI). Chapter 3 – HRV in stable COPD and at exacerbation 
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3.6  Discussion 
This  study  assessed  changes  in  the  prevalence  and  load  of  HRV  infection  in  sputum 
samples from the airways of COPD patients using real-time qPCR in the stable state and at 
acute exacerbation.  
 
Previous  studies  exploring  viral  infection  in  COPD  have  shown  a  higher  rate  of  virus 
detection  at  exacerbation  compared  to  stable  COPD.  Rohde  and  colleagues  detected 
respiratory viruses in 47% of sputum exacerbation samples which was significantly higher 
than the 10% detected in stable state sputum (Rohde et al., 2003). However when using 
nasal samples as opposed to sputum samples, the difference in viral prevalence between 
the two disease states was not significant (Rohde et al., 2003). Similarly, Liao found that 
HRV  increased  significantly  from  5.3%  in  the  stable  state to  21.9%  at  exacerbation in 
sputum samples but from 3.5% to 13.2% in nasal samples (Liao et al., 2014). Tan and 
colleagues reported an increase in viral detection from 7% in the stable state to 64% at 
exacerbation (Tan et al., 2003) and Papi and colleagues found 48.4% of exacerbations to 
be positive for viral infection compared to 6.2% in stable COPD (Papi et al., 2006). In 2001, 
Seemungal and colleagues reported HRV to be the most prevalent virus detected at COPD 
exacerbation  (Seemungal  et  al.,  2001).  Furthermore,  this  group  showed  that  HRV 
prevalence increased from 7.4% in the stable state to 59.1% at exacerbation (Seemungal 
et al., 2000b). The results from the current study are consistent with the findings from Chapter 3 – HRV in stable COPD and at exacerbation 
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these previous studies showing the prevalence of HRV in sputum to increase significantly 
from 17.2% in the stable state, to 41.9% at COPD exacerbation.  
 
Compared to the number of studies examining changes in HRV prevalence in COPD, fewer 
studies have explored changes in HRV load using qPCR techniques however it is important 
to investigate changes in HRV load as well as prevalence to further understand the role of 
HRV in COPD. In 2010, Quint and colleagues explored HRV load changes between stable 
COPD  and  exacerbation  and  found  a  significant  increase  in  HRV  load  at  exacerbation 
compared  to  stable  state  (Quint  et  al.,  2010).  In  2011,  Mallia  and  colleagues 
experimentally infected mild COPD patients with HRV and found that HRV was detected in 
airway  sputum  samples  following  inoculation  and  that  HRV  load  increased  after 
inoculation, peaking on day 5 (Mallia et al., 2011). The results from the current study 
found HRV load to be significantly increased at exacerbation compared with stable COPD 
which is consistent with these previous studies. Furthermore, the load was also found to 
increase from stable COPD to exacerbation when exploring HRV load in absolute terms. 
When evaluating HRV load changes in patients with paired stable state and exacerbation 
state data, it was found that in 68.5% of paired samples there was an increase in HRV load 
from the stable state to exacerbation suggesting that increases in HRV load detected at 
COPD exacerbation, are not driven by just a small number of patients, but occur in the 
majority of cases.  
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While  HRV  prevalence  and  load  have  been  shown  to  be  significantly  higher  at 
exacerbation than in the stable state, it is important to consider viral infection in stable 
COPD. Although HRV was detected in few stable state samples in this sample set, HRV 
loads were low, which suggests that circulating HRV infection may be present in these 
patients,  however  it  did  not  lead  to  the  onset  of  symptoms  or  an  exacerbation. 
Furthermore, in some instances, HRV detection in the stable state may be the end product 
of  a  previous  HRV-associated  exacerbation  or  the  start  of  a  new  one.  In  this  study 
however, patients were only considered stable providing there had been no exacerbation 
onset for four weeks prior to, or two weeks after, the stable state sample being collected. 
 
The main findings from this study confirm the association of HRV infection with COPD 
exacerbations suggested previously by other groups. The significant increase in HRV load 
from the stable state to exacerbation indicates that HRV load may be a critical factor in 
contributing  to  exacerbations  of  COPD.  Conversely,  it  must  be  considered  that  an 
exacerbation  itself  may  create  an  environment  which  allows  HRV  to  increase  in  load 
however, the experimental work by Mallia and colleagues (Mallia et al., 2011) supports 
the initial suggestion and based on the results of the current study, it seems HRV infection 
plays  a  key  role  in  the  onset  of  COPD  exacerbations.  These  findings  illustrate  the 
importance  of  HRV  infection  at  COPD  exacerbation  and  emphasise  the  need  for  the 
development of therapy to treat HRV infections with the aim of reducing exacerbation 
frequency  and  improving  health  status,  particularly  as  it  is  thought  that  current Chapter 3 – HRV in stable COPD and at exacerbation 
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treatments only reduce mortality rates by  approximately 25% (TORCH, 2004). The current 
findings provide further evidence for the role of HRV in COPD exacerbations and should 
provide  a  basis  for  further  study  into  HRV  infection  in  COPD.  The  findings  stress  the 
importance of HRV and emphasise the need for the development of HRV specific antiviral 
therapy.  
 
HRV infection is a common cause of upper respiratory tract infections (Pattemore et al., 
1992)  but  the  ability  of  HRV  to  infect  the  lower  airways  remained  controversial  as 
evidence suggested the optimal growth temperature for most HRV serotype was 33°C 
which  is  the  temperature  of  the  nasal  epithelium  (Papadopoulos  et  al.,  2000,  1999). 
However  a  number  of  studies  showed  that  in  fact  HRV  was  able  to  infect  the  lower 
airways (Gern et al., 1997; Horn et al., 1979; Liao et al., 2014; Papadopoulos et al., 1999; 
Seemungal et al., 2000). Liao and colleagues showed a higher prevalence and load of HRV, 
at  both  the  stable  state  and  at  exacerbation,  in  sputum  samples  compared  to  nasal 
samples  (Liao  et  al.,  2014)  and  Seemungal  and  colleagues  showed  a  40%  higher 
prevalence  of  HRV  in  induced  sputum  samples  from  the  lower  airways  compared  to 
nasopharyngeal  samples  from  the  upper  airway  (Seemungal  et  al.,  2000).  A  study 
exploring the role of viruses and bacteria using nasal swabs, sputum and throat swabs 
found that virus was recovered more often from sputum samples than throat or nasal 
samples, suggesting that viral replication can occur freely in the lower respiratory tract 
(Horn et al., 1979). The findings from these studies indicate that the use of sputum is not Chapter 3 – HRV in stable COPD and at exacerbation 
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only suitable, but preferable, for the detection of viruses so throughout this study sputum 
samples were used for HRV detection and quantification.  
 
An important component of the data analysis performed in this chapter involved using 
both paired and unpaired data. Unpaired analysis is more commonly used than paired 
analysis  in  studies  comparing  differences  in  HRV  infection  between  stable  and 
exacerbation states of COPD (Papi et al., 200; Rohde et al., 2003; Seemungal et al., 2001; 
Tan et al., 2003) which may be due to the challenges that often occur with longitudinal 
studies.  These difficulties  were  overcome  in  the  current  study  and  showed  significant 
increases  in  HRV  prevalence  and  load  from  stable  COPD  to  exacerbation  using  both 
methods of analysis. It must be recognised that paired analysis also introduces its own 
population bias as only chronic sputum producers are included in this analysis.  
 
Until now, studies of natural exacerbations have focused on the changes in HRV infection 
in the stable state and at exacerbation. However, in order to advance our understanding 
of HRV infection in COPD, it is important to explore HRV infection during the time-course 
of exacerbation and recovery in naturally occurring exacerbations. Furthering the current 
knowledge of HRV and investigating changes in the time-course of HRV prevalence and 
load during natural exacerbations will allow the pattern of HRV to be explored leading to 
potential modifications in the current approaches to COPD patient treatment strategies. Chapter 3 – HRV in stable COPD and at exacerbation 
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These  results  may  help  to  provide  better  strategies  for  the  management  of  COPD 
exacerbations  and  health-care  planning.  Chapter  4  investigates  HRV  infection  during 
naturally  occurring  COPD  exacerbation  and  recovery  in  patients  in  the  London  COPD 
cohort.  
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3.7  Conclusion  
The findings from this study showed that the prevalence of HRV in sputum was greater 
at exacerbation than in the stable state. Similarly, HRV load measured by qPCR was 
significantly higher at exacerbation compared with the stable state in both unpaired 
and  paired  analysis.  These  findings  emphasise  the  importance  of  HRV  infection  at 
COPD exacerbation, and stress the significance of HRV as a target for therapy in COPD 
with the objective of reducing exacerbation frequency and improving health status.   Chapter 4 – HRV infection during exacerbation and recovery time-course 
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CHAPTER 4. Time-course of HRV infection 
during COPD exacerbation and recovery 
   Chapter 4 – HRV infection during exacerbation and recovery time-course 
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4.1  Introduction 
The current study aimed to explore HRV infection in COPD patients over the entire 
time-course  of  natural  exacerbations,  from  exacerbation  presentation  until  Day  56 
post-exacerbation. Furthermore, it aimed to examine whether certain inflammatory 
markers could be used as indicators of HRV infection at various time-points during 
COPD exacerbation and recovery. 
 
As reported in the previous chapter, human rhinovirus (HRV) prevalence and load were 
significantly increased in the airways of COPD patients at exacerbation compared to in 
the stable state. As discussed previously, changes in HRV infection between these two 
disease  states  has been  explored by  a  number  of  studies,  however,  HRV  infection 
during the entire time-course of COPD exacerbations and recovery, has not yet been 
investigated in naturally occurring COPD exacerbations.  
 
Experimental  HRV  infection  studies  in  asthma  have  yielded  important  insights  into 
disease  mechanisms  (Message  et  al.,  2008;  Wark  et  al.,  2005)  however  no  similar 
experimental  model  existed  for  COPD  until  2006  when  Mallia  and  colleagues 
performed  a  pilot  investigation  in  which  mild  COPD  patients  were  experimentally 
infected with HRV (Mallia et al., 2006). This work was advanced in 2011 using larger 
study  numbers  and  explored  the  changes  in  HRV  load  over  the  time-course  of 
exacerbations and recovery, and found that in sputum samples HRV load was shown to 
peak at Day 5 post-inoculation with HRV (Mallia et al., 2011). This study is a valid Chapter 4 – HRV infection during exacerbation and recovery time-course 
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model of  HRV  infection  over  the time-course of  COPD  exacerbations and  recovery 
using  experimental  infection,  which  allows  HRV  infection  to  be  measured  in  a 
controlled manner. However this study only involved mild COPD patients and low dose 
HRV for inoculation, which does not necessarily give a true representation of natural 
HRV infection found in COPD patients in the community. It is necessary to investigate 
HRV changes in subjects with varying degrees of disease severity and with natural, 
community-acquired HRV infection. The current study which explores HRV infection 
over  the  time-course  of  naturally  occurring  COPD  exacerbations  and  recovery  will 
provide new insight into the pattern of HRV infection over the time-course that has not 
been investigated previously. The findings of this study may impact on the way in 
which  HRV-associated  exacerbations  of  COPD  are  treated  clinically,  and  stimulate 
further research into HRV infection in natural exacerbations of COPD.  
 
Inflammatory markers are a class of proteins whose levels increase or decrease in 
response to inflammation. They can be used to give an indication of the aetiology of 
COPD exacerbations such as whether they are of an infective or non-infective nature, 
which may impact on exacerbation management. They may also be used to give an 
indication of exacerbation recovery time and prognosis, however are used more widely 
as research tools as opposed to being used clinically. Mallia and colleagues found a 
significant increase in IL-8 levels at Day 9 post-inoculation but saw no change in IL-6 or 
TNF-α.  To  date,  changes  in  the  levels  of  IL-6  and  IL-8  between  stable  COPD  and 
exacerbation  have  been  reported;  Hurst  and  colleagues  showed  that  IL-6  levels  in 
plasma were significantly increased from the stable state to exacerbation (Hurst et al., Chapter 4 – HRV infection during exacerbation and recovery time-course 
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2006),  and  Seemungal  and  colleagues  showed  an  increase  in  sputum  IL-6  at 
exacerbation  compared  to  the  stable  state  but  no  significant  changes  in  IL-8 
(Seemungal et al., 2000). Further studies have shown a relationship between changes 
in inflammatory markers and bacterial or viral infection. It was shown in 2000 that 
increased airway inflammation was associated with the isolation of certain bacterial 
species; in particular, exacerbations associated with H influenzae were found to have 
increased  levels  of  IL-8  and  TNF-α  and  those  associated  with  M  catarrhalis  had 
increased levels of TNF-α (Sethi et al., 2000). Inflammatory markers have also been 
shown to increase with bacterial load increases, in stable chronic bronchitis patients 
(Hill et al., 2000). In 2010, Quint and colleagues showed that interferon-γ-inducible 
protein (IP-10) levels increased significantly from the stable state to exacerbation in 
COPD patients. IP-10 is a chemokine secreted by bronchial epithelial cells, monocytes 
and leukocytes in response to interferon-γ (IFN-γ) and TNF-α. The study reported a 
significant  relationship  between  HRV  load  and  IP-10  levels  showing  IP-10  to  be  a 
successful  marker  of  HRV  infection.  IL-6  levels  were  shown  not  to  correlate  with 
changes  in  HRV  load,  however  increases  in  IL-6  levels  from  the  stable  state  to 
exacerbation were greater in the presence of HRV (Quint et al., 2010). Saldias and 
colleagues showed a significant increase in IL-6, IL-8 and TNF-α at exacerbations with 
IL-6  increasing  particularly  in  the  presence  of  airway  bacteria.  Compared  to  viral 
exacerbations,  bacterial-associated  exacerbations  were  associated  with  a  higher 
degree of systemic inflammation (Saldías et al., 2012). Wilkinson and colleagues also 
showed an increase in IL-8 levels in bacterial exacerbations and showed that patients 
with  more  severe  COPD  exhibited  a  greater  rise  in  inflammation  at  exacerbation Chapter 4 – HRV infection during exacerbation and recovery time-course 
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compared to more mild patients (Wilkinson et al., 2006). These studies illustrate how 
certain inflammatory markers increase at COPD exacerbation and in the presence of 
infection. They have been shown to be important in terms of indicating exacerbation 
onset  by  increasing  significantly  from  the  stable  state  to  exacerbation.  To  date 
however, the changes in levels of inflammatory markers have not been investigated 
over the recovery period in naturally occurring exacerbations association with HRV 
infection.  
 
This study aimed to explore the prevalence and load of HRV over the time-course of 
natural exacerbations, from exacerbation presentation until Day 56 post-exacerbation 
and also to examine the potential use of inflammatory markers as indicators of HRV 
infection at various time-points during COPD exacerbation and recovery.  
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4.2  Characteristics of patients in unpaired analysis 
A total of 537 samples from 71 COPD patients were analysed between April 2010 and 
June 2013 as part of the sample collection performed in the London COPD cohort. 
These  537  samples  were  taken  at  6  different  time-points  during  exacerbation  and 
recovery; 129 samples were taken at exacerbation presentation (ExP), 92 at Day 3 
post-exacerbation, 115 at Day 7, 102 at Day 14, 77 at Day 35 and 22 at Day 56.  The 
baseline clinical characteristics for these patients are shown in Table 4.1.   
 
 
 
 
 
 
 
Table 4.1: Baseline clinical characteristics of 71 patients in the London COPD Cohort, who 
participated in a study of HRV presence during COPD exacerbation and recovery in unpaired 
analysis. Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.19 (±0.5) 
FVC, litres  2.45 (±0.8) 
FEV1/FVC, %  46.2 (±14.9) 
Predicted FEV1, %  45.9 (±19.6) 
Current Smoker, %  33 
Age, years  72 (±8.0) 
Male gender, %  61 Chapter 4 – HRV infection during exacerbation and recovery time-course 
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4.3  Results – unpaired analysis 
4.3.1   Change in HRV prevalence over time 
From a total of 129 exacerbation presentation (ExP) samples, 46.5% (60/129) were 
found to be positive for HRV. Of the 92 samples taken at Day 3, 30.4% (28/92) were 
positive for HRV, 23.5% (27/115) at Day 7, 13.7% (14/102) at Day 14, 5.2% (4/77) at 
Day 35 and 4.5% (1/22) at Day 56. There was a significant fall in the prevalence of HRV 
from ExP to each time point during the recovery period (all p<0.014). There were also 
significant  decreases  in  HRV  prevalence  from  Day  3  to  Day  14  (p=0.004),  Day  35 
(p<0.001) and Day 56 (p<0.001), and from Day 7 to Day 35 (p=0.001) and Day 56 
(p=0.044) (Figure 4.1).   
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Figure  4.1:  Change  in  the  HRV  prevalence  during  the  time-course  of  COPD 
exacerbations from presentation (ExP) and during recovery in unpaired analysis.  
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4.3.2  Change in HRV load over time  
In the exacerbations positive for HRV at presentation (ExP) (n=60), the median (IQR) 
HRV load decreased significantly from ExP (10
3.27(1.68-4.90) pfu/ml) to Day 3 (10
1.29(0-2.56) 
pfu/ml),  to Day  7  (10
0(0-1.67)  pfu/ml),  to Day  14  (10
0(0-0)  pfu/ml),  to  Day  35  (10
0(0-0) 
pfu/ml) and to Day 56 (10
0(0-0) pfu/ml) (all p<0.001). There was also a significant fall in 
median HRV load from Day 3 to Day 14, Day 35 and Day 56 (all p<0.001) and from Day 
7 to Day 35 and Day 56 (both p≤0.003) (Figure 4.2). 
 
Figure 4.2: Change in the  HRV load during the time-course of COPD exacerbations from 
presentation (ExP) and during recovery in unpaired analysis. Data shown as mean (±95% CI). Chapter 4 – HRV infection during exacerbation and recovery time-course 
154 
 
4.3.3  Treatment 
Of  the  129  exacerbations,  93  (72.1%)  were  treated  with  corticosteroids  at 
presentation; 91.1% of these for 7 days of corticosteroids treatment. There was no 
difference  in  the  HRV  load  at  any  time  point,  from  ExP  to  Day  56,  between 
exacerbations treated with corticosteroids compared to those not treated. Similarly 
with antibiotics, of the 129 exacerbation, 122 (94.6%) were treated with antibiotics at 
presentation; 92.6% of these for 7 days. There was no difference in HRV load at any 
time point, from ExP to Day 56, between exacerbations treated with antibiotics and 
those that were not.  
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4.4  Characteristics of patients in paired analysis 
In a sub-analysis of 22 patients, paired sputum samples i.e. samples taken at each of 
the 5 time-points from exacerbation presentation (ExP) to Day 35 post-exacerbation 
were analysed (there was only a small number of patients who attended the Day 56 
post-exacerbation visits) over 28 exacerbations. This paired analysis aimed to reduce 
or avoid any bias that may occur when different patients are used to show changes 
and differences in HRV infection at different during COPD exacerbation and recovery.  
 
For the paired analysis, there were 140 samples from these 22 patients; 28 samples 
were taken at each of the five time-points from ExP and during recovery until Day 35. 
The baseline clinical characteristics for these 22 patients are shown in Table 4.2.   
 
 
 
 
 
 
Table 4.2: Baseline clinical characteristics of 22 patients in the London COPD Cohort, who 
participated in a study of HRV presence during COPD exacerbation and recovery in paired 
analysis. Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.15 (±0.5) 
FVC, litres  2.29 (±0.9) 
FEV1/FVC, %  46.2 (±14.9) 
Predicted FEV1, %  44.9 (±20.3) 
Current Smoker, %  35 
Age, years  70.4 (±8.0)  
Male gender, %  61 Chapter 4 – HRV infection during exacerbation and recovery time-course 
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4.5  Results – paired analysis 
4.5.1  Change in HRV prevalence over time  
From a total of 140 samples, 28 were taken at each time point from ExP until Day 35 
post-exacerbation. Of the 28 samples taken at ExP, 53.6% (15/28) were found to be 
positive for HRV. At Day 3 the HRV prevalence was 42.9% (12/28), 35.7% (10/28) at 
Day 7, 14.3% (7/28) at Day 14 and 3.6% (1/28) at Day 35. There was a significant fall in 
the  prevalence  of  HRV  from  ExP  to  Day  14  (p=0.002)  and  Day  35  (p<0.001)  post-
exacerbation. There were also significant decreases in HRV prevalence from Day 3 to 
Day 14 (p=0.018) and Day 35 (p<0.001), and from Day 7 to Day 35 (p=0.002) (Figure 
4.3). 
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Figure  4.3:  Changes  in  the  HRV  prevalence  during  the  time-course  of  COPD 
exacerbations from presentation (ExP) and during recovery, in paired analysis.  
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4.5.2  Change in HRV load over time  
In exacerbations positive for HRV at ExP (n=15) in this paired analysis, the median (IQR) 
HRV  decreased  significantly  from  ExP  (10
2.51(1.72-3.88)  pfu/ml)  to  Day  3  (10
1.42(0-2.05) 
pfu/ml) (p=0.043) as well as to Day 7 (10
0(0-1.37) pfu/ml), Day 14 (10
0(0-1.48) pfu/ml) and 
Day 35 (10
0(0-1.48) pfu/ml)  (all p<0.002). There was also a significant decrease in the 
median HRV load from Day 3 to Day 7, from Day 7 to Day 14 and from Day 14 to Day 
35 (all p<0.001) post-exacerbation (Figure 4.4).  
 
 
Figure 4.4: Change in the HRV load during the time-course of COPD exacerbations from 
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4.5.3  Treatment 
Of the 28 exacerbations investigated in this paired analysis, 23 (82.1%) were treated 
with  corticosteroids  at  presentation;  95.7%  of  these  for  7  days.  There  was  no 
difference  in  the  HRV  load  at  any  time  point,  from  ExP  to  Day  35,  between 
exacerbations treated with corticosteroids compared to those not treated. Of the 28 
exacerbations, 100% were treated with antibiotics at presentation, 92% were treated 
for 7 days.  
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4.6  HRV infection and inflammatory markers  
Data  was  available  for  inflammatory  markers  IL-6,  IL-8,  IL-1β,  IL-18,  TNF-α,  CRP, 
fibrinogen and IFN-γ at all time-points during the exacerbation and recovery period, 
from ExP (n=105) until Day 35 post-exacerbation.   
 
Inflammatory marker levels were investigated in two groups; exacerbations positive 
for HRV infection and exacerbations negative for HRV infection. At Day 7, the levels of 
sputum IL-6 were significantly higher in the presence of HRV compared to without HRV 
(p=0.014) (Figure 4.5D) but no difference was seen in IL-6 levels at any other time 
points. At Day 14, the levels of IFN-γ were higher in the presence of HRV compared to 
without HRV (p=0.048) (Figure 4.5C) but no differences were seen at any other time 
point.  There  was  no  significant  difference  between  the  levels  of  any  of  the  other 
inflammatory markers meaured, in the presence of HRV compared to without HRV, at 
any other time point (Figure 4.5). Chapter 4 – HRV infection during exacerbation and recovery time-course 
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Figure 4.5: Changes in inflammatory marker levels in the stable state, exacerbation presentation (ExP) and during recovery in samples positive for HRV 
(thick dotted line) and samples negative for HRV (thin solid line). A) HRV, B) TNF-α, C) IFN-γ, D) IL-6, E) IL-1β, F) IL-8, G) CRP, H) fibrinogen and I) IL-18. 
Data shown as mean (±95% CI). Chapter 4 – HRV infection during exacerbation and recovery time-course 
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4.7  Discussion 
For the first time, this study has explored changes in HRV infection over the entire 
time-course of COPD exacerbation and recovery period using both unpaired and paired 
analyses.  The  prevalence  and  load  of  HRV  was  measured  at  6  time-points  from 
exacerbation presentation through to Day 56 post-exacerbation. It was shown in the 
previous chapter (Chapter 3) that HRV prevalence and load increased significantly at 
COPD exacerbation compared to the stable state, however until now, changes in HRV 
prevalence and load from exacerbation presentation, and during the recovery period, 
had not been investigated in natural COPD exacerbations.  
 
It is impossible to compare the results of the current study with any other of its kind as 
this is novel work that has only been explored previously using experimental infection. 
As discussed previously, the changes in HRV load during exacerbation and recovery 
have  been  explored  using  experimental  models  of  HRV  infection  where  Mallia  and 
colleagues  showed  that  HRV  load  was  highest  at  COPD  exacerbation  and  then 
decreased over the recovery period in mild COPD patients who were experimentally 
infected with HRV (Mallia et al., 2011). The current study found similar results to the 
Mallia work when exploring natural HRV infection in COPD exacerbations. It was found 
that both the prevalence and load of HRV were highest at exacerbation presentation 
and decreased over the time-course with significant falls in the load from presentation Chapter 4 – HRV infection during exacerbation and recovery time-course 
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to Day 3 post-exacerbation and from Day 3 to Day 7 until no HRV was detected by Day 
56. HRV prevalence and load were shown to be highest at exacerbation presentation 
suggesting that patients may become infected with HRV a few days before presenting 
to the clinic which highlights the importance of early sampling of COPD patients to 
capture  an  exacerbation  as  early  as  possible.  This  is  also  important  in  terms  of 
exacerbation  treatment  with  the  aim  of  treating  patients  as  early  as  possible  at 
exacerbation onset to try and reduce exacerbation symptoms and length. Furthermore, 
finding HRV prevalence and load to be highest at presentation is important, as one of 
the many obstacles in the development of antiviral therapies is that it is considered 
that patients are likely to present with symptoms, and be prescribed therapy, too late 
for the antiviral to have an effect. These findings however illustrate that HRV load is 
highest  when  patients  report  to  the  clinic  suggesting  that  viral  replication  may  be 
ongoing  and  therefore  antiviral  therapy  may  be  effective  at  this  time  point.  This 
highlights the need for the rapid development of antiviral therapies for the treatment 
of  COPD  exacerbations  as  patients  have  highest  HRV  loads  at  exacerbation 
presentation.  
 
At  present  there  are  no  antivirals  in  use  for  the  treatment  of  HRV  in  COPD.  The 
development of an antiviral is essential for patients with HRV-associated exacerbations 
of COPD however until this need it met, the development of guidelines for clinicians to 
aid treatment in this sub-population of COPD patients may be of use. The findings from Chapter 4 – HRV infection during exacerbation and recovery time-course 
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this study add to the knowledge of the natural history of these common and important 
events. The results give further insight into the pattern of HRV infection and may be 
useful  in  helping  clinicians  counsel  and  educate  patients  about  HRV-associated 
exacerbations.  Furthermore,  focusing  on  natural  HRV  infection  and  natural 
exacerbations allows the generation of genuine results based on COPD patients in the 
community.  This  work  allows  further  investigation  into  the  mechanisms  of  HRV 
infection and HRV-induced exacerbations of COPD and should stimulate research into 
novel antiviral therapies for HRV-infected COPD patients. Although there have been a 
number of molecules that have demonstrated activity against HRV serotypes in vitro, 
these have not been developed for use in humans. This is mainly due to the lack of 
mouse models for HRV therapy research. The majority of HRV serotypes are part of the 
major group of HRVs which bind to human ICAM-1 receptors in the nasal epithelium 
and therefore cannot infect mice. A study that developed a transgenic mouse that 
expressed  human  ICAM-1  found  that  infected  mice  had  increased  chemokines, 
cytokines, neutrophils and viral RNA (Bartlett et al., 2008). When using an anti-ICAM-1 
antibody in the mouse model, there was a decrease in inflammatory cells and cytokines 
and  a  significant  reduction  in  HRV  replication  was  shown  (Traub  et  al.,  2013). 
Furthermore, a study exploring highly conserved regions of the HRV proteome, in the 
mouse model, with the aim of finding them to be useful candidates for a broadly cross-
reactive  vaccine,  found  that  conserved  regions  of  the  HRV  capsid  induced  cross-
reactive  immune  responses  and  were  therefore  potential  candidates  for  use  in  a Chapter 4 – HRV infection during exacerbation and recovery time-course 
165 
 
subunit  vaccine  (Glanville  et  al.,  2013).  These studies  were  the  first  to  successfully 
demonstrate a therapeutic intervention in a small animal model of HRV infection which 
provides optimism for the prospect of testing potential compounds in vitro with the 
possibility of use in humans (Gunawardana et al., 2014). 
 
Previous studies have shown changes in the levels of inflammatory markers between 
stable state COPD and exacerbation (Bhowmik et al., 2000; Hurst et al., 2006; Quint et 
al., 2010); the time-course of an exacerbation and recovery has been explored to a 
lesser extent at present. The levels of IL-8 have been shown to increase in the sputum 
of experimentally infected COPD patients, peaking on Day 9 post-inoculation. However 
no significant changes were found in other inflammatory markers such as IL-6 and TNF-
α (Mallia et al., 2011). To date, there have been no studies investigating the changes in 
the  levels  of  inflammatory  markers  over  the  time-course  of  an  exacerbation  and 
recovery, with natural HRV infection, in particular comparing the levels of inflammatory 
markers in the presence of HRV infection and in the absence of HRV infection. The 
current study is the first to explore this, focusing on the inflammatory markers IL-6, IL-
8, IL-1β, IL-18, TNF-α, CRP, fibrinogen and IFN-γ. This panel of inflammatory markers 
were chosen as the best evidence in the literature at the time suggested they would be 
useful (Footitt et al., 2013; Makarova et al., 2013; Mallia et al., 2011; Piper et al., 2013). 
The current study showed that at Day 14 post-exacerbation, the levels of IFN-γ were 
significantly higher in the presence of HRV compared to without HRV, and at Day 7 IL-6 Chapter 4 – HRV infection during exacerbation and recovery time-course 
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levels  were  significantly  higher  in  the  presence  of  HRV  compared  to  without  HRV. 
However  other  than these  differences,  there were  no  significant  differences  in  the 
levels of any of the inflammatory markers measured, at any time point, between the 
two groups. IFN-γ has been shown to be a key constituent of innate immune responses 
to viral infection by the production of interferons (IFN) by infected cells (Mallia et al., 
2011).  It  has  been  shown  that  primary  airway  epithelial  cell  cultures  from  COPD 
patients  demonstrated  increased  expression  of  IFN  in  response  to  HRV  infection 
(Schneider et al., 2010). It has also been shown that levels of IFN-β are lower in HRV-
infected COPD subjects compared to HRV-infected healthy controls which suggests that 
deficient IFN-β production may contribute to increased susceptibility to HRV infection 
in COPD (Mallia et al., 2011). Furthermore, Becker and colleagues showed how IFNs 
significantly reduced HRV replication after high- and low-dose inoculation of primary 
human bronchial epithelial cells suggesting that exogenous IFNs warrant further study 
as potential therapy for asthma exacerbations (Becker et al., 2013), and Djukanovic and 
colleagues showed that inhaled IFN-β may be a used as a potential treatment for virus-
induced deteriorations in asthma (Djukanović et al., 2014). This may be applicable to 
COPD also. Although IFNs have been shown to play a role in HRV infection in terms of 
reducing  HRV  infection  or  as  potential  therapy,  the  results  from  the  current  study 
suggest that IFN-γ does not reflect HRV infection at exacerbation or during recovery 
except at Day 14 when HRV load had significantly decreased compared to exacerbation 
presentation, and is therefore not a good enough indicator of changes in HRV infection Chapter 4 – HRV infection during exacerbation and recovery time-course 
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during exacerbation time-course. IL-6 levels were only shown to be significantly higher 
in  HRV  infected  samples  compared to those not  infected  with  HRV  at  Day  7 post-
exacerbation.  One  study  showed  elevated  IL-6  levels  to  be  associated  with  HRV 
infection at exacerbation (Seemungal et al., 2000) however other studies have shown 
this not to be the case; Quint and colleagues found no relationship between IL-6 levels 
and HRV loads in sputum (Quint et al., 2010) as did the work by Mallia and colleagues 
who found no change in baseline IL-6 levels after infection with HRV (Mallia et al., 
2011). Although the current study found higher levels of IL-6 and IFN-γ in the presence 
of HRV, this was only at Day 7 and Day 14, respectively, when HRV load had fallen 
significantly  from  presentation  which  suggests  that  the  increased  levels  of 
inflammatory markers at these time points, may be due to other sources such as a the 
development of secondary bacterial infection or another viral infection. These findings 
suggest that none of the inflammatory markers measured are representative enough of 
HRV infection over the time-course and therefore cannot be used as suitable or useful 
markers of HRV infection. Further study into associations between HRV infection and 
inflammatory marker levels must be performed before these inflammatory markers, or 
others, can be considered as indicators of HRV infection.  
 
The  limitations  of  this  study  may  have  impacted  on  the  findings.  The  number  of 
samples  may  have  played  a  role,  where  this  part  of  the  study  may  have  been 
underpowered  for  any  significant  associations  with  inflammatory  markers,  to  be Chapter 4 – HRV infection during exacerbation and recovery time-course 
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identified. However by repeating the study with higher study numbers, or performing 
further investigations with other inflammatory markers, more definitive conclusions 
may be made. Furthermore, there may be a threshold value for HRV to be associated 
with greater inflammation which was not reached in this study. These limitations are 
likely to have impacted on the study findings, and further study is required, particularly 
into  IL-6  and  IFN-γ,  before  any  true  associations  between  HRV  infection  and  these 
inflammatory markers during exacerbation recovery, can be determined. Associations 
between  upper  respiratory  tract  (URT)  symptoms  and  HRV  infection  have  been 
discussed in Chapter 5, in which the data suggests URT symptoms may be a better 
indicator of HRV infection than the inflammatory markers measured in this study.  
 
In a small number of the time-courses used in this study, it was not possible to obtain 
data from every patient at every time point during the whole time-course. In some 
cases patients were unable to attend one or more of their clinic visits during the time-
course due to various reasons. In other cases, patients may have attended each of their 
recovery clinic visits, however were unable to produce sputum at certain visits. This 
resulted in missed sample collection at some time-points which led to missing data for 
some patients. Unpaired analysis was used for these time-courses however to minimise 
bias within the data analysis, paired analysis was also used for the time-courses that 
had available data for each of the six time-points throughout an exacerbation.  Chapter 4 – HRV infection during exacerbation and recovery time-course 
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4.8  Conclusion  
For the first time, this study explored the changes in HRV prevalence and load during 
the  entire  time-course  of  naturally  occurring  exacerbations  and  recovery.  HRV 
prevalence and load was highest at exacerbation presentation and decreased over the 
time-course of recovery until it was undetectable by Day 56. There was no difference in 
the levels of inflammatory markers in the presence of HRV compared to the absence of 
HRV over the time-course, except for IFN-γ at Day 14 and IL-6 at Day 7 which were 
higher in the presence of HRV compared to without HRV. This suggests that these 
particular inflammatory markers, measured in this study, are not useful markers of HRV 
infection during exacerbation and recovery, and further study is required. The findings 
of this study may have implications in terms COPD exacerbation treatment and should 
stimulate research into novel antiviral therapies. The results emphasise the importance 
of rapid development of therapies for HRV with the aim of prescribing antiviral therapy 
early at exacerbation onset thus reducing exacerbation length and severity. Chapter 5 – HRV and upper respiratory tract symptoms 
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CHAPTER 5. HRV infection and upper respiratory 
tract symptoms in patients with COPD  
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5.1  Introduction 
This study aimed to determine the association of cold symptoms and sore throats with 
both the prevalence and load of HRV, in the stable state, at COPD exacerbation and during 
the recovery period, in naturally occurring exacerbations.  
 
Relationships between viral infection and upper respiratory tract (URT) symptoms such as 
cold symptoms and sore throats, at exacerbation, have been reported by a number of 
studies.  In  2001,  Seemungal  and  colleagues  investigated  the  relationship  between 
exacerbations  of  COPD  and  viral  infection  by  looking  at  various  parameters  including 
symptoms. The study showed that cold symptoms and sore throats were associated with 
viral detection at COPD exacerbation, and these symptoms were more strongly associated 
with viral infection than all other symptoms measured  although associations between 
symptoms and viral quantities was not explored (Seemungal et al., 2001) (Table 5.1).  
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Symptoms at presentation  Odds ratio  p value 
  Colds*  3.55  <0.001 
  Increased dyspnoea and colds*  3.27  0.001 
  Sore throat  2.27  0.043 
  Increased sputum volume   1.59  0.182 
  Increased dyspnoea  1.38  0.42 
  Increased sputum purulent  1.31  0.421 
  Increased cough  1.22  0.552 
  Increased wheeze  1.09  0.786 
Table 5.1: Effect of symptoms on detection of viruses in nasal samples during exacerbations of 
COPD.  *Colds;  increased  nasal  congestion  and/or  increased  rhinorrhoea.  Adapted  from 
(Seemungal et al., 2001). 
 
A  study  in  2012  comparing  host,  virological  and  environment  factors  associated  with 
symptomatic  and  asymptomatic  HRV  infection  found  that  35%  of  HRV  symptomatic 
subjects had reported cold symptoms (Gandhi et al., 2012). A study exploring HRV load in 
nasopharyngeal  samples  from  immunocompetent  and  immunocompromised  subjects, 
found that HRV loads >10
5 RNA copies/mL were frequently associated with the presence 
of clinical symptoms in the lower or upper respiratory tract, whereas HRV loads <10
5 RNA 
copies/mL were infrequently associated with clinical symptoms (Gerna et al., 2009). It has Chapter 5 – HRV and upper respiratory tract symptoms 
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also been reported that viral-associated exacerbations have a longer recovery time in 
terms of symptoms when compared to non-viral associated exacerbation (Seemungal et 
al., 2001). Seemungal and colleagues reported the median symptom  recovery time of 
viral-associated exacerbations to be 13 days which was significantly longer than the typical 
6 day recovery time seen in non-viral associated exacerbations (p=0.006) (Seemungal et 
al., 2001).  
 
Although there have been studies investigating upper respiratory tract (URT) symptoms 
and viral prevalence, associations between URT symptoms and viral load, in particular HRV 
load, have not yet been explored in COPD. Furthermore, the association of URT symptoms 
and  viral infection  has been  explored  at  COPD  exacerbation but  not during  the time-
course of an exacerbation and recovery period in natural exacerbations. Experimental 
studies have explored the time-course of URT symptoms with HRV infection; Mallia and 
colleagues found an increase in URT daily symptom scores in patients with mild COPD 
experimentally infected with HRV peaking within a week post-inoculation (Mallia et al., 
2011).  Similarly,  a  study  by  Grünberg  and  colleagues  in  which  non-smoking  asthma 
patients were experimentally infected with HRV or placebo, explored the changes in cold 
symptoms (sore throat, headache, nasal discharge, stuffy nose, malaise, cough and fever) 
over the time-course of HRV infection. They showed that in the HRV infected group, the 
cold  symptoms  started  increasing  from  Day  0  onwards,  peaking  on  Day  2  and  then Chapter 5 – HRV and upper respiratory tract symptoms 
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returning to baseline by Day 7 (Figure 5.1) and this increase was significantly different 
from the placebo group (p<0.01) (GRÜNBERG et al., 1999).  
 
Figure 5.1: Cold symptoms (excluding cough score) in asthmatic patients experimentally infected 
with HRV. The closed symbols indicate the mean values (GRÜNBERG et al., 1999).  
 
Although there have been experimental studies into associations between URT symptoms 
and HRV infection during exacerbation and recovery (Mallia et al., 2011), there has not yet 
been any investigations into URT symptoms and HRV infection over the time-course of 
naturally  occurring exacerbations  and  recovery period.  Additionally,  in the  majority  of 
studies in this subject, cold symptoms and sore throats have been examined collectively 
rather  than  as  separate  symptoms.  However,  comparisons  between  HRV  infection  in 
patients reporting one symptom and those reporting multiple symptoms have not been Chapter 5 – HRV and upper respiratory tract symptoms 
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explored. This may be a useful area to explore if the number of symptoms experienced by 
a  patient  is  related  to  HRV  prevalence  or  load  which  may  therefore  impact  on  the 
approach to exacerbation diagnosis and treatment.  
 
For the first time, this study aimed to determine the association of URT symptoms with 
HRV  prevalence  and  load,  in  the  stable  state  COPD,  at  exacerbation  and  during  the 
recovery period, in naturally occurring exacerbations.  
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5.2  Characteristics of patients used in stable state and 
exacerbation analysis 
A  total  of  58  stable  state  samples  and  272  exacerbation  samples  (7  of  the  279 
exacerbation  samples  had  missing  URT  symptom  data)  from  146  COPD  patients  were 
analysed  between  January  2008  and  March  2014  as  part  of  the  sample  collection 
performed in the London COPD cohort. The baseline clinical characteristics of the 146 
patients included are shown in Table 5.2 below.   
 
 
 
 
 
 
 
Table 5.2: Baseline clinical characteristics of 146 COPD patients in the London COPD Cohort, who 
participated  in  study  of  HRV  infection  and  upper  respiratory  tract  symptoms  at  COPD 
exacerbation  (n=272)  and  in  the  stable  state  (n=58).  Data  are  presented  as  mean  (±SD)  or 
percentage (%).  
 
FEV1, litres  1.18 (±0.5) 
FVC, litres  2.56 (±0.9) 
FEV1/FVC, %  46.1 (±14.8) 
Predicted FEV1, %  47.0 (±21.7) 
Current Smoker, %  33 
Age, years  69.8 (±8.5)  
Male gender, %  59 Chapter 5 – HRV and upper respiratory tract symptoms 
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5.3  Results using stable state and exacerbation samples 
5.3.1  URT symptom prevalence in different disease states 
In the stable state, cold symptoms were reported in 16 of the 58 samples (27.6%). This 
prevalence of cold symptoms increased significantly at exacerbation where 115 or the 272 
samples (42.3%) had reported cold symptoms; p=0.038 (Figure 5.2).  
 
Figure 5.2: Comparison of the prevalence of cold symptoms in stable (n=58) and exacerbation 
(n=272) samples; *p=0.038 Chapter 5 – HRV and upper respiratory tract symptoms 
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Sore throats were reported in 2 of the 58 stable samples (3.4%), but increased significantly 
at exacerbation where 38 or the 272 samples (14%) had reported sore throats; p=0.026 
(Figure 5.3).  
 
 
Figure 5.3: Comparison  of  the  prevalence  of  sore throats in  stable  (n=58) and  exacerbation 
(n=272) samples; *p=0.026 
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5.3.2  HRV prevalence with URT symptoms 
At exacerbation (n=272), 115 samples were associated with cold symptoms and 157 were 
not. Of the 115 samples that were associated with cold symptoms, 73 (63.5%) were found 
to positive for HRV. This was significantly higher than in the 157 samples not associated 
with cold symptoms where 44 (28%) were positive for HRV; p<0.001 (Figure 5.4).    
 
 
Figure  5.4:  Comparison  of  the  prevalence  of  HRV  infection  in  samples  with  cold  symptoms 
(n=115) and samples no cold symptoms (n=157), at exacerbation; *p<0.001. Chapter 5 – HRV and upper respiratory tract symptoms 
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Of the same 272 exacerbation samples, 38 samples were associated with sore throats and 
234 were not associated. In the 38 samples that were associated with sore throats, 29 
(63.5%) were found to be positive for HRV which was significantly higher than in the 234 
samples  not  associated  with  cold  symptoms  where  92  (39.3%)  were  positive  for  HRV 
infection; p=0.002 (Figure 5.5).    
 
 
Figure 5.5: Comparison of the prevalence of HRV infection in samples with sore throats (n=38) 
and samples without sore throats (n=234), at exacerbation; *p=0.002. 
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5.3.3  URT symptom prevalence with HRV 
The prevalence of cold symptoms at exacerbation was significantly higher in those with 
(n=117) HRV infection (62.4%) compared to those without (n=155) HRV infection (27.1%); 
p<0.001 (Figure 5.6).  
 
 
Figure 5.6: Comparison of the prevalence of cold symptoms in samples positive for HRV (n=117) 
and negative for HRV (n=155), at exacerbation; *p<0.001. Chapter 5 – HRV and upper respiratory tract symptoms 
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The prevalence of sore throats was significantly higher in those with (n=117) HRV infection 
(21.4%) compared to those without (n=155) HRV infection (8%); p=0.002 (Figure 5.7).  
 
 
Figure 5.7: Comparison of the prevalence of sore throats in samples positive for HRV (n=117) 
and negative for HRV (n=155), at exacerbation; *p<0.001. 
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5.3.4  HRV load with URT symptoms 
HRV-positive exacerbation samples associated with cold symptoms (n=73) had a median 
(IQR) HRV load of 10
4.49(2.49-5.50) pfu/ml which was significantly higher than in HRV-positive 
exacerbations without cold symptoms (n=44), 10
2.51(1.62-4.59) pfu/ml; p=0.004 (Figure 5.8).  
 
 
Figure 5.8: Comparison of HRV load in HRV-positive samples with cold symptoms (n=73) and 
HRV-positive samples without cold symptoms (n=44), at exacerbation; *p=0.004. Data presented 
as median (IQR).  Chapter 5 – HRV and upper respiratory tract symptoms 
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The median (IQR) HRV  load was significantly higher when a sore throat was reported 
(n=25), 10
4.91(3.76-6.56) pfu/ml compared to samples without a reported sore throat (n=92), 
10
3.06(1.66-4.87) pfu/ml; p<0.001 (Figure 5.9).  
 
 
Figure 5.9: Comparison of HRV load in HRV-positive samples with sore throats (n=25) and HRV-
positive samples without sore throats (n=92), at exacerbation; *p<0.001.  
 
When looking at the median (IQR) HRV load in exacerbation samples associated with cold 
symptoms only (n=58), sore throats only (n=8) or both symptoms (n=17), the load was Chapter 5 – HRV and upper respiratory tract symptoms 
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significantly higher in those that had both symptoms (10
6.13(4.07-7.18) pfu/ml) compared to 
those that had cold symptoms only (10
3.84(1.81-5.16) pfu/ml; p=0.002) or a sore throat only 
(10
4.00(2.56-5.12) pfu/ml; p=0.049) (Figure 5.10).   
 
 
Figure  5.10:  Comparison  of  the  HRV  load  at  exacerbation  in  samples  associated  with  cold 
symptoms only (n=56), sore throats only (n=8), or both symptoms (n=17); *p<0.05. Data shown 
as median (IQR).  
The  number  of  HRV-negative  exacerbations  (n=155)  that  had  cold  symptoms  was  42 
(27.1%), 13 (8.4%) had a sore throat and 4 (2.6%) had both symptoms. Chapter 5 – HRV and upper respiratory tract symptoms 
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5.4  Characteristics of patients used in time-course analysis 
A total of 537 samples; 129 taken at exacerbation presentation, 92 at Day 3, 115 at Day 7, 
102 at Day 14, 77 at Day 35 and 22 at Day 56 samples from 71 COPD patients were 
obtained between April 2010 and June 2013. The baseline clinical characteristics for these 
patients are shown in Table 5.3.   
 
 
 
 
 
 
 
Table  5.3:  Baseline  clinical  characteristics  of  71  patients  in  the  London  COPD  Cohort  who 
participated  in  study  of  HRV  infection  with  upper  respiratory  tract  symptoms  during  COPD 
exacerbation and recovery. Data are presented as mean (±SD) or percentage (%). 
 
FEV1, litres  1.19 (±0.5) 
FVC, litres  2.45 (±0.8) 
FEV1/FVC, %  46.2 (±14.9) 
Predicted FEV1, %  45.9 (±20.3) 
Current Smoker, %  33 
Age, years  72 (±8.0)  
Male gender, %  61 Chapter 5 – HRV and upper respiratory tract symptoms 
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5.5  Results using time-course sample analysis 
5.5.1  URT symptom prevalence during the time-course 
At exacerbation presentation (ExP), the percentage of samples that had associated cold 
symptoms was found to be 52.7% (68/129). This prevalence decreased significantly during 
the recovery period to 34.8% at Day 7, 20.6% at Day 14, 15.6% at Day 35 and 22.7% at Day 
56 (all p<0.009) (Figure 5.11).  
 
Figure  5.11:  Change  in  the  prevalence  of  cold  symptoms  during  the  time-course  of  an 
exacerbation and recovery period; *p<0.01.  Chapter 5 – HRV and upper respiratory tract symptoms 
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At exacerbation presentation (ExP), the percentage of samples that had associated sore 
throat was found to be 23.3% (30/129). This prevalence decreased significantly during the 
time-course of the recovery period to 9.8% at Day 14 and 3.9% at Day 35 (both p<0.007) 
(Figure 5.12).  
 
Figure 5.12: Change in the prevalence of sore throats during the time-course of an exacerbation 
and recovery period; *p<0.01.  Chapter 5 – HRV and upper respiratory tract symptoms 
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5.5.2  HRV prevalence with URT symptoms over the time-course 
The  absolute  prevalence  values  of  HRV  were  found  to  be  higher  at  exacerbation 
presentation (ExP) and at each time point during the recovery period until Day 35, in 
samples associated with cold symptoms compared to those not associated, (Figure 5.13) 
however this missed statistical significance for each time point (all p≥0.132) except at Day 
7. At Day 7, the HRV prevalence in samples associated with cold symptoms (37.5%) was 
significantly higher than in samples not associated with cold symptoms (16%) (p=0.016).  
 
Figure 5.13: Comparison of the changes in the prevalence of HRV over the time-course of an 
exacerbation and recovery in samples associated with cold symptoms and those without cold 
symptoms.  Chapter 5 – HRV and upper respiratory tract symptoms 
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The absolute prevalence values of HRV were found to be higher at ExP and at each time 
point during the recovery period until Day 35, in samples associated with sore throats 
compared to those not associated (Figure 5.14), however this did not reach statistical 
significance at any time point (p≥0.115) except Day 3. At Day 3 the HRV prevalence in 
samples associated with sore throats (53.8%) was significantly higher than in samples not 
associated with sore throats (25.3%) (p=0.036).  
 
Figure 5.14: Comparison of the changes in the prevalence of HRV over the time-course of an 
exacerbation  and  recovery  in  samples  associated  with  sore  throats  and  those  without  sore 
throats.  
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The prevalence of HRV was found to be significantly higher in samples associated with 
both cold symptoms and sore throats (57.1%) compared to the HRV prevalence in samples 
with either cold symptoms only (29.9%) or sore throats only (27.3%) in samples from all 
time points; both p<0.010 (Figure 5.15).  
 
Figure  5.15:  Differences  in  the  prevalence  of  HRV  in  samples  associated  with  both  cold 
symptoms and sore throats and those with cold symptoms only or sore throats only, using all 
time points; *p<0.01.  Chapter 5 – HRV and upper respiratory tract symptoms 
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5.5.3  HRV load with URT symptoms over the time-course 
In exacerbations positive for HRV at presentation (ExP), the median (IQR) HRV load was 
significantly higher in patients who reported cold symptoms at ExP (n=34) compared to 
those  that  did  not  (n=26),  10
4.29(2.25-5.22)  pfu/ml  vs  10
2.35(1.39-4.09)  pfu/ml  respectively; 
p=0.006. The median HRV load was also significantly higher in patients who reported cold 
symptoms compared to those that did not at Day 3 (10
1.91(0-4.16) pfu/ml vs 10
0(0-1.77) pfu/ml 
respectively;  p=0.046),  and  at  Day  7,  (10
0(0-3.17)  pfu/ml  vs  10
0(0-0)  pfu/ml  respectively; 
p=0.029).  
 
In both groups, the HRV load fell over the recovery period being highest at Day ExP and 
zero at Day 56. There was a significant fall in the median HRV load from Day ExP to Day 3. 
In patients who reported cold symptoms the HRV load fell from 10
4.29(2.25-5.22) pfu/ml at ExP 
to 10
1.91(0-4.16) pfu/ml at Day 3 (p=0.006) and in patients that did not report cold symptoms 
the load fell from 10
2.35(1.39-4.09) pfu/ml at ExP to 10
0(0-1.77) pfu/ml at Day 3 (p<0.001). There 
was no significant change between any other time-points during the time-course in either 
group (Figure 5.16).   Chapter 5 – HRV and upper respiratory tract symptoms 
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Figure 5.16: The change in HRV load over the time-course of an exacerbation and recovery 
period in samples with cold symptoms and those without cold symptoms. Data shown as mean 
(±SEM).  
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In patients who reported a sore throat, the median HRV load was significantly higher at 
ExP and Day 3 compared to those without a sore throat (both p≤0.018). In those that 
reported  a  sore  throat,  the  HRV  load  at  ExP  was  10
4.91(3.92-5.60)  pfu/ml  compared  to 
10
2.61(1.64-4.61) pfu/ml in those that did not (p=0.006). At Day 3, the HRV load was 10
4.14(1.77-
4.82) pfu/ml in patients who reported a sore throat compared to 10
0(0-1.82) pfu/ml in those 
that did not (p=0.002) (Figure 5.17).  
 
Figure 5.17: The change in HRV load over the time-course of an exacerbation and recovery 
period in samples associated with a sore throat and those without a sore throat. Data shown as 
mean (±SEM).  Chapter 5 – HRV and upper respiratory tract symptoms 
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The median HRV load was significantly higher in patients who had both cold symptoms 
and a sore throat compared to those that had either cold symptoms only or a sore throat 
only, at Day 7 post-exacerbation; the median (IQR) HRV load was 10
4.48(1.85-7.28) pfu/ml in 
those  with  both  symptoms  (n=4)  compared  to  10
0(0-2.74)  pfu/ml  in  those  with  cold 
symptoms only (n=19) (p=0.018) and 10
0(0-0) pfu/ml in those with a sore throat only (n=4) 
(p=0.029). At Day 3, the median (IQR) HRV load in samples associated with both symptoms 
(n=5) was 10
4.22(3.94-4.88) pfu/ml which was significantly higher than in those that had cold 
symptoms only (n=9) (10
0.55(0-1.98); p=0.002) but not in those with a sore throat only (n=2) 
(10
0.89(0-0.89); p=0.095). The median HRV load decreased significantly from ExP to Day 3 in 
samples associated with either cold symptoms (p<0.001) or a sore throat (p=0.049). In 
those associated with both symptoms however, there was no decrease in median HRV 
load between these time-points (Figure 5.18).  
 Chapter 5 – HRV and upper respiratory tract symptoms 
196 
 
 
Figure 5.18: The change in HRV load over the time-course of an exacerbation and recovery 
period in samples associated with both cold symptoms and a sore throat (n=23), cold symptoms 
only (n=67) or a sore throat only (n=16). Data shown as mean (±SEM).  
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5.6  Discussion 
This study investigated the relationship between HRV infection and upper respiratory tract 
(URT)  symptoms,  namely  cold  symptoms  and  sore  throats,  in  the  stable  state,  at 
exacerbation presentation and during recovery until Day 56 post-exacerbation, in natural 
exacerbations of COPD. It also explored changes in URT symptoms in patients who were 
positive for HRV infection and those that were not, and studied these changes in relation 
to the load of HRV as well as the prevalence. For the first time, the association of HRV 
infection and URT symptoms during the complete time-course of naturally occurring COPD 
exacerbations has been investigated.  
 
A study in 2003 which investigated symptom changes at different COPD disease states, 
showed an increase in URT symptoms from the stable state to COPD exacerbation, where 
cold  symptoms  increased  from  23.8%  in  the  stable  state  to  38.8%  at  exacerbation 
(p=0.040), and sore throats increased from 2.4% to 22.4% (p=0.01) (Rohde et al., 2003). In 
2000, Seemungal and colleagues found 61% of exacerbations were associated with colds 
and 30% with sore throats  (Seemungal et al., 2000). The current data supports these 
findings  and  has  found  that  the  prevalence  of  both  cold  symptoms  and  sore  throats 
increased  significantly  from  the  stable  state  to  exacerbation,  verifying  a  relationship 
between an increase in URT symptoms and the onset of COPD exacerbations.   
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URT  symptoms  have  been  shown  to  be  particularly  associated  with  virus-associated 
exacerbations. Kherad and colleagues found cold symptoms in 45% of samples negative 
for HRV but 73% of HRV-positive samples using nasopharyngeal samples (Kherad et al., 
2010) and Seemungal and colleagues showed that viral-associated exacerbations had a 
significantly greater daily symptom score (median=3) compared to non-viral-associated 
exacerbations  (median=2)  (p=0.009)  (Seemungal  et  al.,  2001).  The  current  study  has 
shown that in the presence of HRV, the prevalence of URT symptoms was significantly 
higher than when HRV infection was not present. At exacerbation, the prevalence of HRV 
was significantly higher in patients who reported URT symptoms compared to those that 
did not. These findings suggest that URT symptoms may indicate the presence of an HRV 
infection which could have significant implications in how these exacerbations are treated 
clinically.  Currently,  there  are  no  antiviral  agents  in  use  for  the  treatment  of  HRV 
infections (Mallia et al., 2007). Unlike antivirals such as amantadine and zanamivir which 
have  shown  excellent  activity  against  influenza  viruses  (McKinlay,  2001),  most  of  the 
investigations into the development of antivirals against HRV have failed to show benefits 
in human clinical trials due to adverse events, intolerance and limited potency (McKinlay, 
2001). Pleconaril is an anti-viral drug that was developed in 1997 for the prevention of 
asthma exacerbations and common cold symptoms in patients exposed to HRV infections 
(Turner and Hendley, 2005). It works by inhibiting in vitro replication of most rhinoviruses 
and enteroviruses. It was shown to reduce cold symptom scores and reduce the frequency 
of  picornavirus  infection  cultured  from  nasal  mucus  specimens.  However  it  was  also Chapter 5 – HRV and upper respiratory tract symptoms 
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associated with a higher incidence of nausea and diarrhoea compared to placebo (Hayden 
et al., 2003) and this antiviral is no longer in use. The development of a vaccine for HRV is 
proving difficult due to reasons such as there being over 100 serotypes of HRV with high 
sequence variability in their antigenic sites (Palmenberg et al., 2009). Furthermore, unlike 
influenza,  there  is  limited  knowledge  of  HRV  epidemiology  as  HRV  surveillances  are 
restricted, and also, there are limited animal models for HRV infection and evidence of 
HRV pathophysiology is still scarce (Rohde, 2011). Despite this, and despite not yet being 
close to the clinical development of an HRV vaccine, due to the large number of HRV 
serotypes  (Glanville  et  al.,  2013),  current  research  including  a  study  by  Eldmayr  and 
colleagues,  that  showed  strong  cross-neutralising  activity  for  different  HRV  strains 
(Edlmayr et al., 2011), the development of an HRV vaccine does seem feasible. It must be 
considered that infection with other viruses may lead to the onset of cold symptoms and 
sore throats as well as HRV (Seemungal et al., 2001) and that these viruses may also play a 
role in URT symptom development. However the findings from the current study show an 
association between URT symptoms and HRV infection which must be addressed in terms 
of specific therapy for HRV-associated exacerbations.  
 
To date, the association of URT symptoms and HRV infection over the entire time-course 
of an exacerbation and recovery period has not been investigated in naturally occurring 
exacerbations of COPD. As discussed previously, the study by Mallia in 2011 in which 
patients with mild COPD and healthy controls were experimentally infected with low-dose Chapter 5 – HRV and upper respiratory tract symptoms 
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HRV showed a significant increase in URT symptoms at 2-14 days post-inoculation with 
HRV with symptom counts decreasing during recovery (Mallia et al., 2011). Additionally, 
the study of experimental HRV infection in non-smoking asthmatics found that in patients 
experimentally infected with HRV, cold symptoms started to increase from Day 0, peaking 
on Day 2 before decreasing during exacerbation recovery which was significantly different 
from the placebo group  (Grunberg et al., 1999). The current study, for the first time, 
explored HRV infection over the time-course of exacerbation and recovery in relation to 
URT symptoms in natural exacerbations and reported similar findings to the experimental 
studies described above. The prevalence of URT symptoms was highest at exacerbation 
onset and decreased during recovery up until Day 35 post-exacerbation. The current study 
has shown that at exacerbation presentation and each time point during recovery until 
Day 35, patients who reported having URT symptoms had a higher absolute prevalence of 
HRV  compared  to  those  that  did  not.  HRV  load  was  significantly  higher  in  patients 
reporting cold symptoms or a sore throat at exacerbation presentation, Day 3 and Day 7 
post-exacerbation compared to patients without those symptoms. This is an important 
area of study as measuring the pattern of URT symptoms, not only at exacerbation, but 
during recovery, may give important insight into the pattern of HRV infection which in 
turn may impact on the treatment of exacerbations. Treatment with antiviral or anti-
inflammatory therapy at this point would be preferable. However, as discussed previously, 
there  are  no  current  antivirals  for  the  specific  treatment  of  HRV  infection  in  use  at 
present. Therefore, the development of guidelines with the aim of assisting clinicians in Chapter 5 – HRV and upper respiratory tract symptoms 
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the treatment of the sub-population of HRV exacerbating COPD patients may be the best 
approach now there is an effective method of early identification of HRV in these patients. 
Furthermore, these results may aid clinicians in counselling patients with URT symptoms 
about  their  exacerbation  potentially  lasting  longer  than  other  non-viral  associated 
exacerbations, and that they do not need to seek antibacterial medication at that time.  
 
Not only  was  the  HRV prevalence  and  load  higher  in  the  presence of  URT  symptoms 
compared  to  without  symptoms,  the  prevalence  of  HRV  was  significantly  higher  at 
exacerbation in patients who reported both cold symptoms and a sore throat compared 
to those who reported just one of the symptoms alone. Data from this study showed that 
in patients who reported having either cold symptoms or a  sore throat, the HRV load 
decreased significantly by Day 7. However in patients who reported both symptoms at the 
time of sampling, the HRV load remained elevated until Day 14. This suggests patients 
who have more symptoms at exacerbation have higher HRV loads than those with less 
symptoms, which may indicate more severe exacerbations in terms of greater burden of 
symptoms,  and  that  exacerbations  with  both  symptoms  have  longer  recovery  times 
compared to those with only one symptom. Seemungal and colleagues showed in 2001 
that patients positive with viral infection had a significantly longer recovery time in terms 
of  more  symptoms  than  non-viral  associated  exacerbations  (Seemungal  et  al.,  2001). 
Whether having a higher viral load means a more severe exacerbation compared to those 
with lower loads, has not been explored to date, however the current data shows that Chapter 5 – HRV and upper respiratory tract symptoms 
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patients with higher HRV loads have more symptoms, and therefore potentially more 
severe exacerbations due to these symptoms. The current findings also support the work 
by Seemungal and colleagues, in that in patients with more symptoms, the HRV load 
remained higher for a longer period of time than in patients with only one symptom, 
suggesting longer recovery times for more symptomatic patients.  
 
URT symptoms have been shown to begin before the onset of an exacerbation. In 2000 it 
was shown by Seemungal and colleagues that cold symptoms precede an exacerbation 
with symptoms scores increasing during the prodromal period (7 days before the onset of 
the exacerbation) (Seemungal et al., 2000). In the current study, the median number of 
days between the onset of cold symptoms and exacerbation presentation to the clinic was 
just  2  days,  and  just  1  day  between  the  onset  of  a  sore  throat  and  exacerbation 
presentation. Findings from both the Seemungal study and the current study suggest that 
URT  symptoms  could  be  a  potential  indicator  of  viral  infection  in  these  patients. 
Conversely, this short time frame between symptom onset and exacerbation presentation 
demonstrates how patients are sampled early in their exacerbation in the London COPD 
cohort. A unique advantage of the London COPD Cohort is that patients are prospectively 
followed and reviewed regularly, allowing the identification of exacerbation symptoms 
early at exacerbation onset, therefore optimising viral detection and enabling study of the 
time-course of these events. This allows patients to be treated early in their exacerbation, 
ideally leading to rapid improvement of their symptoms and therefore a less severe, or Chapter 5 – HRV and upper respiratory tract symptoms 
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shorter, exacerbation. Late sampling of an exacerbation, that is when the exacerbation is 
underway and not at the onset, can lead to missed viral detection and therefore poor 
detection  rates.  It  was shown  in  Chapter  4  that  it  is difficult to find  an  accurate  and 
reliable marker of HRV infection in COPD patients, which stresses the importance of these 
findings  all the  more,  as  URT  symptoms  could be  used  as  a potential marker  of  HRV 
infection. 
 
The results of the current study confirm the association of upper airway symptoms and 
HRV infection, and importantly, emphasise that the presence of HRV may be indicated by 
the presence of cold symptoms and/or sore throats. These findings may impact on HRV-
associated  exacerbation  treatment  strategies  now  there  is  an  effective  method  of 
identifying HRV infections in COPD patients.    
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5.7  Conclusion  
For the first time, this study has shown a relationship between HRV infection and upper 
airway symptoms during the entire time-course of naturally occurring exacerbations and 
recovery period. It has been shown throughout the time-course that patients with URT 
symptoms have significantly higher HRV loads than those without, which reinforces the 
concept of URT symptoms and HRV associations. This study highlighted the importance of 
early sampling of COPD patients at exacerbation in order to study their pathophysiology, 
and this emphasises that the presence of HRV may be indicated by the presence of URT 
symptoms.  Furthermore  it  has  been  reported  that  patients  who  report  both  cold 
symptoms and a sore throat have higher HRV loads than those who reported only one 
symptom,  and  that  HRV  loads  remained  elevated  for  longer  in  patients  with  both 
symptoms compared to those reporting just one symptom. These findings highlight the 
importance of treating HRV infection specifically, now that there is an effective method of 
early identification. This further emphasises the need for rapid development of antiviral 
treatment against HRV infection in these patients.  Chapter 6 – Co-infection of HRV and typical airway bacteria 
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CHAPTER 6. HRV infection and secondary 
bacterial infection during COPD exacerbations  
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6.1  Introduction  
This study aimed to explore changes in the prevalence and load of HRV and typical airway 
bacteria during naturally occurring COPD exacerbations and at various time-points during 
the recovery period.  
         
There have been numerous studies investigating the role of bacteria or viruses in COPD 
but little work has explored the subject of bacterial and viral co-infection in COPD. This 
area is becoming of greater interest, however it is still unclear whether an initial bacterial 
infection leads to the development of a secondary viral infection or whether it is an initial 
viral infection that paves the way for secondary bacterial infection. Although few studies 
have  explored this, those  that  have,  generally suggest  the  latter  (Mallia  et  al.,  2012). 
Furthermore  it  has  been  suggested  that  co-infection  of  the  two  pathogens  may  be 
coincidental, or it may be that the presence of virus or bacteria is a bystander in the 
exacerbation. A study by Hutchinson and colleagues reported that 36% of virus-positive 
COPD exacerbations developed a secondary bacterial infection over the following 7 days 
(Hutchinson et al., 2007). A study by Wilkinson and colleagues in 2006 showed how the 
bacterial load of H influenzae at exacerbation, increased significantly in the presence of 
HRV  compared  to  exacerbations  without  both  pathogens  (Wilkinson  et  al.,  2006b).  In 
2006, Papi and colleagues showed that bacterial and/or viral infection was detected in 
78% of exacerbations. When broken down it was found that 29.7% of exacerbations were Chapter 6 – Co-infection of HRV and typical airway bacteria 
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found to be positive for bacteria only, 23.4% had virus only and 25% had co-infection of 
both bacteria and virus (Papi et al., 2006). These studies focused on exacerbation onset, 
however to date, no study has explored this area throughout the whole time-course of an 
exacerbation and recovery period, in natural exacerbations.  
 
In 2012, Mallia and colleagues performed an experimental a study in which moderate 
COPD patients and healthy controls were experimentally infected with a low dose of HRV 
and sampled for sputum at various time-points post-inoculation (Mallia et al., 2012). The 
results showed that HRV load in sputum, measured by qPCR, peaked at Days 5-9 post-
inoculation  but  then  decreased  until  reaching  zero  at  Day  42.  Airway  bacterial  load, 
measured by culture however, started to increase from Day 5, peaking at Day 15 before 
decreasing until Day 42 (Mallia et al., 2012). These results from this experimental model, 
suggest that airway bacterial infection is precipitated by viral infection. This study was 
performed in moderate COPD patients with a low dose of virus and is a valid model of 
human COPD exacerbations allowing measurements to be taken in a controlled manner. 
However, it is essential to further this experimental work and explore the role of viral and 
bacterial co-infection during naturally occurring exacerbation time-courses.  
 
For the first time, this study aimed to explore changes in the prevalence and load of HRV 
and typical airway bacteria, during naturally occurring COPD exacerbation and recovery. 
Furthermore, this study aimed to determine whether an initial HRV infection at COPD Chapter 6 – Co-infection of HRV and typical airway bacteria 
208 
 
exacerbation onset leads to the development of a secondary bacterial infection during the 
recovery period of natural COPD exacerbations. This study was performed by splitting the 
collected data into two groups for analysis; firstly, exacerbations positive for typical airway 
bacteria at exacerbations presentation, and secondly, exacerbation negative for typical 
airway bacteria, at exacerbation presentation.  
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6.2  Characteristics of patients used in analysis of 
exacerbations positive for bacteria  
In exacerbations positive for typical airway bacteria at exacerbation presentation (ExP), a 
total of 263 samples were obtained; 66 taken at ExP, 42 at Day 3, 58 at Day 7, 55 at Day 14 
and 42 at Day 35 from 44 patients were analysed between April 2010 and June 2013. 94% 
of these exacerbations were treated with antibiotic therapy and 88% with oral steroids at 
exacerbation  presentation.  The  baseline  clinical  characteristics  for  these  patients  are 
shown in Table 6.1.   
 
 
 
 
 
 
Table  6.1:  Baseline  clinical  characteristics  of  44  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV and typical airway bacterial presence during naturally occurring 
COPD exacerbations and recovery in exacerbations positive for bacteria at presentation. Data 
are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.11 (±0.5) 
FVC, litres  2.31 (±0.8) 
FEV1/FVC, %  46.2 (±14.9) 
Predicted FEV1, %  44.9 (±20.3) 
Current Smoker, %  33 
Age, years  71 (±7.5)  
Male gender, %  64 Chapter 6 – Co-infection of HRV and typical airway bacteria 
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6.3  Results - exacerbations positive for bacteria at 
presentation 
6.3.1  HRV and bacterial prevalence in exacerbations positive for 
bacteria at presentation  
HRV prevalence fell from 50.0% at ExP to 22.5% at Day 3, 21.8% at Day 7, 14% at Day 14 
and  5.3%  at  Day  35.  Significant  falls  in  HRV  prevalence  from  ExP  were  seen  at  all 
subsequent time-points (all p≤0.004). Typical airway bacterial prevalence decreased from 
100% at ExP to 61% at Day 3, 51.8% at Day 7, 62.7% at Day 14 and 48.8% at Day 35 as 
shown in Table 6.3. Significant decreases in the bacterial prevalence from ExP were seen 
at all following time-points (all p<0.001) but no other significant differences were seen 
between any other time-points (Figure 6.1).  Chapter 6 – Co-infection of HRV and typical airway bacteria 
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Figure 6.1: Changes in the prevalence of HRV and total typical airway bacteria over the time-
course of naturally occurring exacerbations in exacerbations positive for bacteria and HRV at 
presentation (ExP).  
 
Total  bacterial  prevalence  was  broken  down  to  explore  the  prevalence  of  individual 
bacterial species, H influenzae, M catarrhalis and S pneumoniae, over the time-course of 
COPD  exacerbation  and  during  recovery.  The  prevalence  of  S  pneumoniae  decreased 
significantly from 33.3% at ExP to 12.2% at Day 3 (p=0.014), 16.1% at Day 7 (p=0.029), 
15.7%  at  Day  14  (p=0.030)  and  16.4%  at  Day  35  (p=0.032).  There  was  a  significant Chapter 6 – Co-infection of HRV and typical airway bacteria 
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decrease in the prevalence of M catarrhalis from 18.2% at ExP to 0% by Day 3 (p=0.004). 
The  prevalence  remained  at  0%  until  Day  14 when  the  prevalence  increased  to  3.9% 
however this increase in M cararrhalis from Day 7 to Day 14 did not reach statistical 
significance (p=0.135). The prevalence of H influenzae decreased significantly from 81.8% 
at ExP to 51.2% at Day 3, 41.1% at Day 7, 52.9% at Day 14 and 41.5% at Day 35 (all 
p<0.001) as shown in Table 6.3. H influenzae prevalence was found to be significantly 
higher than both M catarrhalis and S pneumoniae at all time-points (all p≤0.015) (Figure 
6.2). 
 
 
Table 6.2: Changes in the prevalence of HRV, all typical airway bacteria, and individual typical 
airway  bacteria  species  over  the  time-course  of  naturally  occurring  exacerbations  in 
exacerbations positive for bacteria at presentation (ExP). HI = H influenzae, MC = M catarrhalis, 
SP = S pneumoniae. 
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Figure 6.2: Changes in the prevalence of individual typical airway bacteria species over the time-
course  of  naturally  occurring  exacerbations  in  exacerbations  positive  for  bacteria  at 
presentation (ExP). SP = S pneumoniae MC = M catarrhalis HI = H influenzae. 
 Chapter 6 – Co-infection of HRV and typical airway bacteria 
214 
 
6.3.2  HRV and bacterial load in exacerbations positive for HRV and 
bacteria  
Out of the 66 ExP samples, 33 (50%) were positive for both typical bacteria and HRV. The 
median (IQR) HRV load fell significantly from 10
2.96(1.59-4.55) pfu/ml at ExP to 10
0.55(0-1.93) 
pfu/ml at Day 3, 10
0(0-1.42) pfu/ml at Day 7 and zero by Day 14 (all p<0.0001). In these 33 
exacerbations, the median (IQR) bacterial load decreased significantly from 10
7.27(6.13-8.43) 
cfu/ml to 10
0(0-6.43) cfu/ml at Day 7 (p<0.001) and then increased significantly from 10
0(0-
6.43) cfu/ml at Day 7 to 10
5.43(0-7.15) cfu/ml at Day 14 (p=0.049) as HRV load reached zero 
(Figure 6.3).  
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Figure 6.3: Changes in the load of HRV and typical airway bacteria over the time-course of 
naturally occurring exacerbations in exacerbations positive for bacteria and HRV at presentation 
(ExP). Data are presented as median (IQR).  
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Changes in HRV load and typical bacterial load were analysed using samples positive for 
both HRV and bacteria at all time-points in the recovery period, as well as at ExP (n=33); 
Day  3  (n=4),  Day  7  (n=3),  Day  14  (n=4)  and  Day  35  (n=2).  Except  for  there  being  a 
significant decrease in the median HRV load from ExP to Day 3 (p=0.004), there were no 
significant differences between any of the time-points for either HRV or bacteria; this is 
presumably as numbers in this samples set were small.  
 
Total  bacterial  load  over  the  time-course  of  COPD  exacerbation  and  recovery  was 
subdivided to explore the changes in load of the individual bacterial species over the time 
period.  M  catarrhalis  was  not  detected  at  any  time  point.  For  bacterial  species  S 
pneumoniae  and  H  influenzae  there  was  a  significant  decrease  in  the  median  load 
between ExP and Day 3 (p=0.043 and p=0.028 respectively) and between ExP and Day 7 
(p=0.008  and  p<0.0001,  respectively).  The  median  load  of  H  influenzae  increased 
significantly from 10
0(0-5.86) cfu/ml at
 Day 7 to 10
4.37(0-6.62) cfu/ml at Day 14 (p=0.049) but no 
difference was seen for S pneumoniae between these two time-points (Figure 6.5). The 
median load of H influenzae was significantly higher than that of S pneumoniae at every 
time point measured (all p<0.005) (Figure 6.4).  
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Figure 6.4: Changes in the load of the three typical airway bacteria S pneumoniae, M catarrhalis 
and H influenzae over the time-course of naturally occurring exacerbations  in exacerbations 
positive for bacteria and HRV at presentation (ExP). Data are presented as median (IQR). SP = S 
pneumoniae MC = M catarrhalis HI = H influenzae. 
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As H influenzae was shown to be the most prevalent bacterial species at all time points, 
and to have the highest bacterial load at all time points, the changes in H influenzae and 
HRV over the time-course of an exacerbation in samples positive for HRV and positive for 
H  influenzae  at  ExP  were  investigated.  The median  load  of  HRV  fell  significantly  from 
10
2.96(1.59-4.55) pfu/ml at ExP to 10
0.55(0-1.93) pfu/ml at Day 3 (p<0.001) reaching zero by Day 
14. The median (IQR) H influenzae load decreased significantly from 10
6.33(3.96-7.63) cfu/ml at 
ExP to 10
4.46(0-6.15) cfu/ml by Day 3 (p=0.028) and 10
0(0-5.86) cfu/ml by Day 7 (p<0.001). The 
median (IQR) load increased from 10
0(0-5.86) cfu/ml at Day 7 (p=0.048) to 10
4.37(0-6.62) cfu/ml 
by Day 14 (p=0.050) (Figure 6.5).  
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Figure  6.5:  Changes  in  the  load  of  HRV  and  H  influenzae  over  the  time-course  of  naturally 
occurring  exacerbations  in  exacerbations  positive  for  HRV  and  H  influenzae  at  presentation 
(ExP). Data are presented as median (IQR).  
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6.4  Characteristics of patients used in analysis of 
exacerbations negative for bacteria at presentation 
In order to verify that the significant increase in bacterial load seen at Day 14 was not due 
to  a  previous  bacterial  infection  returning  at  the  cessation  of  antibiotics,  changes  in 
bacterial  prevalence  and  load  in  exacerbations  negative  for  typical  airway  bacteria  at 
exacerbation  presentation  were  examined.  A  total  of  220  samples  were  taken;  50  at 
exacerbation presentation, 37 at Day 3, 50 at Day 7, 47 at Day 14 and 36 at Day 35 from 
41 patients were analysed between May 2010 and June 2013.  All exacerbations were 
treated with antibiotic therapy and 72% with oral steroids at exacerbation presentation. 
The baseline clinical characteristics for these patients are shown in Table 6.3.   
 
 
 
 
 
 
Table  6.3:  Baseline  clinical  characteristics  of  41  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV and typical airway bacterial presence during naturally occurring 
COPD exacerbation and recovery in exacerbations negative for typical bacteria at presentation. 
Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.12 (±0.5) 
FVC, litres  2.23 (±0.9) 
FEV1/FVC, %  45.9 (±14.7) 
Predicted FEV1, %  44.9 (±20.3) 
Current Smoker, %  33 
Age, years  70.4 (±8.0)  
Male gender, %  61 Chapter 6 – Co-infection of HRV and typical airway bacteria 
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6.5  Results – exacerbations negative for bacteria at 
presentation 
6.5.1  HRV and bacterial prevalence in exacerbations negative for 
bacteria at exacerbation 
HRV prevalence fell from 50% (25/50) at ExP to 25.7% at Day 3, 25% at Day 7, 11.6% 
at Day 14 and 5.9% at Day 35. Significant falls in HRV prevalence from ExP were seen 
at  all  subsequent  time-points  (all  p<0.001).  Typical  airway  bacterial  prevalence 
increased from 0% at ExP to 17.1% at Day 3, 17.4% at Day 7, 46.7% at Day 14 and 
45.5% at Day 35 as shown in Table 6.5. Significant increases in typical airway bacteria 
prevalence from ExP were seen at all following time-points (all p≤0.002). There was a 
significant increase in bacterial prevalence from Day 7 to Day 14 (p=0.006) but no 
significant differences were seen between any other time-points (Figure 6.6).  
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Figure 6.6: Changes in prevalence of HRV and total typical airway bacteria over the time-course 
of naturally occurring exacerbations in exacerbations negative for typical bacteria but positive 
for HRV at presentation (ExP). 
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Total bacterial prevalence was subdivided to explore the prevalence of individual bacterial 
species, H influenzae, M catarrhalis and S pneumoniae, over the time-course of COPD 
exacerbation and recovery. The prevalence of S pneumoniae increased significantly from 
0% at ExP to 14.3% at Day 3 (p=0.006), 13.3% at Day 14 (p=0.008) and to 15.2% at Day 35 
(p=0.005). There was a significant increase in the prevalence of M catarrhalis from 0% at 
ExP to 12.1% at Day 35 (p=0.012) but not at any other time point. The prevalence of H 
influenzae increased significantly from 0% at ExP to 13% at Day 7, 35.6% at Day 14 and 
27.3% at Day 35 (all p<0.024) as shown in Table 6.4. There was a significant increase in H 
influenzae prevalence from Day 7 to Day 14 (p=0.012) but not for either of the other two 
bacteria. The prevalence of H influenzae was found to be significantly higher than both M 
catarrhalis (p=0.001) and S pneumoniae (p=0.014) at Day 14 (Figure 6.7). 
 
Table 6.4: Changes in the prevalence of HRV, all typical airway bacteria, and individual typical 
airway  bacteria  species  over  the  time-course  of  naturally  occurring  exacerbations  in 
exacerbations negative for bacteria at presentation (ExP). SP = S pneumoniae MC = M catarrhalis 
HI = H influenzae. 
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Figure 6.7: Changes in prevalence of individual typical airway bacteria species over the time-
course  of  naturally  occurring  exacerbations  in  exacerbations  negative  for  bacteria  at 
presentation (ExP). SP = S pneumoniae, MC = M catarrhalis, HI = H influenzae. 
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6.5.2  HRV and bacterial load in exacerbations negative for bacteria 
but positive for HRV at presentation 
Out  of  the  50  ExP  samples,  25  (50%)  were  positive  for  HRV  but  negative  for  typical 
bacteria. The median (IQR) HRV load fell from 10
3.17(1.65-4.92) pfu/ml at ExP to zero by Day 
14  (p=0.001).  In  these  25  exacerbations,  the  median  (IQR)  bacterial  load  increased 
significantly from zero at ExP to 10
5.79(0-7.12) cfu/ml by Day 14 (p<0.001) with 52% (13/25) 
of  bacteria-negative  samples  becoming  positive  by  Day  14  (Figure  6.8).  There  was  a 
significant increase in the median total bacterial load from Day 7 (10
0(0-5.00) pfu/ml) to Day 
14 (10
5.79(0-7.12) pfu/ml) (p=0.038). In absolute numbers, there was a decrease in bacterial 
load from Day 14 to Day 35 (10
0(0-6.62) pfu/ml) but this fall however was not significant 
(p=0.492).  Chapter 6 – Co-infection of HRV and typical airway bacteria 
226 
 
 
Figure 6.8: Changes in load of HRV and typical airway bacteria over the time-course of naturally 
occurring  exacerbations  in  exacerbations  negative  for  bacteria  but  positive  for  HRV  at 
presentation (ExP). Data are presented as median (IQR). 
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Total bacterial load over the time-course of COPD exacerbation and during recovery was 
subdivided to explore the changes in the load of individual bacterial species over the time-
course. For all bacterial species, S pneumoniae, M catarrhalis and H influenzae there were 
significant  increases  in  load  between  ExP  and  Day  35  (p=0.021,  p=0.048,  p=0.009 
respectively) but not between any other time points. The median (IQR) H influenzae load 
increased significantly from 10
0(0-0) cfu/ml at
 ExP to 10
0 (0-6.69) cfu/ml at Day 14 (p<0.001) 
and from 10
0(0-0) cfu/ml at
 Day 7 to 10
0  (0-6.69) cfu/ml at Day 14 (p<0.037). In absolute 
numbers, the median H influenzae load decreased from 10
0 (0-6.69) cfu/ml at Day 14 to 10
0 
(0-3.85) cfu/ml at Day 35 however this was not significant (Figure 6.9).  
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Figure 6.9: Changes in load of the three typical airway bacteria S pneumoniae, M catarrhalis and 
H influenzae over the time-course of naturally occurring exacerbations in exacerbations negative 
for bacteria but positive for HRV at presentation (ExP). Data are presented as median (IQR). SP = 
S pneumoniae MC = M catarrhalis HI = H influenza. 
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As H influenzae has been shown to be the most prevalent bacterial species at Day 7 and 
Day  14,  and  to  have  the  highest  bacterial  load  at  those  time  points,  changes  in  H 
influenzae and HRV load over the time-course of an exacerbation in samples positive for 
HRV at ExP but negative for H influenza were investigated. The median load of HRV fell 
significantly  from  10
3.37(1.66-4.92)  pfu/ml  at  ExP  to  10
1.24(0-2.67)  pfu/ml  at  Day  3  (p=0.001) 
reaching zero by Day 14. The median H influenzae load increased significantly from zero at 
ExP to 10
0(0-6.69) cfu/ml by Day 14 (p<0.001) and then decreased significantly to 10
0(0-3.85) 
cfu/ml at Day 35 (Figure 6.10).  
 
Figure 6.10: Changes in load of HRV and H influenzae over the time-course of naturally occurring 
exacerbations in exacerbations negative for H influenzae but positive for HRV at presentation 
(ExP). Data are presented as median (IQR).  Chapter 6 – Co-infection of HRV and typical airway bacteria 
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6.6  Discussion  
This is the first study to investigate co-infection of HRV and typical airway bacteria in 
COPD patients during the time-course of naturally occurring exacerbations and recovery, 
using qPCR techniques.  
 
To date, only a small number of studies have explored the subject of co-infection. In 2006, 
Wilkinson and colleagues found an interaction between H influenzae and HRV infection at 
COPD  exacerbation  showing  that  airway  bacterial  load,  measured  using  culture 
techniques, was markedly increased in the presence of HRV and H influenzae, compared 
to cases where HRV were not present which suggests there is an interactive effect of HRV 
infection with H influenzae, allowing greater proliferation of airway bacteria within the 
airways (Wilkinson et al., 2006). Papi and colleagues reported co-infection of viruses and 
bacteria in 25% of exacerbations (29.7% bacteria only and 23.4% virus only). They showed 
that  exacerbations  associated  with  infection  are  more  severe  in  terms  of  length  of 
hospitalisation and lung function but that exacerbations with co-infection were associated 
with  even  greater  impairment  in  terms  of  lung  function  and  longer  length  of 
hospitalisation. This suggests that co-infection is an even bigger driver of exacerbation 
severity, greater than that of bacteria or virus alone and expresses the importance of 
therapeutic strategies and the need for them to be focused on treating infection (Papi et 
al.,  2006).  In  2013,  Perotin  and  colleagues  showed  that  44%  of  exacerbations  were Chapter 6 – Co-infection of HRV and typical airway bacteria 
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positive for a virus, 42% were positive for bacteria and 27% had co-infection of viruses and 
bacteria. They reported that patients with co-infection did not present greater clinical 
severity scores at exacerbation compared to those with single infections (Perotin et al., 
2013). Wark and colleagues showed virus positivity in 40% of exacerbations, the presence 
of bacteria in 21% and the presence of both in 9%. Conversely to the work by Perotin, it 
was  reported  that  viral-associated  exacerbations,  in  particular  those  co-infected  with 
bacteria had more severe exacerbations and were more likely to be readmitted to hospital 
(Wark et al., 2013). A study exploring the prevalence of bacterial pathogens associated 
with  viral  infections  of  the  respiratory  tract  found  that  in  nasopharyngeal  samples 
collected from symptomatic children, high levels of bacteria were found more commonly 
in  the  presence  of  RSV  infections  and  that  during  an  RSV  or  HRV  infection,  a  single 
bacterial  species  can  constitute  between  80-95%  of  the  bacterial  community  present 
(Chappell et al., 2013). In 2012 Mallia and colleagues experimentally infected moderate 
COPD patients with HRV and found that secondary bacterial infection developed in 60% of 
COPD subjects, with bacterial load peaking on Day 15 (Mallia et al., 2012). The results 
from the current study support these findings by Mallia and colleagues and report 52% of 
patients negative for bacteria at exacerbation presentation were positive by Day 14 post-
exacerbation with bacterial load increasing significantly by this time-point. The results 
suggest that previous studies of COPD exacerbations have underestimated the rates of 
dual infection caused by viral and bacterial infections at different times. In order for these 
findings  to  be  used  in  clinical  practice,  it  is  important  to  determine  the  effect  of  co-Chapter 6 – Co-infection of HRV and typical airway bacteria 
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infection  on  clinical  outcomes,  with  the  aim  of  treating  exacerbations  to  account  for 
potential secondary bacterial infection. It was shown in experimental infection that the 
development of a secondary bacterial infection is likely to prolong the duration of initially 
virus-induced COPD exacerbations (Mallia et al., 2012) however this area has not yet been 
explored in natural exacerbations and these results should encourage such study. Treating 
respiratory  viral  infection,  in  particular  HRV,  is  crucial  to  improve  COPD  exacerbation 
treatment strategies. The findings from this study should encourage the development of 
novel therapeutic targets for HRV.  
 
In exacerbations positive for typical airway bacteria at presentation, the bacterial load 
decreased significantly from presentation to Day 7 but then significantly increased again 
by Day 14. It could be argued that this finding is due to the cessation of antibiotics as 94% 
of  these  exacerbations  were  treated  with  7  days  of  antibiotics  at  exacerbation 
presentation (one was treated for 10 days). Antibiotic therapy reduces total bacterial load; 
the exacerbations in the current study were almost exclusively treated with a 7-day course 
and the results show a significant decrease in total bacterial load by Day 7 compared to 
exacerbation presentation. The significant increase in bacterial load from Day 7 to Day 14 
may be explained by antibiotic cessation at Day 7, if bacterial growth increased after 
antibiotic therapy was discontinued. However, in exacerbations negative for bacteria at 
presentation, the total bacterial load was significantly increased at Day 14 compared to 
presentation even though all of these exacerbations were also treated with 7 days of Chapter 6 – Co-infection of HRV and typical airway bacteria 
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antibiotic  therapy  at  exacerbation  presentation.  This  finding  suggests  a  genuine  link 
between HRV infection and the development of a secondary bacterial infection, rather 
than bacterial load increasing at Day 14 solely because of antibiotic cessation.    
 
The fact that all of the exacerbations that were negative for bacteria at presentation and 
became positive by Day 14 were treated with antibiotics, suggests that in exacerbations 
with an initial viral infection followed by a secondary bacterial infection, antiviral therapy 
at exacerbation may be more effective than antibiotics at reducing or eradicating viral 
infection and may prevent the development of a secondary bacterial infection. It is more 
likely, however, that antibiotics may be beneficial in the latter part of the exacerbation 
when a secondary bacterial infection may develop, so in these cases, both therapies may 
be required. Additionally, lengthening the duration of antibiotic treatment may prevent 
secondary infection. Patients in this study were given antibiotics for 7 days. Increasing this 
to 14 days may be a way of suppressing bacterial growth after or during HRV infection 
however  to  date  there  is  no  evidence  that  this  would  be  the  case.  Furthermore,  the 
potential benefits of extending a course of antibiotics or giving multiple antibiotic courses, 
must be balanced against the risk of side effects associated with this.  
 
When exploring the changes in prevalence and load of individual bacterial species over the 
time-course of exacerbation onset and recovery, H influenzae was found to be the most 
prevalent  species  and  was  found  at  higher  loads  than  both  S  pneumoniae  and  M Chapter 6 – Co-infection of HRV and typical airway bacteria 
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catarrhalis. This finding supports previous work evaluating the prevalence and load of S 
pneumoniae, M catarrhalis and H influenzae in the stable state and at COPD exacerbation 
which showed H influenzae to be the most prevalent bacterial species at both disease 
states (Garcha et al., 2012; Hill et al., 2000; A. J. White et al., 2003) and studies showing H 
influenzae to be the most common bacterial cause of exacerbations (Murphy, 2006). In 
the current study, H influenzae load increased most significantly from Day 7 to Day 14 
post-exacerbation  compared  to  S  pneumoniae  and  M  catarrhalis,  when  HRV  infection 
became undetectable. H influenzae was also found to have a higher prevalence and load 
than  both  S  pneumoniae  and  M  catarrhalis  at Day  14  post-exacerbation  suggesting  H 
influenzae  is  the  main  bacterial  species  involved  in  the  development  of  secondary 
bacterial infection. This finding supports the work by Wilkinson and colleagues who found 
that the load of typical airway bacteria increased significantly in the presence of HRV and 
H influenzae at COPD exacerbation compared to the load without HRV (Wilkinson et al., 
2006).  
 
In two major clinical trials in which the effects of ICS in COPD were evaluated (TORCH and 
INSPIRE trials) it was found that ICS usage was related to a higher rate of pneumonia 
development in COPD patients than that seen with other treatments  (Calverley et al., 
2011, 2007; Wedzicha et al., 2008). This association between the use of ICS therapy and 
the rate of pneumonia suggests that the use of steroids can play a role in the development 
of bacterial infection. Furthermore, it was shown in 2012 that higher bacterial load was Chapter 6 – Co-infection of HRV and typical airway bacteria 
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significantly related to higher inhaled corticosteroid dosage in stable COPD (Garcha et al., 
2012) which suggests the use of ICS therapy could lead to the amplification of secondary 
bacterial infection. In the current study, 88% of exacerbations positive for typical airway 
bacteria  and  HRV  at  presentation  were  treated  with  oral  steroids  and  72%  of 
exacerbations negative for typical airway bacteria and positive for HRV at presentation 
were treated for a median of 7 days. There was no difference in the bacterial or HRV load 
at any time point in the time-course between exacerbations treated with oral steroids 
compared to those not treated. This makes the suggestion of HRV paving the way for 
secondary bacterial infection, plausible, and not just due to the cessation of oral steroids 
after  day  7.  Despite  this,  the  potential  role  of  oral  steroids  in  the  development  of 
secondary bacterial infection must be considered.  
 
The data from the current study shows that secondary bacterial infection occurs after 
initial HRV infection however the mechanism by which this occurs is unknown. A number 
of  hypotheses  have  been  suggested  in  order  to  explain  the  mechanism.  Sajjan  and 
colleagues suggested that HRV facilitates the transmigration of bacteria across the airway 
epithelium allowing bacterial infection to develop, (Sajjan et al., 2008) whether a de novo 
infection or one from colonising bacteria already in the airway. Similarly, HRV infection 
may impair the innate immune response in alveolar macrophages and thereby provide an 
environment  that  allows  the  proliferation  of  colonising  airway  bacteria  or  the 
development of a new infection (Oliver et al., 2008). It has been suggested that HRV may Chapter 6 – Co-infection of HRV and typical airway bacteria 
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increase the susceptibility of bacterial adherence to airway epithelial cells; a study by 
Ishizuka  and  colleagues  in  2003  showed  that  HRV  infection  stimulated  S  pneumoniae 
adhesion to airway epithelial cells via binding to the receptor, platelet activating factor 
receptor (PAF-R) (Ishizuka et al., 2003). Determining the predominant mechanism requires 
further study perhaps using more sophisticated techniques such as bacterial sequencing.  
 
Exacerbation recurrence is an important concept in COPD. Hurst and colleagues showed in 
2008 that exacerbations are not random events and cluster together in time such that 
there is a high-risk period for recurrent exacerbation in the 8-week period after the initial 
exacerbation  (Hurst  et  al.,  2009).  The  mechanisms  of  exacerbation  recurrence  are 
unknown, but possible suggestions such as persistence  of an existing organism or the 
acquisition of a new pathogen have been proposed (Hurst et al., 2009). Similarly the idea 
of persistent inflammation in these patients has been hypothesised (Hurst et al., 2009). It 
was shown in 2006 that heightened systemic inflammation is associated with recurrent 
exacerbations within 50 days and that patients who had a recurrent exacerbations had 
significantly higher levels of CRP at 14 days post-initial exacerbation compared to those 
that did not suffer a recurrent exacerbation (Perera et al., 2007). Systemic corticosteroids 
given at exacerbation have been shown to be effective in accelerating the recovery of 
FEV1 (Davies et al., 1999). However if they fail in suppressing inflammation, recurrent 
exacerbations  are  a potential risk  (Hurst  et  al.,  2009).  Results  from the  current  study 
suggest a possible mechanism of exacerbation recurrence involving the role of secondary Chapter 6 – Co-infection of HRV and typical airway bacteria 
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bacterial infection. This data shows that bacterial load peaks at Day 14 post-exacerbation 
as HRV infection disappears, which could trigger a second exacerbation. If this is to be the 
case, it is even more crucial that the initial exacerbation is treated rapidly in order to 
minimise the risk of a recurrent exacerbation developing.  
 
Other  studies  investigating  co-infection  of  viruses  and  bacteria  at  COPD  exacerbation 
found a lower incidence of co-infection than the current study. This may be due to the 
larger number of samples collected from patients during each exacerbation in this study 
compared to others. A study by Papi in 2006, showed 25% co-infection at exacerbation 
however only one sample was taken at exacerbation (Papi et al., 2006). Similarly, Perotin 
showed in 2013 that 27% of exacerbation samples were positive for co-infection with only 
one sample per patient (Perotin et al., 2013). Hutchinson and colleagues collected two 
samples during exacerbation and reported that 36% of exacerbations in which a virus was 
detected at onset went on to develop a secondary bacterial infection over the following 
week.  They  also  reported  that  78%  of  exacerbations  positive  for  H  influenzae  were 
preceded  by  viral  symptoms  (Hutchinson  et  al.,  2007).  In  the  current  study,  multiple 
samples were collected during exacerbations and a higher incidence of co-infection was 
detected than the studies described above. This suggests that repeated sampling over the 
duration of an exacerbation is more likely to identify the presence of co-infection.  
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This study was limited to HRV infection and although other viruses have been considered 
in  other  studies,  HRV  has  been  shown  to  be  the  most  commonly  detected  at  COPD 
exacerbation (Seemungal et al., 2001). Similarly, this study was limited to three typical 
airway bacteria detected at COPD exacerbation although these have been shown to be 
the main three detected at COPD exacerbation and it is likely that they are the main 
contributors in the aetiology of exacerbations. 
 
These findings reinforce the urgent need for the rapid development of antiviral therapies 
as they may not only reduce the severity of an exacerbation or prevent-virus induced 
exacerbations, but may also have the potential to prevent secondary bacterial infections 
occurring.  
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6.7  Conclusion 
Secondary bacterial infection is common after an initial HRV infection and has important 
implications in terms of therapy and exacerbation recurrence. Treating viral infection at 
exacerbation onset is crucial in terms of exacerbation length, severity and recurrence. The 
unmet  need  for  rapid  development  of  therapeutic  targets  for  the  prevention  and 
treatment of HRV infection in COPD patients must be addressed. 
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CHAPTER 7. HRV infection and patient reported 
outcomes in patients with COPD 
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7.1  Introduction 
This  study  aimed  to  explore  associations  between  the  EXACT  questionnaire,  the  CAT 
questionnaire,  and  exacerbation  frequency,  with  HRV  infection,  at  exacerbation 
presentation and during the recovery period in natural exacerbations. 
 
Patient reported outcome measures (PROs) are reports that come directly from patients 
giving  information  about  how  they  feel  or  function  in  relation  to  a  particular  health 
condition  and  its  therapy.  PROs  are  an  important  element  of  in  many  research  areas 
including COPD. In the London COPD cohort patients are followed prospectively, being 
reviewed every 3 months in the stable state, seen early at exacerbation onset and at 5 
time-points during the recovery period. At each clinic visit, patients in the cohort undergo 
a series of measurements prior to treatment. These include spirometry, sputum sampling 
and venous blood sampling in order to measure the levels of certain blood inflammatory 
markers.  Patients  are  also  asked  to  fill  in  a  variety  of  questionnaires  including  the 
“exacerbation of chronic pulmonary disease tool” (EXACT) and “COPD assessment test” 
(CAT). These are important patient reported outcome measures that provide information 
on the severity, duration and frequency of COPD exacerbations.  Chapter 7 –HRV and patient reported outcome measures 
242 
 
7.1.1  EXACT 
Measuring the severity of an exacerbation is an important outcome measure in COPD. 
Daily diary cards used to record exacerbation symptoms are able to accurately detect the 
onset of exacerbations, either reported or unreported, however most daily diary cards are 
not sensitive enough to measure the severity of an exacerbation (Mackay et al., 2014). 
The  EXACT  is  a  daily  symptom  diary  designed  to  capture  the  severity  of  COPD 
exacerbations (Leidy et al., 2011). It is comprised of 14 questions that assess attributes 
such  as  sputum,  cough,  chest  symptoms,  tiredness,  anxiety  and  breathlessness.  The 
majority of questions are answered by choosing one of five answers (two of the questions 
have 6 answer options). The answers are converted to a 0-100 scale with higher total 
EXACT scores indicating more symptomatic exacerbations. It has been shown that EXACT 
scores are sensitive to changes that occur during the recovery period after exacerbation 
onset  (Leidy  et  al.,  2011)  however  to  date,  no  published  data  have  examined  the 
relationship between EXACT scores and HRV infection during COPD exacerbations and 
recovery. As HRV has been shown to be the most commonly detected virus at COPD 
exacerbation (Seemungal et al., 2001), it is important to establish whether there is an 
association between HRV infection and the EXACT questionnaire. In this study, patients 
filled in an EXACT questionnaire at each clinic visit (exacerbation and during recovery) 
based on the symptoms they felt and experienced that day.  Chapter 7 –HRV and patient reported outcome measures 
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7.1.2  CAT 
The CAT is a short and simple questionnaire intended to measure the health status of 
COPD  patients  and  the  impact  that  COPD  has  on  their  quality  of  life  in  an  objective 
manner (Jones et al., 2009). It is a validated 8-item questionnaire that is designed to 
assess and quantify the impact of COPD symptoms on patient health status (Jones et al., 
2009).  Like  the  EXACT,  the  CAT  can  be  self-administered  by  patients  and  used  in  an 
ongoing manner. Patient recognition of exacerbation symptoms and prompt treatment 
improves  exacerbation  recovery  and  reduces  further  risk  of  hospitalisation  in  COPD 
patients (Wilkinson et al., 2004).  Comparing different CAT scores for a particular patient 
at different time-points may provide valuable information on the impact of their disease 
on their quality of life, long-term. Each item in the questionnaire contains two opposing 
statements. Patients decide where on a scale of 0-5, between the two statements, they 
fit. The scores from the 8 items are summed to give a final score out of 40 to indicate 
disease impact without the need for complex calculation (Jones et al., 2009). A higher CAT 
score indicates worse health status, and exploring answers to individual questions in the 
questionnaire can provide insight into the influence that individual components of COPD 
may have on patient quality of life (Jones et al., 2009). It has previously been shown that 
the CAT questionnaire provides a reliable score of exacerbation severity and that CAT 
scores are increased at exacerbation compared to the stable state (Mackay et al., 2012). It 
has  also  been  shown  to  reflect  severity  in  terms  of  lung  function  and  duration  of Chapter 7 –HRV and patient reported outcome measures 
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exacerbations (Mackay et al., 2012). As with the EXACT, in this study, patients filled in the 
CAT questionnaire at each clinic visit based on how they were feeling on that day.  
7.1.3  Exacerbation frequency  
There is considerable interest in the frequent exacerbator phenotype with many studies 
exploring  exacerbation  frequency  among  COPD  patients.  It  has  been  shown  that 
exacerbations  of  COPD  impact  on  quality  of  life  (Seemungal  et  al.,  1998),  accelerate 
decline in lung function (Donaldson et al., 2002), lead to an increase in mortality (Soler-
Cataluña  et  al.,  2005)  and  are  associated  with  increases  in  airway  and  systemic 
inflammation (Hurst et al., 2006). Thus exacerbations are important events in COPD and 
their prevention is a key element in the management of COPD.  
 
To date, it has been shown that exacerbations become more frequent and more severe as 
COPD  severity  increases  and  that  the  most  important  determinant  of  frequent 
exacerbations, is a history of exacerbations (Hurst et al., 2010). Furthermore it has been 
shown that exacerbations cluster together in time with a high-risk period for recurrent 
exacerbation  in  the  first  8-weeks  after  an  initial  exacerbation,  suggesting  that 
exacerbations are not random events (Hurst et al., 2009).  
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The majority of COPD exacerbations are associated with infection (Hurst and Wedzicha, 
2007) and it has been suggested that the mechanism of exacerbation recurrence is due to 
the persistence of an  existing  organism  or  to  the  acquisition  of  a new  organism.  The 
failure to eradicate bacteria with exacerbation therapy has been shown to be associated 
with incomplete recovery of inflammatory markers (A J White et al., 2003). From this, it 
has been suggested that exacerbation recurrence and therefore exacerbation frequency is 
related  to  persistence  of  inflammation  (Perera  et  al.,  2007)  likely  due  to  infection, 
however the association of viral infection, in particular HRV, and exacerbation frequency 
over  the  time-course  of  natural  COPD  exacerbation  and  recovery  has  not  yet  been 
explored.  
   
The  impact  of  HRV  on  patient  health  status  is  an  important  aspect  to  consider  in 
exacerbations  of  COPD,  and  treating  patients  appropriately  with  the  aim  of  reducing 
exacerbations  is  essential.  So  for  the  first  time,  this  study  aimed  to  explore  the 
relationship of HRV with the EXACT questionnaire, with the CAT questionnaire, and with 
exacerbation frequency, at exacerbation presentation and during the recovery period in 
natural exacerbations.  
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7.2  Characteristics of patients used for EXACT analysis 
Of the 537 time-course sputum samples, 330 had available EXACT data. The 330 samples 
from 57 patients were analysed between April 2010 and June 2013 as part of the sample 
collection performed in the London COPD cohort. These  330 samples were taken at 6 
different  time-points  during  exacerbation  and  recovery;  90  samples  were  taken  at 
exacerbation presentation (ExP), 55 at Day 3 post-exacerbation, 70 at Day 7, 60 at Day 14, 
42 at Day 35 and 13 at Day 56.  The baseline clinical characteristics for these patients are 
shown in Table 7.1.   
 
 
 
 
 
 
 
Table  7.1:  Baseline  clinical  characteristics  of  57  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV infection and EXACT scores. Data are presented as mean (±SD) or 
percentage (%). 
 
 
FEV1, litres  1.28 (±0.5) 
FVC, litres  2.24 (±0.8) 
FEV1/FVC,   0.49 (±0.15) 
Predicted FEV1, %  48.9 (±19.6) 
Current Smoker, %  32 
Age, years  72.4 (±7.6)  
Male gender, %  63 Chapter 7 –HRV and patient reported outcome measures 
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7.3  Results – EXACT  
The mean(±SEM) EXACT scores decreased significantly from 51.1(±1.11) at exacerbation 
presentation (ExP) to Day 3, 7, 14 and 35 during the recovery period (all p≤0.010). The 
mean EXACT score then increased from 40.6(±1.10) at Day 35 to 46.2(±2.31) at Day 56 
(p=0.025) (Figure 7.1).  
 
Figure 7.1: Change in EXACT scores during COPD exacerbation and recovery period. Data shown 
as mean (±95% CI). Chapter 7 –HRV and patient reported outcome measures 
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When exploring the changes in EXACT scores in the presence of HRV infection, it was 
found that samples positive for HRV (n=90) had a significantly higher mean EXACT score 
than samples that were not found to be positive for HRV (n=240) (Figure 7.2). In HRV-
positive samples, the mean EXACT score was 48.4(±1.33) which was significantly higher 
than the mean EXACT score in samples negative for HRV, 44.9(±0.64) (p=0.010). Samples 
at all time-points were included in the analysis. 
 
 
Figure 7.2: Comparison of mean EXACT scores in samples positive for HRV (n=90) and samples 
negative for HRV (n=240); all time-points included *p=0.010. Chapter 7 –HRV and patient reported outcome measures 
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The  mean  EXACT  scores  were  highest  at  ExP  and  decreased  over  the  time-course  of 
exacerbation recovery until Day 35, as did HRV load. There was a significant fall from ExP 
to Day 3 for both variables (both p<0.010) (Figure 7.3).  
 
Figure 7.3: Change in EXACT scores and HRV load over the time-course of COPD exacerbation 
and recovery; *p<0.010.  
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There  was  a  significant  relationship  between  HRV  load  and  EXACT  scores  with  EXACT 
scores increasing as HRV load increased. All time-points included; r=0.208, p=0.011 (Figure 
7.4).  
 
 
Figure  7.4:  Relationship  of  EXACT  scores  and  HRV  load  over  the  time-course  of  COPD 
exacerbation and recovery. All time-points included; r=0.208, p=0.011.  
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The EXACT questionnaire assesses lower respiratory tract symptoms and attributes such 
as  cough,  sputum  production,  wheeze  and  breathlessness  as  well  as  tiredness,  sleep 
quality,  and  anxiety.  As  described  in  Chapter  5,  HRV  infection  is  associated  with  the 
presence of upper respiratory tract (URT) symptoms such as cold symptoms and sore 
throats. It was shown that HRV prevalence and load were higher at certain time-points 
during  exacerbation  recovery  in  patients  who reported  URT  symptoms  at  the time  of 
sampling, compared to those that did not.  
 
The severity of a COPD exacerbation is one of the attributes the EXACT is designed to 
measure, so exploring any differences in EXACT scores between patients who reported 
URT symptoms and those that did not, requires investigation.  
 
In samples associated with cold symptoms at the time of sampling (n=127), the mean 
EXACT score was found to be 49.8(±1.02) which was significantly higher than in those that 
were not associated with cold symptoms at the time of sampling (n=203), 43.5 (±0.68); 
p<0.001. All time-points included (Figure 7.5).  Chapter 7 –HRV and patient reported outcome measures 
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Figure 7.5: Comparison of EXACT scores in patients that reported cold symptoms at the time of 
sampling (n=127) and those that did not (n=203); All time-points included*p<0.001.  
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Similarly, in samples associated with a sore throat at the time of sampling (n=50), the 
mean EXACT score was found to be 50.4(±1.42) which was significantly higher than in 
those not associated with a sore throat at the time of sampling (n=280), 45.1 (±0.65); 
p=0.021. All time-points included (Figure 7.6).  
 
Figure 7.6: Comparison of EXACT scores at all time-points in patients that reported having a sore 
throat at the time of sampling (n=50) and those that did not (n=280); *p=0.021.  
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7.4  Characteristics of patients used for CAT analysis  
Of the 537 time-course sputum samples, 388 had available CAT data. The 388 samples 
from 68 patients were analysed between April 2010 and June 2013 as part of the sample 
collection performed in the London COPD cohort. These  388 samples were taken at 6 
different  time-points  during  exacerbation  and  recovery;  103  samples  were  taken  at 
exacerbation presentation (ExP), 69 at Day 3 post-exacerbation, 84 at Day 7, 71 at Day 14, 
48 at Day 35 and 13 at Day 56.  The baseline clinical characteristics for these patients are 
shown in Table 7.2.   
 
 
 
 
 
 
 
Table  7.2:  Baseline  clinical  characteristics  of  68  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV infection and CAT scores. Data are presented as mean (±SD) or 
percentage (%). 
 
FEV1, litres  1.28 (±0.5) 
FVC, litres  2.23 (±0.9) 
FEV1/FVC,   0.46 (±0.14) 
Predicted FEV1, %  48.9 (±19.6) 
Current Smoker, %  33 
Age, years  72.9 (±7.6)  
Male gender, %  63 Chapter 7 –HRV and patient reported outcome measures 
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7.5  Results - CAT 
The mean(±SEM) CAT scores decreased significantly from 22.9(±0.84) at ExP to Day 7, 14 
and  35  during the  recovery  period  (all  p<0.015).  The  mean  CAT  score  also  decreased 
significantly from 22.1(±0.88) at Day 3 to 19.9(±0.87) at Day 7, 19.1(±0.94) at Day 14 and 
17.3(±0.95) at Day 35 (all p≤0.003). There was also a significant decrease in mean CAT 
score from Day 7 to Day 35 (p=0.046) (Figure 7.7).  
 
Figure 7.7: Change in CAT scores during COPD exacerbation and recovery period. Data shown as 
mean (±95% CI). Chapter 7 –HRV and patient reported outcome measures 
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When exploring differences in CAT scores with or without HRV infection, it was found that 
samples positive for HRV (n=107) had a significantly higher mean CAT score than those 
samples in which HRV was not detected (n=281) (Figure 7.8). In HRV-positive samples, the 
mean CAT score was 22.12(±0.8) which was significantly higher than the mean CAT score 
in those samples found to be negative for HRV, 19.95(±0.5) (p=0.018). Samples at all time 
point were included in the analysis. 
 
 
Figure 7.8: Comparison of mean CAT scores in samples positive for HRV (n=107) and samples 
negative for HRV (n=281). All time-points included; *p=0.018. 
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The  mean  CAT  scores  were  highest  at  ExP  and  decreased  over  the  time-course 
exacerbation recovery, as did HRV load. There were significant falls from exacerbation 
presentation (ExP) to Day 7 for both variables (both p<0.015) (Figure 7.9).  
 
 
Figure 7.9: Change in CAT scores and HRV load over the time-course of COPD exacerbation and 
recovery; *p≤0.015.  
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There was a significant relationship between HRV load and CAT scores with CAT scores 
increasing as HRV load increased; r=0.149, p=0.003. All time-points included (Figure 7.10).  
 
 
Figure 7.10: Relationship of CAT scores and HRV load over the time-course of COPD exacerbation 
and recovery. All time-points included; r=0.149, p=0.003.  
 
The CAT is designed to assess and quantify the impact of COPD symptoms on patient 
health status and like the EXACT, exploring any differences in CAT scores between patients 
who reported URT symptoms and those that did not, requires investigation.  Chapter 7 –HRV and patient reported outcome measures 
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In  samples  associated  with  cold  symptoms  at  the  time  of  sampling  (n=144),  the 
mean(±SEM)  CAT  score  was  found  to  be  22.8(±0.67)  which  was  significantly  higher  in 
those not associated with a cold (n=244), 19.3(±0.50); p<0.001. All time-points included 
(Figure  7.11).  There  was  no  significant  difference  between  the  mean  CAT  scores  in 
samples associated with sore throats (n=58) and those that were not (n=330); p=0.201.  
 
 
Figure  7.11:  Comparison  of  CAT  scores  at  all  time-points  in  samples  associated  with  cold 
symptoms at the time of sampling (n=144) and those that were not (n=244); All time-points 
included *p<0.001.    Chapter 7 –HRV and patient reported outcome measures 
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7.6  Characteristics of patients used for exacerbation 
frequency analysis 
For  73  patients  there  was  data  on  the  number  of  exacerbations  they  had  per  year 
retrospectively. The 73 samples taken from 73 patients were analysed between May 2010 
and December  2011  as  part of the  sample  collection performed  in the  London  COPD 
cohort. The baseline clinical characteristics for these patients are shown in Table 7.3.   
 
 
 
 
 
 
 
Table  7.3:  Baseline  clinical  characteristics  of  73  patients  in  the  London  COPD  Cohort,  who 
participated in a study of HRV infection and exacerbation frequency. Data are presented as 
mean (±SD) or percentage (%). 
 
FEV1, litres  1.28 (±0.5) 
FVC, litres  2.25 (±0.9) 
FEV1/FVC,   0.49 (±0.15) 
Predicted FEV1, %  48.9 (±19.6) 
Current Smoker, %  32 
Age, years  72.4 (±7.6)  
Male gender, %  63 Chapter 7 –HRV and patient reported outcome measures 
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7.7  Results – exacerbation frequency  
Of these 73 exacerbations, patients positive for HRV (n=43) during their first sampled 
exacerbation, had a significantly higher exacerbation frequency than those patients in 
whom HRV was not detected (n=30). The median (IQR) number of exacerbations per year 
in those with HRV infection was 3.01 (2.02-5.28) compared to 2.51 (1.88-3.51) in those 
without HRV detected (p=0.040) (Figure 7.12).  
 
 
Figure 7.12: Comparison of the number of exacerbations per year in patients with HRV (n=43) 
and those without HRV (n=30) at exacerbation. *p=0.04. Data shown as median (IQR).  Chapter 7 –HRV and patient reported outcome measures 
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In  addition,  HRV  load  at  exacerbation  was  significantly  related  to  the  annual  rate  of 
exacerbations (r=0.265, p=0.024) (Figure 7.13).  
 
 
Figure 7.13: Relationship of exacerbation frequency and HRV load over the time-course of COPD 
exacerbation and recovery; r=0.024, p=0.265.  
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7.8  Discussion  
7.8.1  EXACT questionnaire 
The  EXACT  questionnaire  is  a  patient  reported  outcome  measure  that  allows  the 
standardisation  of  COPD  exacerbation  severity  (Leidy  et  al.,  2011).  The  EXACT  is  a 
validated patient reported outcome tool that has been used to enhance the detection of 
exacerbation events in clinical trials such as the FORWARD trial that aimed to reduce 
exacerbations with a combination inhaler (Singh et al., 2013) and a trial exploring the 
effectiveness  of  alerting  COPD  patients  when  they  are  at  a  high  risk  of  exacerbation 
(Halpin  et  al.,  2011).  Previous  studies  have  also  investigated  the  effectiveness  of  the 
EXACT at predicting exacerbations by recording EXACT scores over the time-course of an 
exacerbation and recovery period. It was found that EXACT scores accurately reflected 
exacerbation  recovery  with  scores  increasing  significantly  at  COPD  exacerbation  and 
decreasing during recovery (Leidy et al., 2011; Mackay et al., 2014). Furthermore, EXACT 
scores  measured  over  seven  days  were  shown  to  be  higher  at  each  time  point  in 
exacerbating patients compared to stable patients (Leidy et al., 2011). The current study 
shows EXACT scores to be highest at exacerbation and decreasing during the recovery 
period, consistent with previous studies. For the first time, the current study explored the 
association of EXACT scores over the entire time-course of COPD exacerbations with HRV 
infection. The results showed that COPD patients with HRV infection during the time-Chapter 7 –HRV and patient reported outcome measures 
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course of an exacerbation and recovery had higher EXACT scores than those without HRV. 
Furthermore there was a significant relationship between HRV load and EXACT scores over 
the  time-course  with  EXACT  scores  increasing  as  HRV  load  increased.  These  findings 
suggest that exacerbations associated with HRV infection are more severe in terms of 
greater  burden  of  symptoms.  Both  EXACT  scores  and  HRV  load  were  highest  at 
exacerbation presentation and decreased during recovery with significant decreases in 
both from exacerbation presentation to Day 3 post-exacerbation. This implies that EXACT 
scores  and  HRV  load  follow  a  similar  pattern  over  COPD  exacerbation  time-course 
suggesting the EXACT questionnaire could be used to track symptomatic recovery in HRV-
infected patients which in turn may affect the timing of therapy in COPD exacerbations.  
 
Interestingly, EXACT scores were found to be higher in the presence of upper respiratory 
(URT) symptoms such as cold symptoms and sore throats. The EXACT questionnaire is 
comprised  of  questions  that  largely  focus  on  symptoms  of  the  lower  airway  such  as 
breathlessness, cough and sputum, chest symptoms and difficulty bringing up sputum as 
opposed  to  questions  about  URT  symptoms  such  as  sore  throats  or  nasal  symptoms. 
However it seems from the results reported in this study that there is an association 
between URT symptoms and EXACT scores with EXACT scores being significantly higher in 
samples associated with URT symptoms compared to those without symptoms. In Chapter 
5  it  was  reported  that  URT  symptoms  may  be  used  to  indicate  the  presence  of  HRV 
infection as HRV prevalence and load was shown to be higher in the presence of URT Chapter 7 –HRV and patient reported outcome measures 
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symptoms. This raises questions about the potential ability of the EXACT questionnaire, in 
conjunction  with  URT  symptoms,  to  indicate  the  presence  of  HRV  infection  at  COPD 
exacerbation and determine the severity of these HRV-associated exacerbations. Personal 
communication from research fellows in the London COPD cohort suggests that patients 
often have difficulty completing the EXACT questionnaire due to its length and complexity 
and prefer to use the CAT questionnaire. This must be taken into consideration when 
preparing to use the EXACT as it appears too complex for clinical use, however may be of 
potential benefit in further HRV research studies.  
7.8.2  CAT questionnaire 
Similar results were found when exploring the association of HRV prevalence and load 
with  CAT  scores.  The  CAT  is  designed  to  assess  and  quantify  the  impact  of  COPD 
symptoms on patient’s health status (Jones et al., 2009). It provides clinicians and patients 
with a simple and reliable measure of COPD-related health status allowing the assessment 
and  long-term follow-up  of  individual  patients  (Jones  et  al., 2009).  The  CAT  has  been 
shown  to  be  associated  with  changes  in  systemic  inflammation  following  COPD 
exacerbations and is responsive to treatments given (Tu et al., 2014). It has also been 
shown to improve in response to pulmonary rehabilitation programmes and  is able to 
differentiate between categories of response (Dodd et al., 2011). CAT scores have been 
shown to be significantly higher at COPD exacerbation compared to the stable state (Jones Chapter 7 –HRV and patient reported outcome measures 
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et  al.,  2011;  Mackay  et  al.,  2012)  and  can  distinguish  between  patients  of  different 
degrees of COPD severity (Jones et al., 2011). Scores have been shown to reflect recovery 
after exacerbations of COPD with the time taken for scores to return to baseline being 
significantly related to recovery time as judged by symptom diary cards (Mackay et al., 
2012). Results from the current study are consistent with these results and found CAT 
scores to be highest at exacerbation presentation before decreasing during the recovery 
period. For the first time, the association of CAT scores and HRV infection during COPD 
exacerbations  and  recovery  has  been  explored  where  CAT  scores  were  found  to  be 
significantly higher in HRV-positive samples compared to those without HRV infection, 
throughout the time-course. Furthermore, both HRV load and CAT scores were shown to 
be  highest  at  exacerbation  presentation  and  decrease  significantly  by  Day  7  post-
exacerbation and were found to be weakly but significantly related during the time-course 
with higher HRV loads correlating with higher CAT scores. Results from the current study 
also indicate that CAT scores are higher in the presence of cold symptoms. As discussed in 
relation to EXACT scores, it was shown in Chapter 5 that HRV infection is associated with 
URT symptoms. Therefore together, URT symptoms along with EXACT and CAT scores 
could be used as potential indicators of HRV infection at exacerbation. Moreover, the 
EXACT and CAT scores could be used to assess efficacy of novel therapies by determining 
exacerbation severity in future trials of antiviral therapy at COPD exacerbation and during 
recovery. Additionally the results from this study reinforce the importance of developing 
antiviral therapies for HRV to allow appropriate treatments to be given to COPD patients Chapter 7 –HRV and patient reported outcome measures 
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and  should  encourage  further  research  into  the  development  of  treatment  for  HRV 
infection. 
7.8.3  Exacerbation frequency 
Exacerbation  frequency  has  been  shown  to  be  an  important  phenotype  in  COPD 
(Donaldson et al., 2013). Some patients with COPD are particularly susceptible to having 
exacerbations and are termed ‘‘frequent exacerbators’’ (Hurst et al., 2010). It has been 
shown  that  patients  are  able  to  shift from  being  frequent  exacerbators  to  infrequent 
exacerbators  or  vice  versa  and  therefore  all  patients  are  at  some  risk  of  becoming  a 
frequent  exacerbators  during  the  course  of  COPD  (Donaldson  et  al.,  2013).  In  2002, 
Donaldson  and  colleagues  reported  that  exacerbation  frequency  is  an  important 
determinant  of  lung  function  in  COPD  and  showed  that  patients  with  frequent 
exacerbations had a significantly faster decline in FEV1 and peak expiratory flow (PEF) 
compared to infrequent exacerbators (Donaldson et al., 2002). It was also reported that 
patients with frequent exacerbations were often admitted to hospital with longer length 
of stay (Donaldson et al., 2002).  A study by Patel and colleagues explored exacerbation 
frequency and lower airway bacterial colonisation in stable COPD patients and found that 
lower  airway  bacterial  colonisation  in  stable  COPD  modulates  the  frequency  of  COPD 
exacerbations  as  colonisation  with  a  pathogen  was  associated  with  an  increased 
exacerbation frequency (Patel et al., 2002). In 2005 it was shown that patients with the Chapter 7 –HRV and patient reported outcome measures 
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frequent  exacerbator  phenotype  are  more  likely  to  develop  colds  compared  to  non-
frequent exacerbators (Hurst et al., 2005a). In the study, frequent exacerbators developed 
significantly  more  colds  than  infrequent  exacerbators  but  it  was  concluded  that  the 
likelihood of developing an exacerbation during a cold was not affected by exacerbation 
frequency  but  that  frequent  exacerbators  were  more  susceptible  to  acquiring  a  cold 
(Hurst  et  al.,  2005).  Various  mechanisms  were  suggested  to  explain  why  frequent 
exacerbators  have  an  increased  frequency  of  colds;  frequent  exacerbators  being 
intrinsically more susceptible to viral infection, the host-viral interaction in these patients 
is such that an exacerbation is more likely, or that patients with frequent colds may be 
coming into contact with more viruses in the community (Hurst et al., 2005). It is also 
known  that  HRV  is  able  to  infect  the  lower  airways  as  well  as  the  upper  airways 
(Seemungal et al., 2000). The data suggests frequent exacerbators are predisposed to the 
acquisition of colds rather than greater risk of exacerbation during a cold.  
 
This  work  by  Hurst  and  colleagues  focussed  on  cold  symptoms  and  exacerbation 
frequency but did not explore HRV infection specifically, in these patients. For the first 
time,  the  current  study  explored  the  association  of  HRV  prevalence  and  load  with 
exacerbation frequency in COPD patients during the entire time-course of an exacerbation 
and  recovery  period.  The  results  showed  that  COPD  patients  with  HRV  infection  at 
exacerbation had a significantly higher exacerbation frequency than those without HRV. 
The results also demonstrated a weak but significant correlation between exacerbation Chapter 7 –HRV and patient reported outcome measures 
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frequency  and  HRV  load  showing  that  HRV  load  increased  as  exacerbation  frequency 
increased. This suggests that frequent exacerbators are more susceptible to respiratory 
viral  infection  or  are  less  able  to  prevent  viral  replication.  A  proposed  mechanism  of 
increased viral susceptibility is the modulation of intracellular adhesion molecule (ICAM)-1 
on  respiratory  epithelial  cells.  ICAM-1  functions  as  the  receptor  for  major  group  HRV 
(Staunton et al., 1989). It has been shown that ICAM-1 is upregulated in the bronchial 
mucosa of patients with chronic bronchitis (Di Stefano et al., 1994), which may lead to 
increased HRV infection in these patients. Furthermore, frequent exacerbators have been 
shown to have increased airway inflammation in the stable state (Bhowmik et al., 2000) 
and that COPD is associated with increased nasal inflammation (Hurst et al., 2005; Vachier 
et al., 2004). Inflammation leads to the upregulation of ICAM-1 (Staunton et al., 1989) 
which in turn suggests that the increases ICAM-1 and therefore HRV infection, due to 
inflammation  in  the  upper  airway  of  frequent  exacerbators,  could  account  for  these 
findings. The potential mechanisms suggested by Hurst and colleagues to explain why 
frequent exacerbators have an increased frequency of colds (Hurst et al., 2005a) could be 
applied  to  these  results  to  explain  increased  susceptibility  to  HRV  infection  seen  in 
frequent exacerbators.  
 
This  increase  in  susceptibility  to  HRV  infection  in  frequent  exacerbators  may  have 
important  consequences  in  terms  of  treatment  of  exacerbations  and  should  promote 
further study into the development of an HRV-specific antiviral or vaccine. These results Chapter 7 –HRV and patient reported outcome measures 
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emphasise  the  importance  of  treating  HRV  infections  with  the  aim  of  reducing 
exacerbation frequency and preventing exacerbation recurrence in these patients.  
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7.9  Conclusion  
For the first time, this study has explored the association of HRV infection with EXACT 
scores, CAT scores and exacerbation frequency. COPD patients with HRV infection have 
higher EXACT and CAT scores throughout the time-course of an exacerbation and recovery 
compared to those without HRV. Furthermore, as HRV load increases, both EXACT and 
CAT scores also increase suggesting both questionnaires could be used in future trials of 
antiviral therapy and also to track symptom recovery.  
 
This study also showed an association between HRV infection and exacerbation frequency. 
COPD patients with HRV infection had higher exacerbation frequency than those without 
HRV and HRV load at exacerbation was greater in patients with a higher exacerbation 
frequency.  These  results  emphasise  the  importance  of  the  development  of  an  HRV-
specific antiviral to prevent HRV-associated exacerbations and with the aim of reducing 
exacerbation frequency.  Chapter 8 –RSV in stable COPD and at exacerbation  
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CHAPTER 8. Respiratory syncytial virus in stable 
COPD and at exacerbation 
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8.1  Introduction  
This  pilot  study  aimed  to  investigate  the  prevalence  and  semi-quantitative  load  of 
respiratory  syncytial  virus  (RSV)  in  COPD  patients  in  the  stable  state  and  at  naturally 
occurring exacerbation.  This  study  also  explored  the  association of  RSV  infection  with 
upper and lower respiratory tract symptoms.  
 
As  discussed  in  previous  chapters,  HRV  has  been  shown  to  be  the  most  commonly 
detected respiratory virus at COPD exacerbation (Seemungal et al., 2001) with RSV being 
the second most commonly detected (Seemungal et al., 2001). At exacerbation, RSV has 
been  detected  at  various  prevalence  rates  by  different  groups,  which  reflects  the 
uncertainty around the role of RSV in COPD exacerbations. Seemungal and colleagues 
found RSV to be present in 14.2% of exacerbation samples (Seemungal et al., 2001), and 
Rohde reported RSV in 22%  (Rohde et al., 2003), whereas Falsey and colleagues only 
detected RSV in 7.2% of exacerbation samples (Falsey et al., 2006). RSV commonly infects 
children and infants (Lanari et al., 2014; Martinelli et al., 2014) however it has also been 
shown to cause substantial disease in many adult populations such as the elderly, healthy 
younger populations, immunocompromised individuals and subjects with COPD (Walsh, 
2011). A study exploring RSV infection in adults found that 9-11.4% of COPD patients with 
RSV-associated exacerbations required hospitalisation and 13% of these needed intensive 
care  treatment  (Falsey,  2005).  Another  study  identifying risk  factors for  RSV  illness  in Chapter 8 –RSV in stable COPD and at exacerbation  
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COPD patients found that 11.1% patients were infected with RSV with almost half needing 
medical attention (Mehta et al., 2013). Furthermore it was shown that congestive heart 
failure and exposure to children were risk factors for symptomatic RSV illness (Mehta et 
al., 2013). Persistent RSV infection in COPD patients has been associated with accelerated 
FEV1  decline  (Matsumoto  and  Inoue,  2014;  Wilkinson  et  al.,  2006),  higher  levels  of 
inflammatory markers (Seemungal et al., 2001) and worse lung function (Wilkinson et al., 
2006a).  Interestingly,  the  mortality  rates  of  RSV-associated  COPD  exacerbations  are 
greater than those for influenza despite influenza being a more commonly recognised 
virus (Falsey, 2005) although this may be due to the effect of the influenza vaccination 
given to COPD patients.   
 
RSV  has  been  detected  in  stable  COPD  as  well  as  at  exacerbation  leading  to  some 
controversy  about  RSV  persistence  verses  intermittent  acute  infection.  Some  groups 
suggest that RSV persists in the lung long-term whereas others believe it plays a greater 
role  in  acute  infection.  A  study  by  Borg  and  colleagues  in  2003  reported  a  similar 
prevalence of RSV in both stable COPD and at exacerbation (27.9% vs 28.3%, respectively) 
(Borg et al., 2003) however Seemungal and colleagues reported the prevalence of RSV to 
be higher in stable COPD (23.5%) compared to exacerbation (14.2%) (Seemungal et al., 
2001). Conversely, Papi and colleagues found the prevalence of RSV to be higher at COPD 
exacerbation  compared  to  the  stable  state  and  did  not  find  RSV  to  persist  in  COPD 
patients (Papi et al., 2006). A study exploring the contribution of RSV on cigarette smoke-Chapter 8 –RSV in stable COPD and at exacerbation  
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induced airway inflammation and lung tissue destruction showed that RSV does not just 
colonise  the  lungs  but  is  an  important  aetiological  factor  in  driving  inflammation, 
apoptosis  and  tissue  destruction  in  smoke-exposed  mice  (Foronjy  et  al.,  2014).  Other 
studies report the feasibility of RSV to persist in the airways through evasion and escape 
from the host’s immune system, along with impaired immunity found in COPD patients 
(Sikkel et al., 2008). One study detected RSV using PCR in nasopharyngeal samples from 
28.3% COPD patients that were hospitalised for reasons other than acute exacerbation. 
However, the RSV loads in these patients were found to be lower than the RSV loads 
found in children with acute RSV infection (Borg et al., 2003).  
 
RSV  is  an  enveloped  RNA  virus  in  the  Paramyxoviridae  family  (Walsh,  2011).  RSV  is 
classified  into  two  distinct  groups,  RSV-A  and  RSV-B  based  on  antigenic  and  genetic 
variability (Anderson et al., 1985) however it is not clear whether infection by these two 
strains affects COPD differently, or whether there is a difference in the prevalence and/or 
load of the two groups at different disease states (Mufson et al., 1985). A study in which 
mice were infected with two different strains of RSV-A at similar viral titres, found that 
strain-specific  variations  in  cytokine  expression,  goblet  cell  by  hyperplasia  MUC5AC 
expression  and  airway  hyper-reactivity  occurred  which  suggests  that  RSV  strain 
differences may be an important component of RSV disease severity (Lukacs et al., 2006). 
Studies involving humans however reported no differences in viral effects of infection with 
different  RSV  strains.  In  a  study  of  elderly  patients  and  high-risk  adults,  RSV-A  was Chapter 8 –RSV in stable COPD and at exacerbation  
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responsible for 45% of infection and RSV-B for 55% (Falsey, 2005). To date, there is little 
information about differences in the prevalence of the two strains in stable COPD and at 
exacerbation. There is also no data at present on the changes in load between these two 
disease states for either individual strain.  
 
This pilot study investigated RSV prevalence and semi-quantitative load as a whole in 
COPD patients in the stable state and at naturally occurring COPD exacerbation, but also 
as individual serotypes, RSV-A and RSV-B, at these two time-points. Furthermore, this 
study aimed to explore the association of RSV infection with upper and lower respiratory 
tract  symptoms  at  exacerbation.  The  semi-quantitative  PCR  methodology  for  RSV  is 
described in section 2.5.6.  
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8.2  Characteristics of patients in unpaired analysis 
A total of 416 stable state samples and 119 exacerbation samples from 142 COPD patients 
were collected for RSV analysis between January 2009 and January 2013 as part of the 
sample  collection  performed  in  the  London  COPD  cohort.  The  baseline  clinical 
characteristics for the 142 patients are shown in Table 8.1 below.   
 
 
 
 
 
 
 
Table  8.1:  Baseline clinical  characteristics  of  142  patients  in  the  London  COPD  Cohort, who 
participated in study of RSV presence at COPD exacerbation and in the stable state in unpaired 
samples. Data are presented as mean (±SD) or percentage (%). 
 
FEV1, litres  1.12 (±0.5) 
FVC, litres  2.28 (±0.9) 
FEV1/FVC, %  47.1 (±14.9) 
Predicted FEV1, %  44.9 (±20.3) 
Current Smoker, %  32 
Age, years  68.4 (±7.8)  
Male gender, %  64 Chapter 8 –RSV in stable COPD and at exacerbation  
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8.3  Results - unpaired analysis 
8.3.1  RSV prevalence in unpaired analysis 
From  a  total  of  416  stable  state  samples,  91  (21.9%)  had  RSV  detected.  Of  119 
exacerbation  samples,  18  (15.1%)  were  positive  for  RSV  which  was  not  significantly 
different to the RSV prevalence in the stable state (p=0.092) (Figure 8.1). Only 2 of the 18 
samples positive for RSV at exacerbation were also positive for RSV in the stable state.  
 
Figure 8.1: Comparison of RSV prevalence in the stable state (n=416) and at COPD exacerbation 
(n=119) in unpaired samples.  Chapter 8 –RSV in stable COPD and at exacerbation  
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From  a  total  of  416  stable  state  samples,  90  (21.6%)  had  RSV-A  detected.  Of  119 
exacerbation samples, 15 (12.6%) were positive for RSV-A which was significantly lower 
than in the stable state (p=0.023) (Figure 8.2).  
 
 
Figure  8.2:  Comparison  of  RSV-A  prevalence  in  the  stable  state  (n=416)  and  at  COPD 
exacerbation (n=119) in unpaired samples; *p=0.023.  
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From  a  total  of  416  stable  state  samples,  2  (0.5%)  had  RSV-B  detected.  Of  119 
exacerbation samples, 3 (2.5%) were positive for RSV-B which was significantly higher than 
in the stable state (p=0.044) (Figure 8.3).  
 
 
Figure  8.3:  Comparison  of  RSV-B  prevalence  in  the  stable  state  (n=416)  and  at  COPD 
exacerbation (n=119) in unpaired samples; *p=0.044.  Chapter 8 –RSV in stable COPD and at exacerbation  
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8.3.2  RSV and upper respiratory tract symptoms 
Of the 119 exacerbation samples, 87 had recorded symptom data; 76 of these negative for 
RSV and 11 positive for RSV.  
Of the 11 samples positive for RSV, 3 (27.3%) were associated with cold symptoms at 
exacerbation. Of the 76 samples negative for RSV, 28 (36.8%) were associated with cold 
symptoms. There was no significant difference between the prevalence of cold symptoms 
between these two groups; p=0.536 (Figure 8.4).  
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Figure 8.4: Comparison of the prevalence of cold symptoms at exacerbation in RSV  positive 
samples (n=11) and RSV negative samples (n=76). 
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Of the 11 samples positive for RSV, 0 (0%) were associated with sore throat symptoms at 
exacerbation. Of the 76 samples negative for RSV, 8 (10.5%) were associated with sore 
throat symptoms. There was no significant difference between the prevalence of  sore 
throats between these two groups; p=0.259 (Figure 8.5).  
 
 
Figure 8.5: Comparison of the prevalence of sore throats at exacerbation in RSV positive samples 
(n=11) and RSV negative samples (n=76). 
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Of  the  87  exacerbation  samples  that  had  recorded  symptom  data,  28  (32.3%)  were 
associated with cold symptoms only, 3 (3.4%) were associated with sore throats only and 
3 (3.4%) were associated with both symptoms. The prevalence of cold symptoms only in 
this sample set, was significantly higher than for sore throats only (p<0.001) or for both 
symptoms (p<0.001) (Figure 8.6).  
 
 Figure  8.6:  Comparison  of  the  percentage  of  samples  associated  with  cold  symptoms  only 
(n=28), sore throats only (n=3) or both symptoms (n=3) at exacerbation; *p<0.001. Chapter 8 –RSV in stable COPD and at exacerbation  
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The prevalence of RSV in samples associated with cold symptoms only, was found to be 
3/28 (10.7%). There were no positive RSV samples associated with sore throats only, or 
both symptoms. 
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8.3.3  RSV and lower respiratory tract symptoms  
Of the 11 samples positive for RSV, 7 (63.6%) were associated with an increase in sputum 
volume at exacerbation. Of the 76 samples negative for RSV, 43 (56.6%) were associated 
with  an  increase  in  sputum  volume.  There  was  no  significant  difference  between  the 
prevalence of increased sputum volume between these two groups; p=0.658 (Figure 8.7).  
 
 
Figure  8.7:  Comparison  of  the  prevalence  of  increased  sputum  volume  between  samples 
negative for RSV (n=76) and samples positive for RSV (n=11). Chapter 8 –RSV in stable COPD and at exacerbation  
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Of the 11 samples positive for RSV, 5 (45.5%) were associated with an increase in sputum 
purulence  at  exacerbation.  Of  the  76  samples  negative  for  RSV,  38  (50.0%)  were 
associated  with  an  increase  in  sputum  purulence.  There  was  no  significant  difference 
between  the  prevalence  of  increased  sputum  purulence  between  these  two  groups; 
p=0.778 (Figure 8.8).  
 
 
Figure  8.8:  Comparison  of  the  prevalence  of  increased  sputum  purulence  between  samples 
negative for RSV (n=76) and samples positive for RSV (n=11). Chapter 8 –RSV in stable COPD and at exacerbation  
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There were insufficient sample numbers to analyse sputum volume and sputum purulence 
changes in subjects with RSV-A or RSV-B, specifically.  
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8.3.4  RSV and CRP levels 
CRP data was available for 357 of 416 stable state samples.  
 
In stable state samples positive for RSV (n=75), the median (IQR) CRP value was found to 
be 3 (1-6) pg/ml which was not significantly different to the median level of CRP in stable 
state samples negative for RSV (n=282) which was 3 (1-7) pg/ml; p=0.685 (Figure 8.9). 
 
Figure 8.9: Comparison of the CRP levels in the stable state in RSV negative samples (n=282) and 
RSV positive samples (n=75). Chapter 8 –RSV in stable COPD and at exacerbation  
290 
 
In stable state samples positive for RSV-A (n=74), the median (IQR) CRP value was found to 
be 3 (1-6.25) pg/ml which was not significantly different to the median level of CRP in 
stable state samples negative for RSV-A (n=282) which was 3 (1-7) pg/ml; p=0.682 (Figure 
8.10).  
 
Figure 8.10: Comparison of the CRP levels in the stable state in RSV-A negative samples (n=283) 
and RSV-A positive samples (n=74). 
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8.3.5  RSV semi-quantitative load in unpaired analysis 
The RSV load was measured semi-quantitatively which used the detection threshold (Ct 
value) to compare the amount of RSV between samples allowing relative quantification 
rather  than  absolute  quantification  of  viral  loads  to  be  determined. A  lower  Ct  value 
indicates a higher viral load, as less PCR cycles are required to amplify the cDNA within a 
sample. More specifically, a decrease in Ct value by one, equates to a 2-fold increase in 
viral load.   
 
In unpaired samples that were positive for RSV-A (n=90 in the stable state and n=15 at 
exacerbation),  it  was  identified  that  the  median  (IQR)  detection  threshold  was  38.40 
(37.77-38.73)  in  the  stable  state  which  was  2-fold  lower  than  37.28  (33.26-38.04)  at 
exacerbation (Figure 8.11).  Chapter 8 –RSV in stable COPD and at exacerbation  
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Figure 8.11: Comparison of RSV-A detection threshold in the stable state (n=90) and at COPD 
exacerbation (n=15) in unpaired samples. Note that Ct value is inversely correlated with RSV 
load i.e. higher RSV loads will have a lower detection threshold.  
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In unpaired samples that were positive for RSV-B (n=2 in the stable state and n=3 at 
exacerbation),  it  was  identified  that  the  median  (IQR)  detection  threshold  was  38.96 
(38.61-39.31)  in  the  stable  state  which  was  approximately  16-fold  lower  than  35.19 
(26.22-39.30) at exacerbation (Figure 8.12).  
 
 
Figure 8.12: Comparison of RSV-B detection threshold in the stable state (n=2) and at COPD 
exacerbation (n=3) in unpaired samples. Note that Ct value is inversely correlated with RSV load 
i.e. higher RSV loads will have a lower detection threshold. 
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8.1  Characteristics of patients in paired analysis 
A sub-analysis of 32 COPD patients who had paired stable and exacerbation state sputum 
samples was performed to reduce any bias that may occur when different patients are 
used to reflect changes in RSV prevalence and load at different COPD states. Pairs  of 
sputum samples, one taken in the stable state and one at exacerbation were analysed. A 
total of 45 stable state samples and 45 exacerbation samples from the 32 patients were 
analysed between April 2009 and December 2012. This sub-analysis involved stable state 
samples being obtained less than 365 days prior to an exacerbation. The baseline clinical 
characteristics of the 32 patients included are shown in Table 8.2 below.   
 
 
 
 
 
 
Table  8.2:  Baseline  clinical  characteristics  of  32  patients  in  the  London  COPD  Cohort,  who 
participated in study of RSV presence at COPD exacerbation and in the stable state in paired 
samples. Data are presented as mean (±SD) or percentage (%). 
FEV1, litres  1.12 (±0.5) 
FVC, litres  2.27 (±0.9) 
FEV1/FVC, %  46.9 (±14.9) 
Predicted FEV1, %  44.9 (±20.3) 
Current Smoker, %  32 
Age, years  78.6 (±8.0)  
Male gender, %  64 Chapter 8 –RSV in stable COPD and at exacerbation  
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8.2  Results – paired analysis 
8.2.1  RSV prevalence in paired analysis  
From a total of 45 stable state sputum samples, it was found that 8 (17.8%) were positive 
for  RSV.  Of  45  exacerbation  samples,  3  (6.7%)  showed  such  presence  which  was  not 
significantly different to RSV prevalence in the stable state (p=0.108) (Figure 8.13).  
 
Figure 8.13: Comparison of RSV prevalence in the stable state (n=45) and at COPD exacerbation 
(n=45) in paired samples.  Chapter 8 –RSV in stable COPD and at exacerbation  
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From a total of 45 stable state sputum samples, it was also found that 8 (17.8%) were 
positive for RSV-A. Of 45 exacerbation samples, 3 (6.7%) showed such presence which was 
not significantly different to RSV-A prevalence in the stable state (p=0.108) (Figure 8.14). 
RSV-B  was  not  detected  in  any  of  the  paired  stable  state  or  exacerbation  samples, 
reflecting the low prevalence in both disease states.   
 
Figure  8.14:  Comparison  of  RSV-A  prevalence  in  the  stable  state  (n=45)  and  at  COPD 
exacerbation (n=45) in paired samples.  Chapter 8 –RSV in stable COPD and at exacerbation  
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8.2.2  RSV semi-quantitative load in paired samples 
As with the unpaired analysis, the RSV load was measured semi-quantitatively which used 
the detection threshold (Ct value) to compare the RSV levels between samples allowing 
relative quantification rather than absolute quantification of viral loads to be determined. 
The lower the Ct value, the higher the viral load as less cycles are required to amplify the 
cDNA within a sample.  
 
In  paired  samples  that  were  positive  for  RSV-A  (n=8  in  the  stable  state  and  n=3  at 
exacerbation),  it  was  identified  that  the  median  (IQR)  detection  threshold  was  38.12 
(37.12-38.66)  in  the  stable  state  which  did  not  change  at  exacerbation,  38.08  (37.62-
38.11)  (Figure  8.15).  RSV-B  was  not  detected  in  any  of  the  paired  stable  state  or 
exacerbation samples.  Chapter 8 –RSV in stable COPD and at exacerbation  
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Figure 8.15: Comparison of RSV-A detection threshold in the stable state (n=8) and at COPD 
exacerbation (n=3) in paired samples. Note that Ct value is inversely correlated with RSV load 
i.e. higher RSV loads will have a lower detection threshold. 
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8.3  Discussion  
This pilot study investigated RSV infection in stable COPD and at exacerbation, exploring 
the prevalence and semi-quantitative load of RSV as a whole, and also of RSV-A and RSV-B 
as separate subtypes of RSV. It also considered the association of RSV infection with upper 
and lower respiratory tract symptoms, and with levels of C-reactive protein (CRP).  
 
Controversy still remains about the role of RSV in COPD; some studies have shown RSV to 
persist in the airways (Borg et al., 2003; Wilkinson et al., 2006) while others consider it to 
play a larger role in acute infection (Papi et al., 2006). RSV has been shown to be the most 
commonly detected virus in stable COPD (Seemungal et al., 2001), however it has also 
been  shown  to  be  the  second  most  commonly  detected  virus  at  COPD  exacerbation 
(Seemungal et al., 2001).  
 
A  study  by  Seemungal  and  colleagues  in  2001  detected  RSV  in  23.5%  of  stable  state 
samples which was higher than the 14.2% detected at COPD exacerbation and there was 
no association of exacerbation samples with higher RSV loads compared to the stable 
state suggesting low-grade asymptomatic infection (Seemungal et al., 2001). Furthermore, 
a study by Wilkinson and colleagues found positive RSV detection in 32.8% of stable state 
samples  from  COPD  patients  using  PCR  and  sequencing  techniques  (Wilkinson  et  al., 
2006). In 2003, Borg and colleagues used quantitative PCR to detect and quantify RSV in Chapter 8 –RSV in stable COPD and at exacerbation  
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nasopharyngeal aspirates from infected children, and in nasal lavage and sputum samples 
from COPD patients, in both the stable state and at exacerbation. RSV detection rates 
were found to be similar in both disease states, 27.9% vs 28.3% respectively. Using viral 
load measurements it was shown that the RSV load was nearly 2000-fold higher in the 
infected  children  compared  to  the  COPD  patients  in  both  the  stable  state  and  at 
exacerbation, which again, suggests low-grade, and potentially persistent, RSV infection in 
patients with COPD (Borg et al., 2003).  
 
Other work contradicts the findings from these studies and suggests that RSV can cause 
intermittent acute infection in patients with COPD (Rohde et al., 2003). A study by Falsey 
and colleagues exploring the RSV persistence in COPD patients, detected RSV in just 0.95% 
of  stable  state  sputum  samples,  however  RSV  was  detected  in  7.2%  of  exacerbation 
sputum samples (Falsey et al., 2006). This low prevalence of RSV in the stable state implies 
it is unlikely that RSV is persisting in these patients and acute infection is more likely to 
occur, perhaps leading to an exacerbation. Furthermore, Papi and colleagues found the 
prevalence of RSV to be 3.1% in stable COPD compared to 6.3% at exacerbation (Papi et 
al., 2006) and Rohde and colleagues found 22% of exacerbation samples to be positive for 
RSV but detected RSV in none of the stable state samples (Rohde et al., 2003) which again 
provides little evidence for the persistence of RSV.  
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The differences in RSV detection levels between these studies may be partly due to the 
methods used for viral detection, as well as differences in study samples. PCR is a sensitive 
technique that can detect low levels of viral prevalence and load. One consideration when 
addressing the variability in the field is whether PCR methods for RSV detection are too 
sensitive and that the RSV being detected actually plays no role in COPD pathogenesis. In 
2001, Walsh and colleagues used a nested PCR method for the detection of RSV and found 
the nested PCR technique to be approximately 100-fold more sensitive than standard PCR 
and  that  the  technique  improved  the  ability  of  detecting  RSV  in  respiratory  samples 
(Walsh et al., 2001). It is important to consider, however, whether the RSV being detected 
by this method actually contributes to disease pathogenesis or whether it is harmless. 
Wilkinson and colleagues showed that patients positive for RSV in the stable state had 
worse  lung  function  and  higher  airway  inflammation  than  those  without  RSV  which 
suggests  that  RSV  does  play  a  role  in  COPD  pathogenesis  and  disease  morbidity. 
Furthermore  clustering  of  RSV  detection  in  individuals  as  opposed  to  a  random 
distribution of positive detections was also shown suggesting contamination was unlikely 
(Wilkinson et al., 2006a).  
 
The results from the current study found no significant difference in the prevalence of RSV 
between  the  stable  state,  21.9%,  and  exacerbation,  14.9%  using  unpaired  analysis, 
however  when  separated  into  the  individual  RSV  subtypes  it  was  found  that  the 
prevalence  of  RSV-A  was  significantly  higher  in  stable  state  samples  compared  to Chapter 8 –RSV in stable COPD and at exacerbation  
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exacerbation. This was not the case for RSV-B where the prevalence was significantly 
higher at exacerbation compared to the stable state however RSV-B was detected at a low 
prevalence in both disease states. By detecting RSV-A in almost a quarter of stable state 
samples, and with this prevalence being significantly higher than at exacerbation, this data 
supports the theory that RSV-A can persist within the airways of COPD patients and that 
low level chronic infection may persist in certain COPD patients. Patients are considered 
to be stable if exacerbation free for four weeks prior, and two weeks after the stable 
samples were collected, thus the RSV-A detected in the stable state samples was unlikely 
to be as a result of a previous exacerbation, or due to the start of a new one. In the paired 
analysis however, this was not the case, probably due to the relatively small sample size. 
There was no significant difference in the prevalence of RSV between the stable state and 
exacerbation, or in the prevalence of RSV-A between the two disease states, although in 
absolute numbers, the prevalence of RSV-A appeared to be higher in the stable state 
compared to exacerbation. RSV-B was not detected in any samples in the paired data set, 
and in only 0.5% of stable state and 2.5% of exacerbation state samples in the unpaired 
data set. These findings suggest that RSV-A is the most prominent subtype of RSV found in 
stable COPD and at exacerbation within the London COPD cohort, but given the variation 
in this field, these findings cannot be generalised to the population.  
 
To date, there has been limited study into the relationship between RSV infection and the 
presence of upper respiratory tract (URT) symptoms such as cold symptoms and sore Chapter 8 –RSV in stable COPD and at exacerbation  
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throats, and lower respiratory tract (LRT) symptoms such as sputum volume and sputum 
purulence.  Falsey  and  colleagues  showed  that  patients  positive  for  RSV  reported 
symptoms such as cough, wheeze, dyspnoea, sore throats and cold symptoms with cough 
being  the  most  common  symptom  reported  (Falsey  et  al.,  2006).  In  Chapter  5  an 
association between HRV infection and the presence of URT symptoms  was described 
where,  at  exacerbation,  HRV  prevalence  and  load  were  found  to  be  higher  when 
associated with cold symptoms and/or sore throats, compared to when no symptoms 
were present, suggesting that URT symptoms could be used as potential markers of HRV 
infection. The current study showed no significant difference in the prevalence of cold 
symptoms, or sore throats in samples positive for RSV or samples negative for RSV from 
patients in the London COPD cohort, which suggests that URT symptoms would not be 
appropriate indicators of RSV infection in these COPD patients. Furthermore, unlike in the 
HRV data, there was no association between the prevalence of RSV and the number of 
symptoms present, whether it were cold symptoms alone, sore throats alone, or both 
symptoms together. Cold symptoms were significantly more prevalent in this data set 
compared to sore throats, or both symptoms, but this did not relate to the prevalence of 
RSV infection. When exploring LRT symptoms such as increases in sputum volume and 
increases  in  sputum  purulence,  there  was  also  no  difference  between  RSV  positive 
samples and RSV negative samples in either of these symptoms. These findings suggest 
that symptoms should not be the preferred method of RSV infection indication and that, 
unlike HRV infection, the use of inflammatory markers may be more useful.  Chapter 8 –RSV in stable COPD and at exacerbation  
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As RSV is considered, by some, to persist in COPD patients (Borg et al., 2003; Wilkinson et 
al., 2006a) rather than cause acute infection (Papi et al., 2006) leading to an exacerbation, 
it was important to explore whether, in the stable state, RSV infection was associated with 
levels of inflammatory markers as potential markers of RSV infection. In 2001, Seemungal 
and colleagues showed that when RSV was detected, mean fibrinogen levels and median 
serum IL-6 levels were elevated (Seemungal et al., 2001). In the current study, levels of 
CRP were explored to measure any differences between samples infected with RSV and 
those without RSV in order to determine whether CRP could be a potential candidate as a 
marker of RSV infection in stable COPD patients. The findings from the current study 
showed no difference in the levels of serum CRP between samples infected with RSV and 
samples not infected with RSV, suggesting that RSV presence in stable COPD does not 
cause an increase in CRP levels, implying that CRP would not be a useful marker of RSV 
infection. As previous studies have shown the levels of CRP to be significantly higher in the 
presence of bacteria compared to when bacteria was not detected (Garcha et al., 2012), it 
is likely that other inflammatory markers, more suitable for viral infection and that have 
not been explored in this study, may be more useful as indicators for RSV infection. In 
particular, as shown in this study, upper and lower respiratory tract symptoms are not 
suitable  markers  of  RSV  infection,  and  therefore,  the  availability  of  an  inflammatory 
marker for this may be beneficial. Conversely, as RSV appears to play little role in the 
onset of COPD exacerbations, having an inflammatory marker to indicate RSV infection Chapter 8 –RSV in stable COPD and at exacerbation  
305 
 
may not be as important as for other viruses. Further study in this area would need to be 
performed for any conclusions to be made. 
 
In the current study RSV load was measured using a semi-quantitative method which 
allowed  comparisons  to  be  made  between  individual  sputum  samples  without  the 
absolute load being known and is a way of performing relative quantification of loads 
rather  than  absolute  quantification.  When  measuring  viral  load  semi-quantitatively,  a 
decrease in one Ct value represents a 2-fold increase in viral load. In the unpaired analysis, 
the  detection  threshold  for  RSV-A  was  found  to  be  approximately  2-fold  higher  at 
exacerbation, relative to the stable state. The detection threshold for RSV-B was found to 
be approximately 16-fold higher at exacerbation, relative to the stable state. This suggests 
that the load of RSV-A and RSV-B was higher at exacerbation compared to the stable state 
however in order to make conclusions about changes in RSV load between these two 
disease  states,  the  RSV  load  needs  to  be  measured  fully-quantitatively.  In  the  paired 
analysis, there was no change in the detection threshold between the stable state and 
exacerbation. 
 
Certain limitations of this study have prevented definite conclusions to be made; sample 
numbers, particularly in the paired analysis, are likely to have been too small resulting in 
the study being underpowered, particularly regarding exacerbation samples. Additionally, 
qPCR was used to semi-quantitatively detect RSV load. Although this method allowed Chapter 8 –RSV in stable COPD and at exacerbation  
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relative comparisons to be made between different samples in different disease states, it 
did not allow absolute viral loads of be compared and so it was therefore not possible to 
analyse or comment on differences in absolute RSV levels between samples. Further study 
into this field may focus on the absolute quantification of RSV load in stable COPD and at 
exacerbation allowing a better understanding of the role of RSV in COPD.  
 
To date, antiviral therapy for RSV is of limited benefit but given the extent and severity of 
RSV  infection  in  children,  there  is  increasing  interest  in  developing  new  treatments 
(Olszewska  and  Openshaw,  2009).  Ribavirin  and  palivizumab  are  the  only  approved 
pharmacological  agents  for  RSV  treatment  and  prevention,  respectively,  and  are 
predominantly used in children as there is limited data regarding their effectiveness in 
adults (Walsh, 2011). Specific antiviral therapy is often reserved for immunocompromised 
patients or those with severe respiratory failure. Therefore it seems that immunisation 
has  the  greatest  potential  for  reducing  RSV  in adults,  however,  currently,  there  is  no 
effective vaccine available for RSV (Walsh, 2011). In 1966, an RSV vaccine was tested in 
the United States, however the trial had serious consequences as many infants still caught 
RSV,  some  needing  hospitalisation.  Two  infants  died  as  a  result  of  enhanced  disease 
symptoms and since then, no safe vaccine has been developed (Delgado et al., 2009). The 
findings  from  this  study  show  RSV  to  be  present  in  both  the  stable  state  and  at 
exacerbation, but at low prevalence, suggesting RSV is unlikely to play a significant role in 
causing exacerbations of COPD. Trials of anti-RSV therapy may be less beneficial in COPD Chapter 8 –RSV in stable COPD and at exacerbation  
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than in other situations, such as to treat infected infants, and also less beneficial than anti-
viral trials for other viruses such as HRV, which has been shown in previous chapters to be 
closely associated with the onset and recovery of COPD exacerbations.  
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8.4  Conclusion 
The  findings  from  this  study  showed  that  the  prevalence  of  RSV  in  sputum  was  not 
significantly different between stable COPD and exacerbation. In unpaired analysis, RSV-A 
prevalence was significantly higher in the stable state compared to exacerbation however 
this was not reproduced when using paired analysis. RSV-B prevalence was low in both 
disease states. The RSV-A load was found to be higher at exacerbation relative to the 
stable state but this was not the case for RSV-B. These findings suggest that RSV is unlikely 
to play a significant role in causing COPD exacerbations and that trials of specific RSV 
antiviral  therapy  may  be  less  beneficial  in  COPD  than  antiviral  therapies  for  other 
respiratory viruses which may play a more direct role in triggering COPD exacerbations.  Chapter 9 –Summary and future work  
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Chapter 9. Summary and future research 
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9.1  Summary  
The  overall  aim  of  this  study  was  to  investigate  the  relationship  between  human 
rhinovirus (HRV) infection and chronic obstructive pulmonary disease (COPD). It has been 
shown previously that HRV is the most commonly detected respiratory virus at COPD 
exacerbation (Seemungal et al., 2001) and with the development of qPCR techniques, it is 
possible to detect and quantify the levels of viral RNA in sputum samples from COPD 
patients.  Few  studies have  investigated  changes  in  HRV prevalence  and  load  in  COPD 
(Mallia et al., 2011; Quint et al., 2010; Seemungal et al., 2001), and there was an absence 
of literature exploring this virus at different points during COPD exacerbations using qPCR 
techniques.  HRV  infection  over  the  entire  time-course  of  COPD  exacerbations  and 
recovery had not been investigated in naturally occurring exacerbations.  
 
A  number  of  studies  have  explored  the  association  of  upper  respiratory  tract  (URT) 
symptom changes and their recovery with viral-associated COPD exacerbations (Gerna et 
al.,  2009;  Seemungal  et  al.,  2001;  Wright  et  al.,  2007).  It  has  been  shown  that  viral-
associated exacerbations are more severe in terms of greater burden of symptoms and 
often have longer recovery times (Seemungal et al., 2001). However there has been no 
previous  investigation  into  changes  in  HRV  prevalence  and  load  with  URT  symptoms. 
Furthermore, differences in the HRV load between patients with multiple URT symptoms 
compared to the load in those with just one symptom, has also not yet been explored.  Chapter 9 –Summary and future work  
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Viral  and  bacterial  co-infection  in  COPD  is  becoming  important  and  more  extensively 
studied (Mallia et al., 2012; Perotin et al., 2013; Wark et al., 2013). It has been shown that 
patients with both viral and bacterial infections have more severe COPD exacerbations 
compared to those with just one pathogen (Wilkinson et al., 2006) and are more likely to 
be  readmitted  to  hospital  following  their  exacerbation  (Wark  et  al.,  2013).  Using 
experimental viral infection, it has been suggested that an initial viral infection can lead to 
the development of a secondary bacterial infection (Mallia et al., 2012) which can lead to 
further  exacerbations.  There  have  been  no  previous  studies  in  naturally  occurring 
exacerbations that have explored changes in both HRV load and bacterial load using qPCR 
over the entire time-course of an exacerbation and recovery. For the first time, this study 
reported changes in both prevalence and load of HRV and three typical  and common 
airway  bacteria  Haemophilus  influenzae,  Streptococcus  pneumoniae  and  Moraxella 
catarrhalis at exacerbation and during recovery.  
 
Patient  reported  outcomes  (PROs)  are  widely  used  in  COPD  to  assess  exacerbation 
severity and the effects of COPD on patient health status. To date, there has been no work 
into the association between PROs and HRV infection. Similarly, there has been extensive 
interest  in  the  frequent  exacerbator  phenotype  which  has  shown  that  exacerbations 
become more frequent and more severe as COPD severity increases and also that the 
more  important  determinant  of  exacerbation  frequency  is  a  history  of  exacerbations 
(Hurst et al., 2010; Seemungal et al., 1998). In 2001 Seemungal and colleagues showed a Chapter 9 –Summary and future work  
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relationship  between  HRV  prevalence  and  exacerbation  frequency  (Seemungal  et  al., 
2001b), however, to date, there has been no investigation into the relationship between 
HRV load and exacerbation frequency.  
 
Respiratory  syncytial  virus  (RSV)  has  been  shown  to  be  the  second  most  commonly 
detected  respiratory  virus  at  COPD  exacerbation,  after  HRV  (Seemungal  et  al.,  2001). 
There is much controversy about the role of RSV in COPD and whether it is able to persist 
long-term in the airways (Borg et al., 2003; Wilkinson et al., 2006) or whether it has a 
larger role in acute infection (Papi et al., 2006). In this thesis, the pilot study explored 
semi-quantitatively, the changes in RSV between stable COPD and exacerbation, and also 
changes in the individual RSV subtypes, RSV-A and RSV-B.   
 
The findings of this study are summarised below.  
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9.2  Study findings  
9.2.1  HRV prevalence and load in the stable state and at 
exacerbation 
  The changes in HRV prevalence and load at COPD exacerbation and in the stable 
state were compared in  Chapter 3. In a sputum sample population of 337 (58 
stable state and 279 exacerbation), it was found that the prevalence of HRV was 
significantly higher at exacerbation compared to stable COPD. This was identified 
in both unpaired (41.9% vs 17%; p=0.001) and paired analysis (68.5% vs 16.7%; 
p<0.001). 
  Similarly,  it  was  shown  in  Chapter  3  that  HRV  load  was  significantly  higher  at 
exacerbation compared to the stable state, in both unpaired (p=0.008) and paired 
analysis (p=0.011). In five patients in whom HRV was positive at both stable state 
and exacerbation, there was a significant increase in HRV load from 1.88(±0.48) 
log10  pfu/ml  in  the  stable  state  to  4.01(±0.68)  log10  pfu/ml)  at  exacerbation; 
p=0.034.  Chapter 9 –Summary and future work  
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9.2.2  Time-course of HRV infection during exacerbation and recovery 
  Chapter 4 explored the changes in HRV prevalence over the entire time-course of 
COPD exacerbation and recovery, using qPCR. HRV was detected at exacerbation 
presentation and Days 3, 7, 14, 35 and 56 post-exacerbation. In unpaired analysis, 
described in section 4.3, HRV prevalence was highest at exacerbation presentation 
and  decreased  significantly  to  each  time  point  during  the  recovery  period  (all 
p<0.014).  Similarly  HRV  load  was  highest  at  presentation  and  decreased 
significantly to each time point following (all p<0.001).  
  It was shown in section 4.4 using paired analysis, the prevalence was highest at 
presentation and decreased significantly to Day 14 (p=0.002) and Day 35 (p<0.001) 
post-exacerbation. The HRV load fell significantly from presentation to Day 3, 7, 14 
and 35 (all p≤0.043) as shown in Figure 4.4.   
  There was no significant difference between changes in inflammatory markers (IL-
6, IL-8, IL-1β, IL-18, TNFα, CRP, fibrinogen or IFNγ) over the time-course of an 
exacerbation and recovery between HRV-positive exacerbations and HRV-negative 
exacerbations as illustrated in Figure 4.5.  Chapter 9 –Summary and future work  
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9.2.3  HRV infection and URT symptoms 
  Section  5.3.1  showed  the  prevalence  of  URT  symptoms  to  be  higher  at 
exacerbation compared to the stable state (cold symptoms, p=0.038; sore throats, 
p=0.026).  Furthermore  the  prevalence  of  URT  symptoms  was  higher  in  the 
presence of HRV compared to without HRV (cold symptoms, p<0.001; sore throats, 
p=0.002).  
  At exacerbation, HRV load was significantly higher in samples associated with URT 
symptoms compared to those without symptoms (colds, p=0.004; sore throats, 
p<0.001) as shown in section 5.3.2. 
  In section 5.5.2 it was shown that at Day 7 post-exacerbation, the prevalence of 
HRV was significantly higher when associated with cold symptoms compared to 
without  symptoms  (p=0.016).  Similarly,  at  Day  3,  the  prevalence  of  HRV  was 
significantly  higher  when  associated  with  a  sore  throat  compared  to  without 
(p=0.036). 
  HRV load was significantly higher in samples associated with cold symptoms at 
exacerbation presentation, Day 3 and Day 7, compared to samples not associated 
with cold symptoms at these time-points (p≤0.046) as shown in Figure 5.16. HRV 
load  was  significantly  higher  in  samples  associated  with  sore  throats  at Chapter 9 –Summary and future work  
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exacerbation presentation and Day 3, compared to samples not associated with 
sore throats at these time-points (p≤0.018) as shown in Figure 5.17.   
  In samples associated with both cold symptoms and sore throats, the HRV load 
was  still  significantly  higher  one  week  post-exacerbation  compared  to  samples 
associated with just one of the symptoms (both p<0.030) as shown in Figure 5.18. 
9.2.4  Co-infection of HRV and typical airway bacteria 
  Chapter  6  showed  that  in  exacerbations  positive  for  HRV  and  bacteria  at 
presentation, HRV load decreased during the time-course until zero at Day 14 (all 
p<0.001).  Bacterial  load  decreased  from  presentation  to  Day  7  (p<0.001)  but 
increased again at Day 14 (p=0.049) as illustrated in Figure 6.3.  
  In exacerbations positive for HRV but negative for bacteria at presentation, HRV 
load decreased during the time-course until zero at Day 14 (p=0.001). Bacterial 
load increased significantly from presentation to Day 14  (p<0.001) with 52% of 
bacteria negative samples becoming positive by Day 14 as illustrated in Figure 6.8.  
  H influenzae was found to be the most prevalent bacterial species and was found 
at the highest loads throughout the time-course compared to S pneumonia and M 
catarrhalis as shown in section 6.3.2 and section 6.5.2.  Chapter 9 –Summary and future work  
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9.2.5  HRV infection and patient reported outcomes 
  In  section  7.3  it  was  shown  that  EXACT  scores  were  significantly  higher  in  the 
presence of HRV compared to without HRV (48.4(±1.33) vs 44.9(±0.64); p=0.010).  
  Figure 7.4 showed that HRV load was significantly correlated with EXACT scores; 
EXACT scores increased as HRV load increased (r=0.208, p=0.011).  
  EXACT scores were higher in the presence of cold symptoms (p<0.001) and sore 
throats (p=0.021) compared to without symptoms as described in section 7.3.  
  Section 7.5 showed that CAT scores were significantly higher in samples associated 
with HRV infection (22.12(±0.8)) than those without (19.95(±0.5); p=0.018).  
  CAT scores were weakly but significantly correlated to HRV load, increasing as HRV 
load increased (r=0.149, p=0.003) as shown in Figure 7.10.  
  CAT scores were significantly higher in the presence of cold symptoms compared 
to without cold symptoms (p<0.001) but this did not reach statistical significant for 
sore throats as shown in section 7.5.  
  It  was  shown  in  section  7.7  that  the  median  (IQR)  number  of  exacerbations 
experienced per year was higher in patients with HRV infection, 3.01 (2.02-5.28) 
compared to those without HRV, 2.51 (1.88-3.51); p=0.040.   Chapter 9 –Summary and future work  
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  As  HRV  load  increased,  exacerbation  frequency  increased  showing  a significant 
relationship between the two (r=0.265, p=0.024) as shown in Figure 7.13.   
9.2.6  RSV infection in the stable state and at exacerbation  
  Chapter 8 showed no significant difference in the prevalence or semi-quantitative 
load of RSV between the stable state and exacerbation.  
  When  broken  down  into  subtypes,  the  prevalence  of  RSV-A  was  shown  to  be 
significantly  higher  in  the  stable  state  compared  to  exacerbation  as  shown  in 
Figure 8.2. 
  Section 8.3.2 showed no significant difference in the prevalence of URT symptoms 
between RSV-positive samples and RSV-negative samples at exacerbation, or in 
lower respiratory tract symptoms as shown in section 8.3.3.  
  Levels of CRP were not significantly different between RSV-positive samples and 
RSV-negative samples in the stable state as shown in Figure 8.11.  
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9.2.7 Clinical implications of findings 
  The findings from this study present strong evidence relating HRV infection to the 
onset of COPD exacerbations. Firstly, it has been shown that the prevalence of HRV 
increases significantly at exacerbation compared to in the stable state, as does HRV 
load, which provides strong evidence for the role of HRV in COPD exacerbations. 
Furthermore, by measuring the prevalence and load of HRV over the entire time-
course  of  an  exacerbation  and  recovery  period,  it  was  possible  to  follow  the 
pattern  of  HRV  infection  and  show  that  HRV  was  highest  at  exacerbation 
presentation and decreased significantly during recovery.  
The finding that HRV load is highest at exacerbation presentation is an important 
development,  as  one  of  the  obstacles  in  the  consideration  of  antiviral  therapy 
development is that it is considered that patients are likely to present to the clinic 
and be prescribed therapy too late for antivirals to be effective. However, this data 
shows that HRV is highest when patients present to the clinic suggesting treatment 
at the time of presentation may in fact be beneficial, which stresses the need for 
antiviral development for COPD exacerbations. 
 
  At  certain  time-points  during  the  time-course,  HRV  prevalence  and  load  were 
higher  in  samples  associated  with  URT  symptoms  compared  to  when  no  URT 
symptoms were reported. Furthermore, HRV prevalence and load were higher in Chapter 9 –Summary and future work  
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samples associated with both cold symptoms and sore throats compared to those 
associated  with  just  one  symptom  only.  The  loads  also  remained  higher  for  a 
longer  period  of  time  with  the  presence  of  more  symptoms  suggesting  that 
exacerbations with more symptoms may be more severe and have longer recovery 
times  than  those  with  one  symptom  only.  The  fact  that  URT  symptoms  were 
reported a median of 2 days before exacerbation onset demonstrates how the 
London  COPD  cohort  captures  exacerbations  early  allowing  early  sampling  and 
early treatment. These findings suggest that URT symptoms could be used as early 
indicators of HRV infection allowing treatment to be started earlier with the aim of 
reducing exacerbation severity or even preventing an exacerbation from occurring 
to  start  with.  However,  as  some  other  respiratory  viruses  also  cause  similar 
symptoms, ultimately rapid diagnosis criteria, specifically for HRV, is required.  
 
  This  study  showed  that  secondary  bacterial  infection  occurs  after  initial  HRV 
infection which may also have strong implications in terms of therapy at COPD 
exacerbation. Secondary bacterial infection may be one of the causes of recurrent 
exacerbations that can occur in some COPD patients. The results from this work 
further emphasise the importance of being able to treat HRV infections, not only to 
manage the HRV-associated exacerbation itself but also with the aim of preventing 
the  development  of  a  secondary  bacterial  infection  which  may  then  lead  to 
another exacerbation. Whether antibiotic therapy would be required later into the Chapter 9 –Summary and future work  
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recovery period once a secondary bacterial infection had developed, would need 
further  investigation,  however,  the  accessibility  of  antiviral  therapy  for  the 
treatment  of  HRV-associated  exacerbations  is  crucial  in  reducing  exacerbation 
frequency, severity and recurrence. One of the important features of secondary 
bacterial infection is that they may drive recurrent exacerbations and therefore 
follow up of COPD exacerbations is key, particularly at Day 14 after the onset of 
the  event,  in  order  to  detect  any  recurrence.  This  is  consistent  with 
recommendations in the NICE quality standards for COPD, which suggests that all 
severe exacerbations need to be followed up 14 days after an exacerbation event 
(NICE Guidelines). 
 
  An association between HRV infection and EXACT scores, and HRV and CAT scores 
was reported in this study. The results showed significantly higher EXACT and CAT 
scores in HRV infected subjects compared to those without HRV. Furthermore it 
was  shown  that  as  HRV  load  increases,  EXACT  and  CAT  scores  also  increase 
suggesting that these questionnaires could be used, alongside URT symptoms, to 
indicate HRV infection. This suggests the potential use of both questionnaires in 
early indication of HRV infection in COPD patients which may lead to appropriate 
treatment, early on at exacerbation onset. The EXACT questionnaire seems to be 
suitable for research studies, and studies of COPD exacerbations could be designed Chapter 9 –Summary and future work  
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with the EXACT as the primary outcomes, as it responds well to many aetiology 
factors of exacerbations.  
 
  There was no significant difference in the prevalence of RSV between the stable 
state  and  exacerbation,  however  the  prevalence  of  RSV-A  was  found  to  be 
significantly  higher  in  the  stable  state  compared  to  exacerbation.  RSV-B  was 
detected at a low prevalence in both disease states. These findings suggest that 
RSV is unlikely to play a significant role in causing COPD exacerbations so trials of 
anti-RSV therapy may be less beneficial in COPD than trials for other viruses that 
play a larger role in exacerbation onset, such as HRV.  
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9.3  Conclusion  
This study has explored the role of HRV infection in chronic obstructive pulmonary 
disease,  in  the  stable  state,  at  exacerbation  presentation  and  during  exacerbation 
recovery,  in  naturally  occurring  COPD  exacerbations.  It  has  been  shown  that  HRV 
prevalence and load are significantly higher at exacerbation compared to the stable 
state and decrease over the recovery period. HRV is associated with upper respiratory 
tract symptoms and patient reported outcomes and patients with HRV infection have 
higher  exacerbation  frequencies  than  those  without  HRV.  Secondary  bacterial 
infection is common after HRV infection which has important implications in terms of 
therapy and exacerbation recurrence. The treatment of respiratory viral infections in 
COPD  patients,  in  particular  HRV,  may  be  fundamental  in  reducing  exacerbation 
frequency. These findings emphasise the unmet need for the rapid development of 
therapeutic targets for both the prevention and treatment of HRV infection in patients 
with COPD.  
   Chapter 9 –Summary and future work  
324 
 
9.4  Future work 
  Although  it  has  been  shown  that  HRV  prevalence  and  load  increase  at  COPD 
exacerbation, it is not conclusive whether HRV is causing an exacerbation or is just 
contributing  to  the  severity  of  an  exacerbation  once  it  has  already  arisen. 
Collecting sputum samples in the prodrome phase, prior to an exacerbation, will 
allow  the  role  of  HRV  in  these  exacerbations  to  be  further  defined  and  thus 
determine to what degree it may be causative. 
 
  In this study, HRV was identified using primers that are designed to detect as many 
serotypes of HRV as possible, to give a general view of the role of HRV in COPD. In 
terms of antiviral development, it is important to know what the most prevalent 
HRV  serotypes  involved  in  COPD  exacerbations  are,  so  sequencing  HRV  that  is 
detected  in  sputum,  would  be  useful  for  the  development  of  strain-specific 
therapy. There are known difficulties in vaccine development for HRV due to there 
being over 100 serotypes, however knowing the main serotypes detected at COPD 
exacerbation may help in addressing this problem as vaccine development could 
then be aimed at targeting the most prevalent HRV serotypes.  
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  It has been shown that secondary bacterial infection is common after initial HRV 
infection; however in this study the mechanism by which this occurs has not been 
examined.  Further  study  into  the  method  of  secondary  bacterial  infection 
development may provide further information in this area allowing any necessary 
changes to be made to therapeutic approaches. 
 
  In  2001  Seemungal  and  colleagues  reported  HRV  to  be  the  most  commonly 
detected virus at COPD exacerbation with RSV being the second (Seemungal et al., 
2001a) which is why this study has focused on HRV infection and then addressed 
RSV to a lesser extent. Other viruses have also been detected at exacerbation, at 
lower prevalences such as influenza, parainfluenza and adenovirus, but may also 
play an important role in COPD exacerbations. These other viruses may also lead to 
the development of secondary bacterial infection in some patients. It is important 
to be aware of these viruses and the role they may play in COPD.  
 
  As all patients in the secondary bacterial infection analysis were given antibiotics at 
exacerbation, it was not possible to determine any differences in the development 
of  secondary  bacterial  infection  between  patients  treated  with  antibiotics  and 
those  not  treated.  Further  work  may  explore  patients  with  HRV  infection  at 
exacerbation  presentation,  half  of  which  are  treated  with  antibiotics  at Chapter 9 –Summary and future work  
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exacerbation and the other half given placebo. Of all patients in the study, 74% 
received oral prednisolone therapy and thus the effect of prednisolone on its own 
on  secondary  bacterial  infection  needs  to  be  explored.  This  would  allow  any 
differences in secondary bacterial infection development between the two groups 
to be determined giving further insight into this area allowing appropriate changes 
to be made to treatment options if necessary.  
 
  The results from this study have shown associations between HRV and various 
aspects involved in COPD. Without the development of therapy against HRV, HRV-
associated exacerbations will continue causing increased morbidity and mortality 
in COPD patients, secondary bacterial infections will continue to occur resulting in 
recurrent  exacerbations  and  increasing  exacerbation  frequency.  These  findings 
significantly  emphasise  the  importance  of  rapid  developments  in  therapeutic 
targets for the prevention and treatment of HRV infection in patients with COPD. 
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Appendicies 
 
1.  Original article - Human rhinovirus infection during naturally occurring COPD 
exacerbations (published in ERJ 2014). 
2.  Human rhinovirus load in stable COPD and at exacerbation (BTS 2011). 
3.  Changes  in  human  rhinovirus  load  during  naturally  occurring  COPD 
exacerbations: a prospective cohort study (ATS 2012). 
4.  The prevalence of clinically relevant micro-organisms in stable and exacerbated 
COPD using PCR techniques (ERS 2012). 
5.  Time-course  of  rhinovirus  and  bacterial  infection  during  COPD  exacerbation 
recovery (BTS 2012). 
6.  Human  rhinovirus  infection  and  secondary  bacterial  infection  in  COPD 
exacerbations (ATS 2013). 
7.  Human rhinovirus infection and exacerbation frequency at COPD exacerbation 
(BTS 2013). 
8.  Human rhinovirus infection and EXACT scores during COPD exacerbation (ATS 
2014). 
9.  Time-course  of  human  rhinovirus  infection  and  upper  respiratory  tract 
symptoms during COPD exacerbations (BTS 2014). 
10. Front of daily diary card 
11. Back of daily diary card 
12. EXACT questionnaire 
13. CAT questionnaire 
 